BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: USC KECK SCHOOL OF MEDICINE

MAYER AUDITORIUM 1975 ZONAL AVENUE LOS ANGELES, CA

DATE: APRIL 29, 2009

9: 31 A. M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 82461

INDEX	
ITEM DESCRIPTION NO.	PAGE
CALL TO ORDER	186
ROLL CALL	186
CONSENT ITEMS:	
APPROVAL OF TECHNICAL AMENDMENTS TO GRANTS	53
REPORTS:	
CHAIRMAN'S REPORT.	240
PRESI DENT' S REPORT.	8
COMMUNICATIONS REPORT	54
ACTION ITEMS:	
CONSIDERATION OF RECOMMENDATIONS FROM GRANTS WORKING GROUP ON EARLY TRANSLATIONAL RESEARCH AWARDS APPLICATIONS.	141/240
CLOSED SESSION	201
CONSIDERATION OF NEW SCIENTIFIC MEMBERS FOR GRANTS WORKING GROUP.	72
CONSIDERATION OF EVALUATION PROCEDURES FOR PERFORMANCE EVALUATION FOR CHAIR, VICE-CHAIR, AND PRESIDENT.	203
CONSIDERATION OF FEDERAL LEGISLATION, H. R. 1427 AND H. R. 1548.	85
CONSIDERATION OF COMMENTS ON NIH DRAFT GUIDELINES FOR RESEARCH UTILIZING HUMAN EMBRYONIC STEM CELLS.	74
CONSIDERATION OF REQUEST FOR CIRM TO COSPON THE ANNUAL MEETING IF THE ISSCR	SOR 290
CONSIDERATION OF AMEMDED VERSION OF SB 471	188

183

1	LOS ANGELES, CALIFORNIA; WEDNESDAY, APRIL 29, 2009
2	09: 31 A.M.
3	
4	CHAIRMAN KLEIN: ALL RIGHT. IF YOU CAN
5	HEAR ON THESE MICS, FOR THE BOARD MEMBERS, YOU HAVE
6	TO PUSH TO GET THESE MICS ON. RIGHT NOW THEY'RE ALL
7	ON GREEN. SO IF YOU DON'T WANT CONVERSATIONS ABOUT
8	BREAKFAST TO BE PROJECTED THROUGH THE AUDITORIUM,
9	PUSH THE BUTTON AND TURN YOUR MICS OFF. SO IT WOULD
10	BE BEST IF EVERYONE, WHEN THEY'RE GOING TO SPEAK
11	THIS MORNING, TURN THE MIC ON AT THAT TIME.
12	WHILE WE ARE COLLECTING THE LAST FEW BOARD
13	MEMBERS, I'D LIKE TO RECOGNIZE THAT DR. ARLENE CHIU
14	IS IN THE AUDIENCE.
15	(APPLAUSE.)
16	CHAIRMAN KLEIN: ONE OF OUR GREAT AND
17	DISTINGUISHED ALUMS FOR THIS ORGANIZATION. AND
18	THANK YOU, DR. CHIU, FOR LEADING US IN THE EARLY
19	DAYS.
20	I WOULD LIKE TO SAY OUR FORMAT FOR THIS
21	MORNING HERE, AS SOON AS WE CAN GET SHERRY LANSING
22	AND A COUPLE OF OTHERS UP, IS TO OPEN THE PUBLIC
23	MEETING. WE'LL OPEN IT JUST FOR A FEW MINUTES. WE
24	HAVE AN ITEM THAT'S TIME SENSITIVE BECAUSE SENATOR
25	ROMERO HAS A HEARING AT 10:30. THERE IS A BILL THAT
	184

SHE HAS WHICH HAS NOW BEEN MODIFIED TO BE PART OF
THE EDUCATION CODE. SO IT'S NOT MODIFYING OUR BASIC
CHARTER OR OUR BASIC LEGISLATION. IT'S ISOLATED
FROM THAT. DOESN'T REQUIRE A 70-PERCENT VOTE IN
THAT MANNER. AND VERY CLEANLY IS INTENDED TO
STIMULATE STEM CELL EDUCATION IN THE STATE WITHOUT
MODIFYING OUR BASIC LEGISLATION.
SO WITH EVERYONE SEATED, QUESTION FOR
MELISSA. DO WE HAVE A QUORUM?
MS. KING: WELL, WHEN DR. FONTANA JOINS
US.
CHAIRMAN KLEIN: IF STAFF COULD SEND OUT A
SEARCH PARTY. WHAT I'M GOING TO DO IS OPEN THE
SESSION WHILE WE'RE WAITING FOR HER RETURN. AND I'D
LIKE TO AGAIN THANK DR. PULIAFITO AND THE SCIENTISTS
AT USC FOR THEIR FABULOUS PRESENTATION THIS MORNING.
(APPLAUSE.)
CHAIRMAN KLEIN: CERTAINLY DRY MACULAR
DEGENERATION AND THE GENERATION OF RETINAL PIGMENT
EPITHELIAL CELLS IS ON THE LEADING EDGE OF THE
FRONTIER, AND IT WAS A TREMENDOUS BRIEFING. YOU MAY
HAVE NOTICED WE'VE GONE TO A TWO-CAMERA FORMAT SO WE
GET HIGHER QUALITY VIDEOS SO THAT WE CAN PUT IT ON
OUR WEBSITE, AND IT CAN GO ON YOUTUBE TO EDUCATE
GENERALLY. IT ALSO CAN BE USED BY HIGH SCHOOL AND
185

	DIMMISTERS REPORTING SERVICE
1	COLLEGE SCIENCE CLASSES AS AN ILLUSTRATION OF THE
2	POTENTIAL APPLICATIONS. TRYING TO GET THROUGH DON'S
3	LEADERSHIP, DON GIBBONS' LEADERSHIP, MULTIPLE
4	APPLICATIONS FOR EVERY EXPENDITURE. AND BY STEPPING
5	UP THE QUALITY SLIGHTLY, WE GET A LOT GREATER VALUE
6	OUT OF OUR SPOTLIGHTS.
7	SO IN OPENING THIS MORNING, MELISSA, COULD
8	YOU LEAD US IN THE FLAG SALUTE, AND THEN WE'LL GO
9	THROUGH AND DO THE ROLL CALL.
10	(THE PLEDGE OF ALLEGIANCE.)
11	MS. KING: RICARDO AZZIZ. ROBERT PRICE
12	FOR ROBERT BIRGENEAU.
13	DR. PRI CE: HERE.
14	MS. KING: FLOYD BLOOM. DAVID BRENNER.
15	DR. BRENNER: HERE.
16	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
17	DR. LEVIN: HERE.
18	MS. KING: MARSHA CHANDLER. MARCY FEIT.
19	MICHAEL FRIEDMAN.
20	DR. FRIEDMAN: HERE.
21	MS. KING: LEEZA GIBBONS.
22	MS. GIBBONS: HERE.
23	MS. KING: MICHAEL GOLDBERG. SAM HAWGOOD.
24	BOB KLEIN.
25	CHAIRMAN KLEIN: HERE.
	10/
	186

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

ı	
1	MS. KING: SHERRY LANSING.
2	MS. LANSING: HERE.
3	MS. KING: GERALD LEVEY.
4	DR. LEVEY: HERE.
5	MS. KING: TED LOVE.
6	DR. LOVE: HERE.
7	MS. KING: ED PENHOET.
8	DR. PENHOET: HERE.
9	MS. KING: PHIL PIZZO. CLAIRE POMEROY.
10	FRANCI SCO PRI ETO.
11	DR. PRI ETO: HERE.
12	MS. KING: CARMEN PULIAFITO.
13	DR. PULI AFI TO: HERE.
14	MS. KING: ROBERT QUINT.
15	DR. QUINT: HERE.
16	MS. KING: JEANNIE FONTANA FOR JOHN REED.
17	DR. FONTANA: HERE.
18	MS. KING: DUANE ROTH.
19	MR. ROTH: HERE.
20	MS. KING: JOAN SAMUELSON.
21	MS. SAMUELSON: HERE.
22	MS. KING: DAVID SERRANO-SEWELL.
23	MR. SERRANO-SEWALL: HERE.
24	MS. KING: JEFF SHEEHY.
25	MR. SHEEHY: HERE.
	187

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

MS. KING: JON SHESTACK. OSWALD STEWARD.
AND ART TORRES.
MR. TORRES: HERE.
MS. KING: WE DO HAVE A QUORUM.
CHAIRMAN KLEIN: THANK YOU, MELISSA. AND
THANK YOU, MELISSA AND JENNA, WHEREVER SHE IS, FOR
ORGANIZING ANOTHER GREAT MEETING WITH A TREMENDOUS
AMOUNT OF COORDINATION THAT NEEDS TO HAPPEN TO GET
US ALL HERE.
I'D LIKE TO GO IMMEDIATELY TO A QUICK
PRESENTATION BY DON GIBBONS ON A BILL PENDING IN THE
STATE LEGISLATURE THAT IS UP FOR A HEARING IN ABOUT
AN HOUR OR 50 MINUTES FROM NOW.
MR. GIBBONS: WHILE MELISSA PULLS UP MY
ONE SLIDE, I'M GOING TO TELL YOU A 30-SECOND HISTORY
OF THIS BILL. LATE LAST FALL WHEN THE CALIFORNIA
BUDGET WAS IN COMPLETE MELTDOWN, PRESIDENT PRO TEM
STEINBERG'S STAFF CALLED ME AND SAID HE IS VERY
CONCERNED ABOUT EDUCATION GETTING THE SHORT END OF
THE STICK. IS THERE ANY WAY WE CAN TIE EDUCATION TO
THE NEW BUDDING ECONOMIES IN CALIFORNIA INCLUDING
STEM CELLS?
SO I TOLD HIM ABOUT THE INITIATIVES I HAD
PLANNED. THEY IMMEDIATELY FELT THAT THOSE WERE VERY
GOOD IDEAS, AND THEY WANT TO SUPPORT THEM THROUGH
188

1	LEGISLATION. SO WE'VE BEEN BACK AND FORTH WITH
2	THEM. ART TORRES CAME ON AT A VERY GOOD TIME TO
3	HELP MOVE THIS IN THE RIGHT DIRECTION TO WHERE IT'S
4	A STRONG VOTE OF SUPPORT WITH NO UNFUNDED MANDATES
5	FOR THE PEOPLE INVOLVED, RELYING VERY HEAVILY ON
6	EXISTING PROGRAMS.
7	SO SENATOR ROMERO IS HEAD OF THE EDUCATION
8	COMMITTEE, HAS BEEN CARRYING THE BALL FOR SENATOR
9	STEINBERG ON THIS, AND SHE'S BEEN VERY, VERY
10	SUPPORTI VE AS HAS HER STAFF.
11	THEY'LL BE HEARING THREE BILLS THIS
12	MORNING IN SACRAMENTO DEALING WITH DIFFERENT ASPECTS
13	OF TYING EDUCATION TO NEW PARTS OF THE CALIFORNIA
14	ECONOMY.
15	SO BIO DOES SUPPORT THIS BILL NOW. THEY
16	ORIGINALLY DID NOT. THEY DO SUPPORT IT IN ITS
17	CURRENT FORM. SO, AGAIN, AS I MENTIONED LAST NIGHT,
18	THE 2006 STRATEGIC PLAN CALLED FOR CREATING
19	EDUCATION MATERIALS. I HAVE A CONTRACT IN PLACE
20	WITH LAUREL BARCHAS, WHO I MENTIONED YESTERDAY
21	EVENING, TO DO SOME INVESTIGATIVE PHASES OF WHAT
22	WOULD BE DOABLE. I MENTIONED SENATOR STEINBERG AND
23	ROMERO HAVE REALLY BEEN INCREDIBLY SUPPORTIVE IN
24	THIS. AND THE STEM CELL BILL ITSELF WOULD DO VERY
25	SPECIFIC THINGS: PROMOTE LINKAGES BETWEEN CIRM

1	THE RELATED BIOTECH INITIATIVES, THE INDUSTRY IS
2	VERY GOOD IN THIS FIELD, HAVE A LOT OF INITIATIVES
3	IN VARIOUS PARTS OF THE STATE TO LINK WITH HIGH
4	SCHOOLS, SO LINK WITH THEM AND THEN BRING IN THE
5	STATE SCHOOLS.
6	IT WILL MANDATE STEM CELL SCIENCE IN THE
7	HIGH SCHOOL CURRICULUM. AGAIN, THE BOARD OF
8	EDUCATION VOTED TO DO THAT MARCH 11TH. THIS PUTS IT
9	IN STATUTE, WHICH IS REALLY IMPORTANT FOR SOME OF
10	THE MORE CONSERVATIVE PARTS OF THE STATE. THE STATE
11	BOARD OF EDUCATION CAN DICTATE CURRICULUM IN ONE
12	THROUGH EIGHT. THEY CANNOT IN THE HIGH SCHOOLS. SO
13	HAVING THIS IN LEGISLATION IS IMPORTANT, SO IT
14	DOESN'T GET BUMPED OUT IN MORE CONSERVATIVE
15	DI STRI CTS.
16	IT FOCUSES ON WORKING WITH EXISTING
17	PROGRAMS. AGAIN, IT WANTS TO STRENGTHEN EXISTING
18	PROGRAMS WITH THE NEW SCIENCE OF STEM CELLS AND
19	OTHER ASPECTS OF BIOTECHNOLOGY, NOT ADDING NEW
20	LAYERS. AND THE ONE THING THAT IMPACTS US IN A VERY
21	REMOTE FASHION, IT ASKS THE ICOC TO CONSIDER
22	EDUCATION AND WORKFORCE ISSUES IN THE ALLOCATION OF
23	FUNDS. IT'S SOMETHING YOU ALREADY DO. OBVIOUSLY
24	THE BRITISH PROGRAM DID THAT IN SPAIN, SO IT'S
25	NOTHING NEW FOR YOU. IT'S MORE OF A REMINDER TO DO
	100

1	WHAT YOU ALREADY HAVE A PENCHANT FOR DOING.
2	I HAVE A COLLEAGUE IN SACRAMENTO STANDING
3	BY. THEY WOULD LOVE TO HAVE A LETTER OF SUPPORT FOR
4	US WHICH WE HAVE DRAFTED. IT'S VERY SIMPLE. THE
5	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE AND
6	ITS GOVERNING BOARD WOULD LIKE TO EXPRESS THEIR
7	SUPPORT FOR THE CALIFORNIA STEM CELL AND
8	BIOTECHNOLOGY EDUCATION AND WORKFORCE DEVELOPMENT
9	ACT. THE BURGEONING FIELD OF REGENERATIVE MEDICINE
10	WILL REQUIRE AN EDUCATED PUBLIC AND A WELL-TRAINED
11	WORKFORCE IN ORDER TO REACH ITS FULL POTENTIAL.
12	THIS BILL HAS THE POTENTIAL TO HAVE A SIGNIFICANT
13	POSITIVE IMPACT ON THOSE GOALS.
14	SO, ART, I'D ASK YOU TO RUN THIS THROUGH A
15	MOTION OR
16	CHAIRMAN KLEIN: ART, WHY DON'T YOU GO
17	STRAIGHT INTO A QUICK DISCUSSION OF THIS BILL. IT
18	MIGHT BE GOOD TO PUT A MOTION ON THE TABLE AS A
19	BASIS OF DISCUSSION.
20	MR. TORRES: SO MOVED.
21	MR. HARRISON: ONE PROCEDURAL MATTER. THE
22	FACT THAT THE SENATE EDUCATION COMMITTEE WAS GOING
23	TO BE MEETING TODAY CAME TO OUR ATTENTION AFTER THE
24	AGENDA WAS POSTED. SO WE'VE ADDED THIS ITEM TO THE
25	AGENDA MORE THAN 48 HOURS AGO. UNDER BAGLEY-KEENE,
	101

1	IN ORDER FOR THE BOARD TO CONSIDER IT, THE BOARD HAS
2	TO MAKE A DETERMINATION BY TWO-THIRDS OF THE MEMBERS
3	OF THE BOARD THAT THE MATTER CAME TO THE BOARD'S
4	ATTENTION AFTER THE AGENDA WAS POSTED, AND THAT IT'S
5	NECESSARY FOR THE BOARD TO TAKE ACTION ON IT NOW,
6	WHICH, GIVEN THE PENDENCY OF THE EDUCATION COMMITTEE
7	HEARING THIS MORNING, IS RATHER OBVIOUS; BUT
8	NONETHELESS, WE NEED TO GO THROUGH THAT FORMALITY.
9	MR. TORRES: WELL, THAT'S THE FIRST MOTION
10	THEN. SO MOVED.
11	MS. LANSING: SECOND.
12	CHAIRMAN KLEIN: SHERRY LANSING WAS THE
13	SECOND. AND DISCUSSION ON PUTTING THIS ON THE
14	AGENDA? I CAN ATTEST FROM THE EXECUTIVE COMMITTEE
15	THAT WE HAD REALLY NO NOTICE THIS WAS GOING TO BE ON
16	A HEARING. ANY ADDITIONAL DISCUSSION ON THAT? ANY
17	DISCUSSION FROM THE PUBLIC ON THAT? SEEING NONE,
18	CALL THE QUESTION. ALL IN FAVOR? OPPOSED? THAT
19	MATTER PASSES.
20	MS. KING: I WILL CALL MEMBERS WHO ARE ON
21	THE PHONE.
22	MARCY FEIT.
23	MS. FEIT: YES.
24	MS. KING: CLAIRE POMEROY.
25	DR. POMEROY: YES.
	192

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

ĺ	Diministers Reforming Service
1	MS. KING: PHIL PIZZO.
2	DR. PI ZZO: YES.
3	MS. KING: I UNDERSTAND MICHAEL GOLDBERG
4	IS WITH YOU. MICHAEL GOLDBERG.
5	MR. GOLDBERG: YES.
6	MS. KING: THANK YOU. THAT MOTION
7	CARRI ES.
8	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
9	MR. TORRES: MR. CHAIRMAN, MY SECOND
10	MOTION IS TO APPROVE A POSITION OF THIS BOARD OF
11	SENATE 471 BY SENATORS ROMERO AND STEINBERG.
12	CHAIRMAN KLEIN: POSITION IN SUPPORT.
13	MR. TORRES: YES.
14	CHAIRMAN KLEIN: IS THERE A SECOND?
15	MS. LANSING: SECOND.
16	CHAIRMAN KLEIN: IS THERE DISCUSSION?
17	MR. TORRES: YES. I JUST WANT TO THANK
18	THIS INCREDIBLE STAFF. IN MY 20 YEARS IN THE
19	LEGISLATURE, I HAD GREAT STAFF. BUT, BOY, COMING
20	INTO THIS INSTITUTION, IT'S BEEN PHENOMENAL. AND IT
21	IS A TEAM EFFORT. THERE ARE NO TAKING CREDIT FOR
22	SOMETHING. IT'S A TEAM EFFORT. AND I JUST REALLY,
23	REALLY RESPECT THAT.
24	DON, THANK YOU FOR YOUR HELP IN THIS.
25	IAN, IN TERMS OF TALKING WITH THE STAFF.
	193

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	(APPLAUSE.)
2	MR. TORRES: LET ME TELL YOU IT MAKES LIFE
3	SO MUCH EASIER AND SO MUCH MORE EFFICIENT WHEN WE'RE
4	ALL ON THE SAME PAGE, NOT LOOKING OVER OUR
5	SHOULDERS, BUT LOOKING FORWARD. SO I WANT TO THANK
6	YOU.
7	I ALSO WANT TO THANK SENATOR ROMERO FOR
8	WORKING WITH US ON THIS AND MAKING SURE THAT THE
9	AMENDMENTS WERE APPROPRIATE SO THAT IT WAS
10	CONSISTENT WITH OUR VISION AND OUR MESSAGE. I ALSO
11	WANT ALSO THANK SENATOR ALQUIST, THE NEW CHAIR OF
12	THE HEALTH COMMITTEE, FOR DROPPING HER LEGISLATION,
13	IN SHORT, BECAUSE OF CONCERNS WE HAD WITH IT.
14	SO I INVITED HER TO COME TO THE SAN
15	FRANCISCO HEADQUARTERS TO GET A BRIEFING, AND SHE'S
16	ALL EXCITED ABOUT DOING THAT, SO SHE'LL BE COMING
17	SHORTLY WITH HER STAFF. IT'S PART OF THE
18	COMMUNICATIONS WITH THE POLICYMAKERS IN THIS STATE
19	AND OBVIOUSLY AT THE FEDERAL LEVEL, WHICH WE'LL
20	DISCUSS LATER AS WELL, THAT IS SO IMPORTANT TO
21	ENSURE THE CONSISTENCY OF MESSAGE AND ENSURE OUR
22	SUCCESS FOR AT THE END OF THE DAY, IT'S ALL ABOUT
23	THE PATIENTS.
24	CHAIRMAN KLEIN: THANK YOU VERY MUCH, ART.
25	I'D LIKE TO SECOND THAT. SENATOR GLORIA ROMERO WAS
	104

1	EXTREMELY RESPONSIVE WHEN WE POINTED OUT THE
2	PROBLEMS OF TRYING TO AMEND OUR STATUTE TO INCLUDE
3	ISSUES LIKE THIS THAT ARE VALUABLE TO THE STATE, BUT
4	NOT CRITICALLY INTEGRATED INTO OUR LEGISLATION,
5	WHICH HAS, OF COURSE, PROBLEMS IN THAT PROCESS IN
6	THAT YOU'VE GOT TO GET A 70-PERCENT VOTE, AND THERE
7	CAN BE OTHER FORCES THAT WANT TO PUT SOME NONRELATED
8	AMENDMENTS INTO OUR LEGISLATION. SO SHE IMMEDIATELY
9	RESPONDED, PUT THIS IN THE EDUCATION CODE WHERE IT'S
10	TOTALLY APPROPRIATE. AND WE THANK HER FOR BEING SO
11	RESPONSI VE.
12	ANY OTHER DISCUSSION? ANY PUBLIC COMMENT?
13	DR. LOVE: I HAVE ONE QUESTION. WHAT FORM
14	DOES MANDATED STEM CELL SCIENCE IN THE HIGH SCHOOL
15	CURRICULUM TAKE? I MEAN I CAN SEE IF THERE AREN'T
16	MATERIALS PROVIDED WHERE A MANDATE WITHOUT RESOURCES
17	COULD BE A CHALLENGE. SO IS THERE A PLAN TO
18	ULTIMATELY PROVIDE THE RESOURCES SO THAT THE SCHOOL
19	SYSTEMS HAVE THOSE AVAILABLE?
20	MR. GIBBONS: THE AMENDMENT IN THE CODE
21	THE BOARD OF EDUCATION VOTED ON MARCH 11TH JUST SAYS
22	THAT BURGEONING FIELDS OF SCIENCE, INCLUDING STEM
23	CELLS, SHOULD BE IN THE CURRICULUM. IT DOESN'T TALK
24	ABOUT LAB COMPONENTS. WE KNOW THAT WOULD BE VERY
25	DIFFICULT TO CELL CULTURE ISSUES. AND IT IS THE
	105

1	ULTIMATE GOAL OF CIRM TO HELP DEVELOP CURRICULA
2	PIECES THAT WILL BE PLUG AND PLAY FOR THE TEACHERS.
3	OUR GOAL IS TO LOOK AT HOW DEVELOPMENTAL BIOLOGY IS
4	CURRENTLY TAUGHT. WE GUESS IT'S PROBABLY FAIRLY
5	PEDANTIC AND SOMEWHAT BORING. WE THINK WE CAN USE
6	CASE EXAMPLES OF STEM CELL BIOLOGY, LIKE THE ONE
7	THIS MORNING, AND TEACH DEVELOPMENTAL BIOLOGY IN A
8	MUCH MORE COMPELLING FASHION.
9	THERE WAS A HIGH SCHOOL MEMBER ADDED TO
10	THE BOARD AT THE MARCH 11TH BOARD MEETING. HER
11	FIRST MEETING, VERY EXCITED. AND WHEN I MENTIONED
12	WE MIGHT WANT TO DO THIS IN A MORE EXCITING FASHION
13	WITH STEM CELLS, SHE'S NODDING HER HEAD YES, YES,
14	YES. I THINK WE CAN DO THAT.
15	THE ULTIMATE RFP, I MENTIONED IT LAST
16	NIGHT, FOR CURRICULUM DEVELOPMENT WOULD POTENTIALLY
17	DO THAT. THE GROUP WE WERE INTRODUCED TO THROUGH
18	THE MEETING THAT DUANE LED OFF WITH LAST SATURDAY IN
19	SAN DIEGO, BIO BRIDGE, WE DID PUT A GRANT
20	APPLICATION OR A LETTER OF INTENT INTO THE
21	DEPARTMENT OF EDUCATION MONDAY NIGHT. SO WE MIGHT
22	BE ABLE TO TAKE IT OUT OF CIRM'S BUDGET AND PUT IT
23	IN THE FEDERAL BUDGET.
24	DR. LOVE: I WAS JUST GOING TO POINT OUT I
25	DO THINK THAT THERE ARE A LOT OF COMPLEXITIES AND

	DARRISTERS REPORTING SERVICE
1	CONTROVERSIES IN STEM CELL RESEARCH, AND I THINK
2	THAT MAKING SURE THAT IT'S DONE PROPERLY AND
3	CONSISTENTLY WOULD BE AN OBJECTIVE, AT LEAST I WOULD
4	THINK, WOULD BE IMPORTANT TO MAKE SURE THAT THE
5	MANDATE IS ACTUALLY HAVING THE APPROPRIATE EFFECT.
6	MR. GIBBONS: WE WOULD EXPECT TO PILOT
7	TEST ANYTHING FIRST.
8	CHAIRMAN KLEIN: OKAY. ADDITIONAL
9	QUESTIONS? ADDITIONAL COMMENTS? I'D LIKE TO CALL
10	THE QUESTION. BECAUSE WE HAVE MEMBERS ON THE PHONE,
11	IT HAS TO BE A ROLL CALL VOTE; IS THAT CORRECT?
12	MR. HARRISON: NO. IT CAN BE A VOICE VOTE
13	OF THE MEMBERS PRESENT, BUT THOSE ON THE PHONE HAVE
14	TO BE POLLED INDIVIDUALLY.
15	CHAIRMAN KLEIN: THANK YOU, COUNSEL. ALL
16	IN FAVOR? OPPOSED? AND, MELISSA, PLEASE CALL THE
17	ROLL ON THOSE ON THE PHONE.
18	MS. KING: MARCY FEIT.
19	MS. FEIT: YES.
20	MS. KING: MICHAEL GOLDBERG.
21	MR. GOLDBERG: YES.
22	MS. KING: PHIL PIZZO.
23	DR. PI ZZO: YES.
24	MS. KING: CLAIRE POMEROY.
25	DR. POMEROY: YES.
	107
	197

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
2	MS. KING: MOTION CARRIES.
3	CHAIRMAN KLEIN: AT THIS POINT I'D LIKE TO
4	VERY QUICKLY, BEFORE WE GO INTO EXECUTIVE SESSION ON
5	THE TRANSLATIONAL GRANTS, CALL THE ATTENTION OF THE
6	BOARD THROUGH THE ABBREVIATED CHAIRMAN'S REPORT THAT
7	THE STAFF, AS ART SAYS, IS PHENOMENAL. AND IN THE
8	CASE OF THE FINANCINGS THAT WERE JUST COMPLETED,
9	JAMES HARRISON AND LYNN HARWELL WERE AT THE CORE OF
10	THAT EFFORT. MELISSA DID A PHENOMENAL JOB OF
11	COORDINATING ALL OF US AND KEEPING US INTEGRATED AND
12	MOVING ON THIS. ART IS WORKING ON A THIRD PHASE TO
13	THIS INITIATIVE.
14	WE ESSENTIALLY HAVE ABOUT EIGHT DIFFERENT
15	CONCURRENT FINANCING INITIATIVES MOVING. WHAT WE'VE
16	DONE IN THIS FINANCING THAT JUST CLOSED OR SERIES OF
17	DIFFERENT SEGMENTS OF FINANCING THAT JUST CLOSED IS
18	ADDRESSED FOUR OF THOSE OPTIONS OF THE EIGHT
19	CONCURRENT PATHS WE'RE FOLLOWING.
20	I WOULD LIKE, THOUGH, TO TAKE A MOMENT AND
21	GIVE JAMES HARRISON, LYNN HARWELL, AND MELISSA A
22	HAND OF APPLAUSE.
23	(APPLAUSE.)
24	DR. PENHOET: AND A MOMENT TO GIVE OUR
25	CHAIR A HAND OF APPLAUSE. THANK YOU, BOB.
	100
	198

1	(APPLAUSE.)
2	CHAIRMAN KLEIN: HOWEVER DEDICATED OUR
3	STAFF IS, WE KNOW WE WOULDN'T BE SUCCESSFUL EXCEPT
4	FOR THE LEADERSHIP OF THE GOVERNOR'S OFFICE, THE
5	GOVERNOR'S DEPARTMENT OF FINANCE, THE TREASURER'S
6	OFFICE ALL WORKING IN UNISON. IT'S GREAT TO HAVE A
7	CONSENSUS POSITION BECAUSE IN TIMES OF SCARCE
8	RESOURCES, IF THERE'S ANY TURBULENCE IN THE
9	POSITIONS, IT KNOCKS OUT ANY REQUEST THAT YOU HAVE.
10	SO TO HAVE CONSENSUS ACROSS THOSE STAFFS IS
11	EXTREMELY IMPORTANT, AND THEY WORKED WITH US AT
12	EVERY LEVEL.
13	ADDITIONALLY, CHAS CARDALL AT ORRICK WAS
14	VERY HELPFUL TO US IN PROVIDING BACKUP LEGAL SUPPORT
15	FOR OUR POSITION, THAT 195 MILLION OF THE FUNDS THAT
16	WERE PREVIOUSLY COMMITTED THROUGH OUR POOLED MONEY
17	INVESTMENT FUND PROGRAM OF 250 MILLION PUT INTO THE
18	BUILD AMERICA BOND PROGRAM FOR WHICH THE STATE GOT A
19	35-PERCENT FEDERAL SUBSIDY. MOVING THAT 195 MILLION
20	OPENED UP \$200 MILLION IN DISCRETIONARY FUNDS IN THE
21	TAXABLE PART OF THE PROGRAM THAT DOESN'T QUALIFY FOR
22	THE BUILD AMERICA PROGRAM. AND, OF COURSE, WE'RE
23	VERY THANKFUL TO GET 200 MILLION OUT OF THAT SEGMENT
24	FOR OUR GRANTS AND LOANS.
25	SO IT'S BEEN A TREMENDOUS TEAM EFFORT AND
	100

1	IT WILL CONTINUE TO BE. I WOULD EMPHASIZE FOR THE
2	BOARD AND THE PUBLIC THAT THERE WILL MOST PROBABLY
3	BE A PERIOD OF CONTINUED TURBULENCE IN CALIFORNIA'S
4	PUBLIC BOND MARKETS HERE FOR THE NEXT THREE YEARS OR
5	SO. PART OF IT BECAUSE OF NATIONAL ECONOMIC ISSUES,
6	PART OF IT BECAUSE OF STATE ECONOMIC ISSUES, PART OF
7	IT BECAUSE OF RESTRUCTURING THAT'S TAKING PLACE IN
8	THE STATE BUDGET PROCESS. AND PROBABLY UNTIL 2011
9	THAT RESTRUCTURING IN THE STATE BUDGET PROCESS AND
10	THE VOTING PERCENTAGES IT TAKES TO GET A BUDGET
11	PASSED WILL NOT CHANGE.
12	SO IT WILL CONTINUE TO BE IMPORTANT AS THE
13	STRESSES MOUNT FOR US TO EXECUTE ON OUR PRIVATE
14	PLACEMENT AUTHORITY UNLESS WE CAN BENEFIT FURTHER
15	FROM ADDITIONAL FEDERAL SUBSIDIES AND FEDERAL
16	GUARANTEES OF STATE PUBLIC ISSUANCES, ALL OF WHICH
17	WE'RE ALSO WORKING ON.
18	BUT CERTAINLY ART TORRES HAS BEEN
19	TREMENDOUS IN HELPING ADVANCE OUR PRIVATE PLACEMENT
20	OPPORTUNITIES AND LOOKING AT PENSION FUNDS AS
21	PRIVATE PLACEMENT PURCHASERS. NORMALLY THEY'RE
22	PURCHASERS OF STATE BONDS BECAUSE THEY'RE IN THE
23	TAXABLE MARKET. THIS MOVEMENT OF THE TREASURER'S
24	OFFICE AND THE STATE INTO THE TAXABLE MARKET IS VERY
25	BENEFICIAL TO US AND PROVIDES A GREAT DEAL MORE
	200

1	DEPTH THAN THE TAX-EXEMPT MARKET.
2	AS WE GO FORWARD AND GET AN IRS TAX
3	OPINION ON OUR GRANTS AS BEING QUALIFIED FOR
4	TAX-EXEMPT BONDS, ALL OF THE FUNDS THAT WE PUT OUT
5	IN GRANTS CAN MOVE INTO THE BUILD AMERICA BOND
6	PROGRAM WITH A FEDERAL SUBSIDY. SO THIS IS GOING TO
7	BE A DYNAMIC, EVOLVING PROCESS, BUT WE'LL CONTINUE
8	TO MOVE FORWARD ON THE PRIVATE PLACEMENT SIDE TO
9	AUGMENT THE FUNDS WE'VE BEEN SO FORTUNATE TO BENEFIT
10	BY.
11	WITH THAT, I'D LIKE TO MOVE TO AN
12	EXECUTIVE SESSION. I'D LIKE JAMES HARRISON TO READ
13	THE PROPER STATUTORY AUTHORITY FOR THE EXECUTIVE
14	SESSION ON THE TRANSLATIONAL GRANTS. JAMES.
15	MR. HARRISON: THE BOARD WILL NOW BE
16	CONVENING IN CLOSED SESSION TO CONSIDER CONFIDENTIAL
17	AND INTELLECTUAL PROPERTY OR WORK PRODUCT AND
18	PREPUBLICATION CONFIDENTIAL SCIENTIFIC RESEARCH OR
19	DATA RELATING TO THE EARLY TRANSLATIONAL AWARDS
20	APPLICATIONS UNDER HEALTH AND CODE SECTION
21	125290.30(D).
22	MS. KING: I WOULD JUST LIKE TO LET THE
23	MEMBERS WHO ARE JOINING THE MEETING KNOW OR TO
24	REMIND YOU THAT FOR CLOSED SESSIONS DURING GRANT
25	REVIEW, YOU CANNOT JOIN BY PHONE AS PER OUR POLICY.
	201

1	SO THOSE OF YOU WHO ARE ON THE PHONE, I WILL LOOK TO
2	THE CHAIR TO LET US KNOW APPROXIMATELY HOW LONG THE
3	CLOSED SESSION WILL TAKE SO THAT YOU CAN HANG UP
4	NOW, TAKE A LITTLE FREE TIME, SORRY ABOUT THAT, AND
5	REJOIN US WHEN WE RECONVENE IN OPEN SESSION.
6	CHAIRMAN KLEIN: SO I'D LIKE CONCURRENCE
7	HERE OF JEFF SHEEHY, AS THE VICE CHAIR OF THE GRANTS
8	WORKING GROUP. JEFF, DO YOU THINK WE COULD AIM FOR
9	AN HOUR?
10	MR. SHEEHY: SOUNDS LIKE A PLAN TO ME.
11	CHAIRMAN KLEIN: ALL RIGHT. SO WE WILL
12	AIM FOR AN HOUR. WE WILL CONTINUE TO KEEP THOSE
13	MEMBERS ON THE PHONE UPDATED. WE THANK THEM FOR
14	THEIR PARTICIPATION, AND WE PROMISE THEM AN EXCITING
15	SESSION TO RETURN TO.
16	WITH THAT, IF THE STAFF WOULD SHOW US
17	WHERE WE ARE ADJOURNING TO. WE'RE GOING TO FOLLOW
18	JENNA AT THE TOP OF THE STAIRS. BRING YOUR FILES
19	WITH YOU, PLEASE.
20	(THE BOARD THEN WENT INTO CLOSED
21	SESSION, NOT REPORTED, NOR HEREIN TRANSCRIBED. THE
22	FOLLOWING PROCEEDINGS WERE THEN HAD IN OPEN
23	SESSI ON:)
24	CHAIRMAN KLEIN: THANK YOU FOR YOUR
25	PATIENCE. WE'RE RECONVENING THIS MEETING. THE
	202
	202

1	CHAIR OF THE GOVERNANCE COMMITTEE WITH CONCURRENCE
2	OF THE ACTING VICE CHAIR OF THE GRANTS WORKING
3	GROUP, WHO WAS PRESENT AT THIS PARTICULAR SESSION,
4	HAVE REQUESTED THAT WE HANDLE ONE QUICK ITEM BEFORE
5	WE GO INTO THE GRANT REVIEW BECAUSE SHERRY LANSING
6	HAS TO LEAVE AT A TIME SPECIFIC. SO, SHERRY, IF I
7	COULD ASK YOU PLEASE TO INTRODUCE THIS ITEM, AND I
8	WOULD SAY I HOPE THAT IT'S A SHORT TIMEFRAME BECAUSE
9	OF THE INDIVIDUALS THAT WORKED ON IT, I DON'T KNOW
10	OF ANY DISAGREEMENT, BUT WE CERTAINLY STAND TO BE
11	INFORMED BY THE WHOLE BOARD.
12	MS. KING: BEFORE SHE DOES, I WOULD JUST
13	LIKE TO CHECK AND SEE WHO WE HAVE ON THE PHONE.
14	MARCY FEIT, ARE YOU ON THE LINE? MICHAEL GOLDBERG.
15	MR. GOLDBERG: HERE.
16	MS. KING: PHIL PIZZO.
17	DR. PI ZZO: HERE.
18	MS. KING: AND CLAIRE POMEROY.
19	DR. POMEROY: HERE.
20	CHAIRMAN KLEIN: SO, SHERRY, WOULD YOU
21	LIKE CLAIRE TO LEAD ON THIS ITEM?
22	MS. LANSING: YES. I THINK, CLAIRE, AS
23	LONG AS YOU'RE ON THE PHONE AND PUT SO MUCH HARD
24	WORK IN THIS, I WOULD LOVE YOU TO EXPLAIN THE ITEM.
25	AND WE ARE GOING TO TURN IT OVER TO JAMES HARRISON.
	203

203

1	BOARD: THE GOVERNANCE, FINANCE, AND LEGISLATIVE
2	SUBCOMMITTEES, THE CHAIRS OF THE TWO TASK FORCES,
3	THE INTELLECTUAL PROPERTY TASK FORCE AND THE BIOTECH
4	LOAN TASK FORCE, AND THE VICE CHAIRS OR ACTING VICE
5	CHAIR OF THE THREE WORKING GROUPS; THAT IS, THE
6	STANDARDS, FACILITIES, AND GRANTS WORKING GROUP, IN
7	ADDITION TO TWO MEMBERS AT LARGE OF THE BOARD
8	APPOINTED BY THE BOARD AND THE CHAIR AND THE VICE
9	CHAIRS OF THE BOARD, OF COURSE, PROVIDED THAT THEY
10	WOULD NOT PARTICIPATE IN THE SUBCOMMITTEE'S
11	EVALUATION OF THEMSELVES.
12	THE SECOND STEP OF THE PROCESS WOULD BE
13	FOR THE SUBCOMMITTEE TO DEVELOP WRITTEN PERFORMANCE
14	OBJECTIVES AND DELIVERABLES FOR THE CHAIR, THE VICE
15	CHAIRS, AND THE PRESIDENT, WITH INPUT FROM THE
16	SUBJECT OF THE EVALUATION. THE SUBCOMMITTEE WOULD
17	THEN TAKE THE DRAFT PERFORMANCE OBJECTIVES AND
18	DELIVERABLES AND PRESENT THEM TO THE BOARD FOR ITS
19	EVALUATION AND APPROVAL.
20	BASED ON THOSE APPROVED PERFORMANCE
21	OBJECTIVES AND DELIVERABLES, THE THIRD STEP WOULD BE
22	FOR THE SUBCOMMITTEE TO CONDUCT AN ANNUAL EVALUATION
23	OF THE CHAIR, THE VICE CHAIRS, AND THE PRESIDENT AND
24	PREPARE A DRAFT REPORT SUMMARIZING ITS EVALUATION.
25	THE SUBJECT OF THE EVALUATION WOULD HAVE AN

1	OPPORTUNITY TO REVIEW THE DRAFT REPORT AND SUBMIT
2	ANY WRITTEN COMMENTS AND WOULD HAVE AN OPPORTUNITY
3	TO MEET WITH THE SUBCOMMITTEE IN CLOSED SESSION TO
4	DISCUSS HIS OR HER PERFORMANCE AS WELL.
5	THE FOURTH STEP WOULD ENTAIL A MEETING OF
6	THE BOARD, WHICH WOULD, FIRST, INCLUDE A MEETING
7	WITH THE SUBJECT OF THE EVALUATION IN CLOSED SESSION
8	TO DISCUSS THE CHAIR, THE VICE CHAIRS', OR THE
9	PRESIDENT'S, RESPECTIVELY, PERFORMANCE AND
10	OBJECTIVES FOR THE NEXT YEAR. THE BOARD WOULD THEN,
11	AFTER EXCUSING THE INDIVIDUAL, ASK THE SUBCOMMITTEE
12	TO PRESENT ITS DRAFT REPORT ALONG WITH ANY WRITTEN
13	COMMENTS SUPPLIED BY THE INDIVIDUAL WHO'S THE
14	SUBJECT OF THE REPORT. THE BOARD WOULD THEN
15	DELIBERATE AND COME UP WITH ITS FINAL CONCLUSION,
16	WHICH WOULD THEN BE TRANSMITTED TO THE INDIVIDUAL
17	WHO'S THE SUBJECT OF THE EVALUATION IN THE FOLLOWING
18	MANNER.
19	FOR THE CHAIR, THE CHAIR OF THE GOVERNANCE
20	SUBCOMMITTEE AND ANOTHER MEMBER OF THE BOARD
21	DESIGNATED BY THE BOARD WOULD REPORT TO THE CHAIR ON
22	THE BOARD'S CONCLUSION WITH RESPECT TO HIS OR HER
23	PERFORMANCE. FOR THE VICE CHAIR, THE TEAM WOULD BE
24	COMPRISED OF THE CHAIR OF THE ICOC AND THE CHAIR OF
25	THE GOVERNANCE SUBCOMMITTEE. AND FOR THE PRESIDENT,
	206

1	THE CHAIR OF THE ICOC AND ANOTHER MEMBER DESIGNATED
2	BY THE BOARD WOULD COMMUNICATE THE RESULTS OF THE
3	BOARD'S PERFORMANCE EVALUATION TO THE PRESIDENT.
4	THAT'S THE BRIEF SUMMARY OF THE PROPOSAL
5	BEFORE YOU. I'D BE HAPPY TO ANSWER ANY QUESTIONS.
6	MS. LANSING: ARE THERE ANY QUESTIONS?
7	DR. AZZIZ: I HAVE JUST ONE QUESTION.
8	REGARDING THE AT LARGE MEMBERS, THOSE ARE ICOC
9	MEMBERS?
10	MR. HARRISON: CORRECT.
11	MS. LANSING: YES, OF COURSE. THANK YOU
12	FOR THAT CLARIFICATION.
13	DR. LEVEY: WHO'S GOING TO PUT TOGETHER
14	SORT OF THE TEMPLATE FOR PERFORMANCE EVALUATION?
15	MR. HARRISON: THE TEMPLATE WOULD BE
16	DEVELOPED BY THE EVALUATION SUBCOMMITTEE WITH THE
17	ASSISTANCE OF STAFF. CIRM ALREADY HAS AN EXISTING
18	EMPLOYEE EVALUATION FORM, WHICH IS MODELED ON UC'S,
19	WHICH WOULD PROBABLY FORM THE BASIS FROM WHICH WE
20	WOULD START.
21	DR. LEVEY: THE HOSPITALS IN THE UC SYSTEM
22	HAVE A VERY GOOD ONE.
23	MR. HARRISON: WE WOULD BE HAPPY TO REVIEW
24	OTHER MODELS.
25	MS. LANSING: WE WERE TAKING IT OFF THE
	207
	201

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	UC. I DON'T KNOW IF WE TOOK IT OFF SPECIFICALLY OF
2	THE HOSPITALS, BUT WE'D LOVE IT IF YOU COULD GIVE US
3	THAT.
4	DR. LEVEY: WE CAN GET THAT FOR YOU.
5	MS. LANSING: THANK YOU VERY MUCH.
6	DR. PENHOET: IT SEEMS TO BE A VERY LARGE
7	SUBCOMMITTEE. CAN SOMEONE ILLUMINATE FOR ME AND THE
8	REST OF THE BOARD THE THINKING BEHIND THIS SIZE OF A
9	SUBCOMMITTEE TO DO THIS TASK?
10	DR. POMEROY: YES. MAY I ADDRESS THAT,
11	PLEASE. THIS WAS, OF COURSE, THE SUBJECT OF
12	SIGNIFICANT DISCUSSION, AND WE UNDERSTOOD THAT IT
13	WAS IMPORTANT TO GET DIVERSE PERSPECTIVES. AND THE
14	RESPONSIBILITIES OF INDIVIDUALS REALLY SPAN SUCH A
15	LARGE NUMBER OF GROUPS, FINANCE TO SCIENCE, ETC.;
16	AND IN ORDER TO GET ALL OF THOSE PERSPECTIVES, IT
17	WAS FELT THAT THIS WOULD BE REPRESENTATIVE. I THINK
18	OTHERWISE WE WOULD RUN THE RISK OF NOT HAVING THE
19	FULL UNDERSTANDING OF ALL THE CONTRIBUTIONS THAT
20	THESE PEOPLE ARE MAKING TO CIRM.
21	MR. HARRISON: I'D LIKE TO ADD ONE POINT
22	TO DR. POMEROY'S POINT, WHICH IS THAT THE
23	SUBCOMMITTEE DOES HAVE THE ABILITY, OF COURSE, TO
24	CREATE TWO-PERSON TEAMS WHICH COULD, FOR EXAMPLE,
25	ENGAGE IN INTERVIEWS OR GATHER OTHER INFORMATION AT
	208
	200

1	THE SUBCOMMITTEE'S REQUEST.
2	CHAIRMAN KLEIN: I'D JUST LIKE TO SAY I'M
3	VERY SUPPORTIVE OF THIS. I THINK IT'S VALUABLE, NOT
4	JUST FOR OUR CURRENT PROCESS AND TO LEARN FROM THE
5	INPUT THROUGH A VERY ORGANIZED PROCESS, AS CLAIRE
6	SAYS, THAT SPANS THE SPECTRUM OF ALL OF THE INPUTS
7	AND INTERFACES OF EACH IF THESE INDIVIDUALS. I'VE
8	TALKED TO DR. TROUNSON ABOUT IT. DR. TROUNSON MAY
9	WANT TO ADDRESS THIS SPECIFICALLY. I THINK IT
10	APPROPRIATELY BRINGS THE EXPERTISE FROM EACH OF
11	THOSE AREAS TOGETHER IN AN ORGANIZED WAY.
12	OVER TIME THERE MAY BE COMMITTEES THAT ARE
13	DROPPED AND COMMITTEES THAT ARE ADDED THAT COULD BE
14	INSTITUTED IN AND OUT OF THIS PROCESS TO MAKE SURE
15	WE CONTINUE TO COVER THE WHOLE SCOPE OF AFFAIRS.
16	BUT IT SEEMS TO ME TO BE A VERY SOUND PROCESS, AND
17	IT WILL HELP WITH SUCCESSION BECAUSE IT MEANS THAT
18	PEOPLE, THAT AN INDIVIDUAL THAT WOULD BECOME THE
19	NEXT CHAIR WILL, FOR EXAMPLE, UNDERSTAND HOW THEY
20	WILL BE JUDGED IN PERFORMANCE, AND THAT THEY WILL
21	HAVE THE ASSURANCE THAT EACH OF THEIR AREAS OF
22	CONTRIBUTION, WHICH MAY BE STRONGER IN SOME AREAS
23	AND WEAKER IN OTHERS, WILL BE GIVEN RECOGNITION.
24	MS. LANSING: IT WAS, AS CLAIRE SAID, AN
25	ATTEMPT FOR US TO MAKE SURE THAT WE GOT THE FULL

209

1	BREADTH AND SCOPE OF WHAT THE PEOPLE WERE DOING AND
2	THAT THERE WAS NO BLAS THAT ENTERED INTO IT.
3	DR. AZZIZ: JUST TO MAKE SURE. ARE WE IN
4	THE DISCUSSION SECTION NOW OR JUST QUESTIONS?
5	MS. LANSING: QUESTIONS AND DISCUSSION.
6	DR. AZZIZ: I DID HAVE A QUESTION ABOUT
7	THE INCLUSION OF THE CURRENT CHAIR AND VICE CHAIRS
8	IN THE COMMITTEE. IT SEEMS LIKE, A, THE COMMITTEE,
9	IS QUITE LARGE; B, THERE IS A POTENTIAL FOR THE
10	PERCEPTION OF CONFLICT OF INTEREST. WHILE I THINK
11	IT IS CRUCIAL THAT WE OBTAIN FEEDBACK FROM THE CHAIR
12	AND VICE CHAIRS REGARDING THE OTHER MEMBERS OF THAT
13	GROUP PERFORMANCE, I THINK THAT HAVING THEM AS A
14	MEMBER OF THE GROUP RAISES A SIGNIFICANT RISK OF
15	CONFLICT OF INTEREST.
16	AND I'M UNAWARE OF ANY OTHER EVALUATION
17	TEAM, FOR EXAMPLE, A FINANCIAL OVERSIGHT COMMITTEE,
18	THAT WOULD INCLUDE THE CFO THAT IS COMPOSED
19	SIMILARLY. SO MY QUESTION REALLY IS IS THAT
20	NECESSARY AS OPPOSED TO SIMPLY GATHERING INFORMATION
21	IN A 360 FASHION?
22	DR. POMEROY: SO WE DISCUSSED THIS, AND IT
23	WAS FELT THAT EACH OF THE SCENARIOS, OF COURSE,
24	IS DIFFERENT SO THAT THE CHAIR WAS VERY
25	APPROPRIATELY INCLUDED BECAUSE THEY ARE ON THE VICE
	210

1	CHAIR EVALUATIONS SINCE THAT'S A REPORTING
2	RELATIONSHIP. AND IN DISCUSSIONS WITH JAMES
3	HARRISON, WE TALKED ABOUT THE FACT THAT HE WOULD
4	ADVISE IF THERE WAS ANY CONFLICT OF INTEREST, AND
5	THOSE PEOPLE WOULD BE EXPECTED TO RECUSE THEMSELVES.
6	I ALSO JUST WANT TO POINT OUT THAT SOME
7	PEOPLE SERVE DUAL ROLES ON THESE SOME OF THE ICOC
8	MEMBERS SERVE DUAL ROLES. AND SO THE COMMITTEE WILL
9	NOT END UP BEING AS MANY PEOPLE AS IT MIGHT
10	INITIALLY APPEAR BECAUSE ONE PERSON COULD REPRESENT
11	TWO SLOTS.
12	CHAIRMAN KLEIN: TO MAKE IT CLEAR, SO IF
13	THE CHAIR IS BEING EVALUATED, THE CHAIR IS RECUSED
14	FROM THAT PORTION OF THE EVALUATION. IF THE VICE
15	CHAIR IS BEING EVALUATED, THE VICE CHAIR IS RECUSED
16	FROM THAT PORTION OF THE EVALUATION.
17	MS. LANSING: IT WAS FELT THAT THE VICE
18	CHAIR COULD PARTICIPATE IN THE EVALUATION OF THE
19	CHAIR BECAUSE HE WORKED SO CLOSELY WITH HIM AND VICE
20	VERSA.
21	DR. AZZIZ: I AGREE, BUT I DO THINK THAT
22	THE BOARD NEEDS TO RECOGNIZE THE POTENTIAL FOR
23	CONFLICT PERCEPTION OF CONFLICT OF INTEREST SO
24	THAT WHEN THE VICE CHAIRS ARE BEING EVALUATED, THE
25	CHAIR WILL BE ON IT; AND THEN WHEN THE CHAIR IS

1	BEING EVALUATED, THE VICE CHAIRS ARE ON THE
2	COMMITTEE. THAT'S JUST A LITTLE BIT DIFFERENT THAN
3	MOST STRUCTURES FOR EVALUATION COMMITTEES THAT ARE
4	I NDEPENDENT.
5	MS. LANSING: I AGREE. AND, YOU KNOW, WE
6	WENT THROUGH THIS QUITE A BIT, BUT IT'S ALSO A BIG
7	ENOUGH COMMITTEE AND WE'RE GOING TO GET A LOT OF
8	DIFFERENT INPUT, AND NOT EVERYBODY WILL BE AT EVERY
9	MEETING. SO WE'LL BE ABLE TO BALANCE IT HOPEFULLY.
10	MR. SHEEHY: I DO THINK DR. AZZIZ RAISES
11	AN INTERESTING POINT. IT'S NOT SIMPLY BEING IN ON
12	THE EVALUATION, BUT THE MATERIALS THAT ARE USED FOR
13	THE EVALUATION. LIKE, I DON'T GET TO DESIGN MY
14	EVALUATION FORM. SO I THINK THAT IF WE DO GO WITH
15	THIS MODEL, WE'RE GOING TO HAVE TO BE VERY SENSITIVE
16	IN THAT THE ROLE AND THIS PERHAPS GOES TO WHAT
17	DR. AZZIZ IS TALKING ABOUT. IT'S NOT JUST SIMPLY
18	BEING ON THE COMMITTEE THAT ACTUALLY DOES THE
19	EVALUATION, BUT THERE'S A LOT OF WORK THAT GOES INTO
20	THE EVALUATION, THAT THAT PROCESS ISN'T CONTAMINATED
21	BY PARTICIPATION.
22	FOR INSTANCE, JUST ADOPTING A FORM, IF THE
23	EVALUEES HAVE A ROLE IN ADOPTING THE FORM FOR WHICH
24	THEY'RE EVALUATED FOR, THAT'S NOT THAT RAISES
25	THAT ISSUE.

ı	CHAIRMAN KLEIN: JEFF, I DON'I THINK
2	YOU'RE GOING TO GET ANYONE TO SERVE AS PRESIDENT,
3	VICE CHAIR, OR CHAIR OF THIS ORGANIZATION IF THEY
4	CAN'T LEGITIMATELY PROPOSE ITEMS FOR EVALUATION.
5	THE COMMITTEE WITH THEM RECUSED IS GOING TO DECIDE
6	WHAT'S IN THE FORM. BUT TO TRY AND ISOLATE THEM AND
7	NOT HAVE THE EVALUATION COMMITTEE ASK THEM THE
8	QUESTION OF FOR SUGGESTIONS ON THINGS TO CONSIDER
9	IN THAT FORM WOULD BE INCONSISTENT WITH EVALUATIONS
10	IN MAJOR COMPANIES THAT I'VE WORKED WITH AND/OR EVEN
11	THE MILITARY.
12	MS. LANSING: YOU DON'T HAVE TO ACCEPT
13	WHAT THEY SAY.
14	CHAIRMAN KLEIN: THAT'S RIGHT.
15	MR. SHEEHY: AGAIN, I THINK PERHAPS DR.
16	AZZIZ HAS STEPPED INTO A MINE FIELD HERE. BUT THIS
17	IS KIND OF GETTING TO THE POINT BECAUSE WE'RE
18	ACTUALLY TALKING ABOUT TWO DIFFERENT THINGS. IN
19	COMMITTEE WE DID TALK ABOUT THE EVALUEES, HAVING
20	THAT DIALOGUE WITH EVALUEES ON DELIVERABLES. AND
21	THAT IS SOMETHING WHICH WE WOULD EXPECT THE EVALUEES
22	TO HAVE AN ENORMOUS AMOUNT OF INPUT. AND TO HAVE
23	BUT THEN IF YOU'RE TALKING ABOUT A MORE STRUCTURED,
24	WHAT DOES THE FORM LOOK LIKE? DO WE USE THE UC MED
25	CENTER FORM? WHAT DIFFERENT TYPE OF FORM WE USE,

1	WHICH IS A MORE GENERIC TYPE OF ISSUE. I DON'T KNOW
2	THAT OR IF WE TALK ABOUT PROCESS, I DON'T KNOW IF
3	THE EVALUEE OUGHT TO BE INVOLVED AT THAT POINT. DO
4	YOU SEE? AND, AGAIN, WE'RE ALREADY KIND OF IN THE
5	MINE FIELD, SO I DO THINK IT'S AN INTERESTING POINT
6	TO RAISE.
7	MS. LANSING: WELL, IT IS. DR. AZZIZ.
8	DR. AZZIZ: I HAVE TO AGREE WITH BOB, THAT
9	I THINK THAT GETTING IT WOULD BE IMPRUDENT TO NOT
10	GET INPUT FROM THE INDIVIDUALS BEING EVALUATED
11	REGARDING OBVIOUSLY THE FACTORS THAT SHOULD BE
12	CONSIDERED. AND SO THAT'S ACTUALLY NOT WHAT I'M
13	ACTUALLY QUESTIONING. I THINK THE INPUT IS
14	CRI TI CAL.
15	I WILL GIVE YOU AN EXAMPLE, I THINK, JUST
16	TO FOLLOW UP ON JEFF'S QUESTION, AN EXAMPLE OF WHERE
17	A POTENTIAL ISSUE. IF WE ARE GOING TO BE GETTING
18	CONFIDENTIAL 360 EVALUATIONS WHICH MAY ALLUDE TO THE
19	FACT THAT THE CHAIR, THE LEADERSHIP OF THE ICOC, IN
20	GENERAL IS FLAWED. LET'S ASSUME, OF COURSE, IT IS
21	NOT. HOW ARE WE GOING TO BE ABLE TO DO THAT? ARE
22	PEOPLE REALLY GOING TO BE ABLE TO DISSECT AND SAY
23	THIS VICE CHAIR IS THIS FLAWED, BUT THIS CHAIR IS
24	NOT? USUALLY PEOPLE WILL REFER TO TEAMS. I'M
25	SIMPLY BRINGING THIS UP BECAUSE I HAVE BEEN INVOLVED

1	IN OTHER
2	MS. LANSING: IF YOU HAD LET'S JUST
3	SAY I DON'T WANT TO SAY CHAIR, VICE CHAIR,
4	WHATEVER. IF YOU ARE EVALUATING, FIRST YOU NEED THE
5	MEMBERS WHO ARE BEING EVALUATED TO GIVE YOU INPUT.
6	AND YOU NEED TO MAKE SURE THAT YOU'RE HAVING DUE
7	CONSIDERATION OF THE THINGS THAT THEY FEEL ARE PART
8	OF THEIR JOB DESCRIPTION. NOW, YOU CAN RECUSE
9	YOU CAN SAY, NO, WE DON'T AGREE WITH YOU, BUT AT
10	LEAST YOU' VE HAD THE DI ALOGUE.
11	NOW, WHEN YOU DO THE EVALUATION, THE 360
12	OF THAT HUMAN BEING, THEY'RE NOT THERE. THEY CAN'T
13	BE PART OF THAT. THAT HAS TO BE A SEALED DOCUMENT
14	THAT THEY CAN NEVER SEE.
15	DR. AZZIZ: I UNDERSTAND. I JUST WANT TO
16	MAKE SURE THAT, FOR THE RECORD, THE ISSUE REALLY HAS
17	TO DO WITH WHO COMPOSES THE COMMITTEE. USUALLY MOST
18	EVALUATION COMMITTEES ARE INDEPENDENT UNITS WHICH
19	GATHER AND ARE MANDATED TO GATHER INPUT FROM ALL
20	SOURCES, CHAIRS, VICE CHAIRS, PEOPLE WHO WORK WITH
21	THEM, AND SO ON AND SO FORTH. SO THE GETTING INPUT,
22	I THINK, IS CRITICAL.
23	THE ISSUE IS SIMPLY THE POTENTIAL FOR THE
24	PERCEPTION OF A CONFLICT OF INTEREST BY THE PUBLIC
25	REGARDING THIS ISSUE. I JUST THINK IT'S SOMETHING

1	THAT I WOULD LIKE TO MAKE SURE WE THINK ABOUT. I'M
2	NOT NECESSARILY OPPOSING THE MOTION. I'M JUST
3	SIMPLY BRINGING IT UP BECAUSE IT DOES BRING UP THE
4	ISSUE OF WHETHER INDIVIDUALS WILL BE CANDID ENOUGH,
5	WE'LL BE ABLE TO FUNCTION FREELY ENOUGH IN THE
6	ABSENCE OF ANYBODY IN THE PRESENCE OF SOMEBODY
7	WHO IS ACTUALLY PART OF THE LEADERSHIP TEAM.
8	MS. LANSING: SO I HEAR WHAT YOU ARE
9	SAYING. SO I THINK WHAT IS EXTREMELY, AND JAMES AND
10	CLAIRE JUMP IN, NO ONE'S OBJECTING TO INPUT FROM THE
11	PEOPLE THAT ARE BEING EVALUATED. NO ONE IS
12	OBJECTING TO LISTENING TO EVERYTHING THAT THEY SAY,
13	THEN GOING OFF WITH ALL THAT INPUT FROM OTHER PEOPLE
14	AS WELL AND COMING UP WITH, QUOTE, THE DELIVERABLES.
15	THEN NO ONE IS OBJECTING TO EVALUATION OF
16	THE PEOPLE THAT YOU WORK WITH, THE VICE CHAIR
17	EVALUATING THE CHAIR, THE PRESIDENT EVALUATING THE
18	VICE CHAIR, AND THE CHAIR EVALUATING BOTH OF THEM.
19	THE ONLY WAY THIS WILL WORK IS WHEN WE DO A 360 ON
20	ANY INDIVIDUAL, ON A BOARD MEMBER, ON ANY INDIVIDUAL
21	IS IF WE HAVE THE HIGHEST, HIGHEST CONFIDENTIALITY.
22	AND IF THAT IS EVER LEAKED, THE WHOLE PROCESS FALLS
23	APART BECAUSE OTHERWISE NO ONE WILL SAY ANYTHING.
24	DR. POMEROY: SHERRY, CAN I ALSO JUST ADD
25	SOMETHING TO THAT, WHICH IS I WANT TO ASSURE MY
	216

1	COLLEAGUES AS A GROUP, AND THERE REALLY IS THE
2	BALANCE HERE BETWEEN GETTING ADEQUATE INPUT AND THE
3	CHALLENGES OF MAINTAINING APPROPRIATE
4	CONFIDENTIALITY. AND I THINK MY PERSONAL
5	RECOMMENDATION IS THAT WE NEED TO TRUST OUR LEGAL
6	COUNSEL TO GIVE THE COMMITTEE VERY CLEAR DIRECTION
7	ABOUT CONFLICT OF INTEREST AND WHAT MATERIALS ARE
8	SHARED AND WHEN PEOPLE NEED TO RECUSE THEMSELVES.
9	AND I, AFTER TALKING WITH JAMES, HAVE
10	CONFIDENCE THAT WE CAN GET THAT DIRECTION.
11	MS. LANSING: THANK YOU. I DO TOO.
12	MR. SHEEHY: DID WE IDENTIFY THE CHAIRS OR
13	THE CHAIR OR CO-CHAIRS OF THE EVALUATION COMMITTEE?
14	DID WE SAY THAT IN THE SLIDE? THAT MIGHT BE HELPFUL
15	T00.
16	MR. HARRISON: WE HAVE NOT IDENTIFIED WHO
17	THE CHAIR OR VICE CHAIR OF THE EVALUATION COMMITTEE
18	WOULD BE, AND YOU HAVE THE OPTION EITHER OF
19	DESIGNATING THEM AS A BOARD.
20	MR. SHEEHY: COULD I PERHAPS MAKE I
21	KNOW WE DON'T HAVE A MOTION, MAYBE A MOTION TO ADOPT
22	WOULD BE IN ORDER AND PERHAPS SUGGEST THAT THE
23	CO-CHAIRS OF THE GOVERNANCE COMMITTEE SERVE AS THE
24	CHAIRS OF THE EVALUATION COMMITTEE SINCE IT IS IT
25	DOES SEEM NATURAL TO FLOW FROM GOVERNANCE INTO
	047

1	EVALUATION, AND THE EVALUATION STARTED IN
2	GOVERNANCE. AND I THINK IDENTIFYING LEADERSHIP FOR
3	THE COMMITTEE, ESPECIALLY GIVEN ALL THE WORK THAT'S
4	BEEN DONE AT GOVERNANCE IN THIS PROCESS AND THE
5	RELATIONSHIP WITH COUNSEL VIS-A-VIS THIS CONFLICT OF
6	INTEREST ISSUE, I PERSONALLY WOULD MOVE TO ADOPT IT
7	WITH THE CO-CHAIRS OF THE GOVERNANCE COMMITTEE AS
8	THE CO-CHAIRS OF THIS COMMITTEE.
9	CHAIRMAN KLEIN: I WOULD OPPOSE THAT
10	RESOLUTION. I THINK THE EVALUATION COMMITTEE NEEDS
11	TO DECIDE WHO ITS CHAIRS ARE. FROM TIME TO TIME
12	THOSE MAY CHANGE, AND PARTICULARLY TAKING TWO PEOPLE
13	OFF OF ONE COMMITTEE THAT REPRESENTS ONE PORTION OF
14	THE WORK OF THIS AGENCY. IF YOU HAVE SEVEN
15	DIFFERENT SECTORS OF WORK OF THIS AGENCY, TO TAKE
16	BOTH OF THE CO-CHAIRS FROM ONE SECTOR JUST DOESN'T
17	SEEM TO MAKE SENSE TO ME.
18	MR. SHEEHY: THEN WE'RE ON THIS SLIPPERY
19	SLOPE THAT I IDENTIFIED. THEN THE EVALUEES PICK THE
20	CHAIRS OF THE COMMITTEE THAT EVALUATE THEM.
21	CHAIRMAN KLEIN: YOU'VE GOT A LARGE ENOUGH
22	GROUP, JEFF, THAT
23	MR. SHEEHY: AND TYPICALLY WE HAVEN'T
24	ELECTED CHAIRS OF COMMITTEES FROM COMMITTEES.
25	THEY'VE BEEN APPOINTED. GIVEN THAT THIS IS A BOARD
	210

1	FUNCTION, I THINK THE BOARD SHOULD APPOINT THE
2	CHAI RS.
3	MR. SERRANO-SEWELL: I DO SUPPORT IN
4	SPIRIT WHAT BOB IS SAYING, SHERRY. I WOULD PREFER
5	FOR THE EVALUATION COMMITTEE TO CONVENE FIRST AND
6	TAKE UP THIS ISSUE AND MAKE A DECISION. I HAVE
7	EVERY CONFIDENCE THAT WHOMEVER THEY SELECT WILL BE
8	OF THE HIGHEST INTEGRITY AND STANDARDS AND SENSITIVE
9	TO ALL THE ISSUES, BUT TO PREORDAIN THAT AT THIS
10	TIME AS A MOTION I COULDN'T SUPPORT.
11	MS. LANSING: I THINK WE WERE AWARE THAT
12	THERE WASN'T SUPPORT FOR THAT, WHICH IS WHY WE
13	DIDN'T BRING IT FORWARD. SO WHY DON'T WE MORE
14	DI SCUSSI ON?
15	DR. LOVE: I WOULD JUST ECHO THAT. GOING
16	IN THAT DIRECTION, WE MIGHT AS WELL DELEGATE ALL
17	THIS TO THE GOVERNANCE COMMITTEE. SINCE WE'RE NOT
18	DELEGATING IT TO THE GOVERNANCE COMMITTEE, I WOULD
19	THINK THAT IT MAKES SENSE TO CONSTITUTE THE
20	COMMITTEE AND HAVE THE COMMITTEE USE ITS OWN
21	JUDGMENT ABOUT ITS LEADERSHIP.
22	MS. LANSING: MORE DISCUSSION?
23	MR. SHEEHY: THERE IS A MOTION ON THE
24	FLOOR THAT'S BEEN SECONDED.
25	MS. LANSING: I NEED A ROLL CALL VOTE.
	210

1	DR. PRIETO: CAN WE RESTATE THE MOTION?
2	MR. HARRISON: THE MOTION IS TO ADOPT THE
3	PROCEDURE SET FORTH IN THE SLIDES IN TAB 13 WITH ONE
4	MODIFICATION, WHICH IS TO DESIGNATE THE CHAIR AND
5	CO-CHAIRS OF THE GOVERNANCE SUBCOMMITTEE AS THE
6	CHAIR AND CO-CHAIR OF THE EVALUATION SUBCOMMITTEE.
7	CHAIRMAN KLEIN: WAS THAT SECONDED?
8	MR. HARRISON: DR. POMEROY SECONDED IT.
9	MR. SERRANO-SEWELL: POINT OF ORDER,
10	SHERRY, OR WHOEVER IS CHAIRING THIS PORTION OF THE
11	MEETING. IN LIGHT OF THE COMMENTS THAT A COUPLE OF
12	MEMBERS HAVE MADE, WILL THE MAKER OF THE MOTION
13	CONSIDER WITHDRAWING THE ASPECT OF
14	MR. SHEEHY: NO.
15	MS. LANSING: ART, DID YOU HAVE SOMETHING?
16	MR. TORRES: YES. I'M JUST GRATEFUL FOR
17	THE FIRST TIME IN MY LIFE TO BE JUDGED AND EVALUATED
18	BY THE SMALLEST GROUP OF PEOPLE EVER IN MY CAREER.
19	MR. ROTH: I'M TRYING TO FIGURE OUT HOW TO
20	GET OUT OF THIS.
21	DR. PIZZO: WE WON'T TAKE A VOTE ON THAT.
22	MS. KING: SHERRY, BEFORE WE TAKE PUBLIC
23	PEOPLE, YOU MIGHT JUST WANT TO ASK IF THE PEOPLE ON
24	THE PHONE HAVE ANY COMMENTS.
25	MS. LANSING: PEOPLE ON THE PHONE, DO YOU
	220

1	HAVE ANY COMMENT?
2	MS. FEIT: I'M A LITTLE CONFUSED. DO WE
3	HAVE TWO MOTIONS AVAILABLE TO US OR JUST ONE?
4	MS. LANSING: JEFF, MAY I MAKE A FRIENDLY
5	AMENDMENT? WHY DON'T WE TAKE THE FIRST PART?
6	MR. SHEEHY: NO.
7	CHAIRMAN KLEIN: DO WE HAVE TWO MOTIONS?
8	MR. HARRISON: NO. WE HAVE ONLY
9	DR. STEWARD: COULD SOMEBODY CLARIFY WHAT
10	THE MOTION IS?
11	MR. HARRISON: YES. WE HAVE ONLY ONE
12	MOTION PENDING, AND IT'S A MOTION TO APPROVE THE
13	EVALUATION PROCEDURES SET FORTH IN TAB 13 WITH ONE
14	AMENDMENT, AND THAT IS TO DESIGNATE THE CHAIR AND
15	VICE CHAIR OF THE GOVERNANCE SUBCOMMITTEE AS THE
16	CHAIR AND VICE CHAIR OF THE EVALUATION SUBCOMMITTEE.
17	DR. POMEROY: JAMES, JUST CLARIFY IF THIS
18	MOTION WERE TO FAIL, A NEW MOTION COULD BE
19	INTRODUCED TO GO WITH THE ORIGINAL.
20	MR. HARRISON: THAT'S CORRECT.
21	MR. SERRANO-SEWELL: SO LET ME SEE IF I
22	UNDERSTAND WHAT YOU SAID, SHERRY. YOU SAID EARLIER
23	THAT YOU DIDN'T BRING UP THIS PARTICULAR ISSUE OF
24	LEADING THE EVALUATION COMMITTEE.
25	MS. LANSING: I KNEW THAT BOB OBJECTED TO
	221
	<u> </u>

1	IT. IT'S FINE. I DON'T TAKE IT PERSONALLY.
2	DR. PULIAFITO: I'VE GOT TO ECHO DR.
3	AZZIZ' CONCERN AND BOB'S CONCERNS ABOUT THIS. I
4	THINK THIS IS AN EXTRAORDINARILY CONVOLUTED,
5	INTERLOCKING DIRECTORATE STRUCTURE FOR EVALUATING
6	PEOPLE. IT WOULD BE FAR BETTER TO HAVE FOUR OR FIVE
7	MEMBERS OF THE ICOC ELECTED AND THEN HAVE A CHAIR OF
8	THAT GROUP TO EVALUATE THESE PEOPLE. BECAUSE I
9	THINK THAT HAVING THE CHAIR EVALUATE THE VICE CHAIR
10	AND THE VICE CHAIRS, IT LOOKS BAD. IT'S
11	COMPLICATED. AND THEN TO SAY SOMEONE SAID, WELL,
12	WE'RE GOING TO HAVE IT WON'T BE SUCH A LARGE
13	NUMBER OF PEOPLE BECAUSE ONE PERSON CAN DO TWO
14	FUNCTIONS MAKES NO SENSE TO ME, SO I'M GOING TO VOTE
15	AGAINST THIS.
16	DR. POMEROY: CAN I JUST ADDRESS THAT? IT
17	IS (TELEPHONE TRANSMISSION GARBLED AND
18	UNI NTELLI GI BLE).
19	MR. HARRISON: DR. POMEROY, UNFORTUNATELY
20	YOU CUT OFF DURING YOUR COMMENTS, BUT I THINK I
21	UNDERSTOOD YOUR POINT. AND THAT IS THAT THERE ARE
22	CERTAIN MEMBERS OF THE BOARD WHO HOLD TWO POSITIONS
23	LISTED. FOR EXAMPLE, MEMBER LANSING IS CHAIR OF THE
24	GOVERNANCE SUBCOMMITTEE AND ALSO VICE CHAIR OF THE
25	STANDARDS WORKING GROUP. SO THAT WOULD ELIMINATE
	222
	222

1	THE SIZE REDUCE THE SIZE OF THE COMMITTEE BY ONE
2	MEMBER. LIKEWISE, CHAIRMAN KLEIN WOULD BE COUNTED
3	TWICE UP THERE IF YOU LOOKED. OF COURSE, HE'S ONLY
4	ONE INDIVIDUAL. AND SAME WITH DUANE ROTH.
5	MS. SAMUELSON: I WANT TO MAKE TWO
6	OBSERVATIONS QUICKLY BECAUSE I DON'T WANT TO DELAY
7	THIS. BUT THIS IS NOT SERVING OUR IMAGE WELL. AND
8	IT SEEMS TO ME THAT IS BEGINNING TO SAY SOMETHING
9	ABOUT WHAT WE'RE DOING AND HOW WE'RE DOING IT. AND
10	I AM NOT AN EXPERT IN THIS FIELD OF EVALUATION, SO I
11	AM RELUCTANT TO SAY ANYTHING. IT SEEMS TO ME WE'RE
12	A SMALL ORGANIZATION. AND IF WE ARE AGGRESSIVELY
13	PURSUING OUR MISSION, IN THAT CONTEXT WE WILL BE
14	FOCUSING WITH LASER VISION ON OUR LEADERSHIP TO SEE
15	IF THEY'RE LEADING US IN A WAY THAT'S ENABLING US TO
16	DO THIS QUICKLY AND WITH THE RIGHT RESULTS, AND THAT
17	WE'LL ALL KNOW WHAT SORT OF PERFORMANCE WE'RE
18	GETTING OUT OF THESE VARIOUS PEOPLE.
19	MAYBE THAT'S JUST NAIVE OF ME OR I'M JUST
20	NOT UNDERSTANDING THE PURPOSE FOR THIS. BUT IT DOES
21	CONCERN ME THAT THIS IS NOW TRAILING OFF INTO
22	CONFLICT OF INTEREST AND SO ON, AND WE NEVER LOOK
23	GOOD IN THAT CONTEXT WHEN THERE'S THIS KIND OF
24	DEBATE.
25	DR. POMEROY: I JUST WANT TO SAY WE'VE HAD
	223

PEOPLE WORKING IN THESE POSITIONS INFORMALLY WITHOUT
FULLY DOCUMENTED WRITTEN EXPECTATIONS. AND I DON'T
CARE FOR THOSE. THIS WAS AN ATTEMPT TO (TELEPHONE
TRANSMISSION GARBLED) TO DO THAT JOB BETTER.
DR. PIZZO: MAY I SPEAK AS WELL?
MS. LANSING: YES, OF COURSE.
DR. PIZZO: I JUST WANT TO AGREE WITH THE
COMMENTS THAT I JUST HEARD FROM CLAIRE. I THINK
THAT FOR AN ORGANIZATION OF THIS SIZE AND SCOPE,
IT'S VERY IMPORTANT THAT THERE BE AN ORGANIZED
PROCESS FOR REGULAR EVALUATIONS AND FEEDBACK. I
DON'T THINK THAT WE SHOULD CONFUSE THAT PROCESS WITH
CONFLICTS OF INTEREST. I THINK THAT THEY SHOULD
REALLY BE FOCUSED ON PERFORMANCE. AND NOT DOING SO,
I THINK, WOULD BE LACKING OUR OWN DUE DILIGENCE.
MS. LANSING: THERE WAS A FEELING BOB,
PERHAPS YOU CAN ARTICULATE BECAUSE I KNOW HOW
STRONGLY YOU FEEL ABOUT THIS, THAT IF YOU HAD, AND I
UNDERSTAND EVERYTHING THAT YOU'RE SAYING, AND I'VE
BEEN ON CORPORATE BOARDS, WHATEVER. I UNDERSTAND
HOW THIS LOOKS VERY COMPLICATED. AND IT TOOK US A
LONG TIME TO GET TO THIS. IT'S A LOT OF INPUT.
BOB, I'D LOVE YOU TO SPEAK, IF YOU DON'T
MIND. THERE WAS A FEELING THAT IF WE JUST HAD FOUR
OF US, SOUNDS REASONABLE, THAT THOSE FOUR BOARD
224

1	MEMBERS WOULD NOT REMOTELY TO BE ABLE TO UNDERSTAND
2	THE DAY-TO-DAY OPERATIONS BECAUSE WE'RE NOT THERE.
3	AND THAT IF WE DIDN'T HAVE SOMEBODY WHO WORKED WITH
4	ONE OF THE THREE PEOPLE BEING EVALUATED ON A
5	DAY-TO-DAY BASIS, THAT WE COULD PERHAPS MAKE SOME
6	MISTAKES IN OUR EVALUATION POSITIVELY OR NEGATIVELY.
7	AND SO THE FEELING WAS THAT THOUGH THIS
8	WAS CUMBERSOME, I UNDERSTAND IT, THAT IT WAS THE
9	ONLY WAY TO GET A REALLY IN-DEPTH EVALUATION. AND
10	WE HAD A MUCH SIMPLER FORMULA IN THE BEGINNING, AND
11	RIGHTFULLY SO. THERE WAS RESISTANCE FROM THE
12	PEOPLE, I'M SAYING RIGHTFULLY SO, THAT WERE BEING
13	EVALUATED THAT IT WASN'T A FAIR EVALUATION. AND
14	THAT IS NOT SOMETHING WE WANT BECAUSE, IRONICALLY,
15	THIS EVALUATION PROCESS CAME FROM CHAIRMAN KLEIN.
16	HE ASKED FOR IT. AND IT CAME ABOUT IN A VERY
17	HEALTHY WAY.
18	SO I DON'T KNOW EVERYTHING THAT EVERYBODY
19	DOES EVERY SINGLE DAY. I SIT ON THE STANDARDS
20	COMMITTEE. I KNOW EVERYTHING THAT WE DO, BUT I
21	DON'T KNOW EVERYTHING THAT ALL THE OTHER COMMITTEES
22	DO IF I'M NOT THERE. SO THIS WAS THE ATTEMPT.
23	DR. AZZIZ: SO JUST TO BE CLEAR, I THINK
24	WE'RE ACTUALLY SORT OF TALKING OF APPLES AND
25	ORANGES. I STRONGLY AGREE WITH CLAIRE AND PHIL AND
	225

ALL THE REST WHO FEEL THAT WE SHOULD HAVE A FORMAL
EVALUATION. IN FACT, WE HAVE BEEN REMISS AND WE ARE
NOW BACKTRACKING TO MAKE SURE THAT WE HAVE THIS. I
THINK THAT BOB IS ASKING FOR IT. ALL OF US ARE IN
GREAT SUPPORT OF THIS EVALUATION.
THE QUESTION IS ARE WE PRESENTING THE MOST
TRANSPARENT, CLEAR METHOD THAT HAS THE LEAST
POTENTIAL FOR THE PERCEPTION OF CONFLICT OF
INTEREST? THAT'S MY QUESTION. IN FACT, WE SHOULD
BE OBLIGED, WHETHER IT'S THREE MEMBERS OR 19
MEMBERS, THEY SHOULD BE OBLIGED TO GATHER 360
INFORMATION FROM MULTIPLE SOURCES THAT NEED TO BE
CLEARLY DELINEATED. THE QUESTION ISN'T THE
INFORMATION YOU'RE GATHERING. THE QUESTION ISN'T DO
YOU GET INFORMATION FROM ALL THE SITTING WORKING
GROUPS AND FROM THE COMMITTEES AND SO ON AND SO
FORTH. THAT SHOULD BE MANDATORY.
THE QUESTION IS SHOULD THEY BE PART OF THE
GROUP THAT DOES READ ALL THE CONFIDENTIAL COMMENTS
AND MAKES THOSE JUDGMENTS? SO WE'RE TALKING
DIFFERENT ISSUES.
MS. LANSING: NO. THEY CAN'T BE I
THINK THERE'S A MISUNDERSTANDING UNLESS I'M NOT
GETTING IT RIGHT, AND I THINK I AM.
DR. AZZI Z: EVEN
226

226

1	MS. LANSING: THEY ARE NOT PART OF THE
2	CONFIDENTIAL
3	DR. AZZIZ: WE UNDERSTAND THAT THEY WILL
4	BE RECUSED, ETC. BUT MY POINT IS WE ARE PRESENTING
5	A VERY CONVOLUTED SYSTEM FOR SOMETHING THAT MOST
6	ORGANIZATIONS WILL HAVE FOUR BOARD MEMBERS FROM THE
7	EXECUTIVE BOARD TO REVIEW THE CEO, WHO THEN ARE
8	OBLIGED WITH STAFF TO GATHER CONFIDENTIAL INPUT FROM
9	60 DIFFERENT PEOPLE. OF COURSE, ALL 60 ARE NOT PART
10	OF THE COMMITTEE. I'M JUST SIMPLY STATING AGAIN FOR
11	THE RECORD I AM FULLY IN SUPPORT OF THIS CONCEPT.
12	I'M FULLY IN SUPPORT OF GATHERING AS MUCH
13	INFORMATION AS POSSIBLE. WE SHOULD BE AS FAIR AS
14	POSSIBLE. THE INDIVIDUALS WHO ARE BEING EVALUATED
15	SHOULD BE ASKED FOR THEIR INPUT.
16	THE QUESTION IS IS THE COMMITTEE THAT
17	REVIEWS THE CONFIDENTIAL STATEMENTS, SHOULD THAT
18	INCLUDE THOSE SAME INDIVIDUALS OR IN THE GROUP OF
19	INDIVIDUALS? THAT'S MY ONLY STATEMENT.
20	DR. PULIAFITO: I'VE GOT TO RESTATE THIS.
21	I'M IN FAVOR OF EVALUATION, BUT I AM AGAINST THIS
22	COMMITTEE BECAUSE IT GIVES THE APPEARANCE OF HAVING
23	A RELATIVELY SMALL GROUP OF PEOPLE, AND THE
24	PERCEPTION OF SELF-DEALING AND SELF-INTEREST IS
25	THERE. I THINK IT WOULD BE A MISTAKE FOR US TO
	227
	<u> </u>

1	APPROVE THIS COMMITTEE AS CONSTITUTED.
2	CHAIRMAN KLEIN: WELL, SO I ASKED FOR A
3	FORMAL EVALUATION BECAUSE IT'S DIFFICULT AS CHAIR
4	WHEN YOU'RE INTERFACING ACROSS THE BROAD SPECTRUM
5	THAT GOES FROM FINANCE TO IP TO STANDARDS TO
6	GOVERNANCE TO REALLY KNOW WHETHER YOU'RE PERFORMING
7	ACROSS THE WHOLE SPECTRUM. AND I SPECIFICALLY ASKED
8	TO HAVE EXPERTISE OF INDIVIDUALS WITHIN OUR BOARD
9	WHO HEAD SUBCOMMITTEES THAT REPRESENT EACH OF THESE
10	CONTENT AREAS SUBSTANTIVELY.
11	I MEAN WE HAVE TO DEAL WITH LOTS OF
12	CONFLICTS ISSUES AND DO IT PROPERLY. ALL THE
13	PATIENT ADVOCATES ON THIS BOARD, ALL THE
14	INSTITUTIONS ON THIS BOARD, WE'VE PROPERLY ADDRESSED
15	THOSE CONFLICTS AND WE DEAL WITH THEM. WE HAVE
16	RECUSALS AND WE CAN DEAL WITH THEM HERE.
17	BUT I WOULD HAVE A VERY TOUGH TIME
18	SUGGESTING SOMEONE TAKE THIS POSITION OF CHAIR WITH
19	AN EVALUATION THAT DOESN'T INCLUDE THE INPUT FROM
20	THE PEOPLE THAT HAVE TO HELP THIS BOARD ON WORKING
21	GROUPS, WHETHER IT'S ON LEGISLATION, FINANCE, IP,
22	GRANTS WORKING GROUPS, STANDARDS WORKING GROUPS.
23	YOU NEED TO HAVE THE FULL SPECTRUM.
24	WHEN YOU HAVE ELEVEN BOARD MEMBERS ON
25	THERE, YOU'RE GOING TO HAVE A SITUATION WHEREIN
	228

1	DIVERSITY OF OPINION, ANY PARTICULAR ONE PERSON ON
2	THAT BOARD, IF THEY DON'T REPRESENT A FAIR
3	REPRESENTATION OF THE WHOLE GROUP, THEY'RE JUST
4	GOING TO GET CANCELED OUT. ANY TWO OR THREE PEOPLE
5	ARE GOING TO GET CANCELED OUT. SO YOU'RE GOING TO
6	HAVE THROUGH THE DIVERSITY OF REPRESENTATION AN
7	EFFECTIVE CONSENSUS. THAT'S REALLY WHAT YOU'RE
8	LOOKING FOR. IN CONSENSUS WITH TEN OR ELEVEN
9	PEOPLE, THE INDIVIDUAL THE BENEFIT OF HAVING A
10	BIGGER GROUP RATHER THAN THREE OR FOUR PEOPLE IS
11	THAT THE DIVERSITY CANCELS OUT ANY BLAS.
12	SHERRY, WE HAVE AN IMPORTANT GRANTS
13	WORKING GROUP SESSION. IF THE COMMITTEE OR THE
14	BOARD WOULD PREFER TO DEFER IT, I JUST AT SOME POINT
15	WOULD LIKE A FORMAL
16	MS. LANSING: I THINK CLAIRE AND I NEED TO
17	GET A SENSE OF THE BOARD BECAUSE SO I'M GOING
18	TO BECAUSE THIS IS REALLY A SIMPLE PROCESS THAT
19	IS TAKING UP AN ENORMOUS AMOUNT OF TIME. AND I'M
20	NOT IN ANY WAY RESENTING THE TIME. AND REALLY
21	CLAIRE HAS BEEN LEADING THIS EFFORT IN JUST AN
22	EXTRAORDINARY WAY WITH JAMES' HELP. SO I THINK WHAT
23	WE SHOULD DO IS HEAR THE VOTE, AND THEN I'M GOING TO
24	PROPOSE ANOTHER AMENDMENT. AND IF THEY BOTH
25	SUCCEED, GREAT. IF THEY BOTH FAIL, GREAT. THEN
	220

1	WE'LL GO BACK TO THE DRAWING BOARD, BUT LET'S SEE
2	WHERE WE ARE. I'D LIKE TO DO THAT.
3	DR. STEWARD: I'D JUST LIKE TO ASK THAT WE
4	DECOUPLE THE ORIGINAL AMENDMENT. THE MAKER
5	DECLI NED.
6	MR. SHEEHY: I'LL SPEAK BRIEFLY TO THAT.
7	THIS GOES TO THE INTEGRITY OF THE COMMITTEE. AND I
8	THINK THERE WAS AT ONE POINT THE PROPOSAL TO HAVE
9	GOVERNANCE DO THIS, WHICH TO ME SEEMED THE MOST
10	NATURAL AND LOGICAL THING. I DO THINK IT'S A
11	GOVERNANCE FUNCTION. I DO AGREE WITH THE CHAIR,
12	THAT THE MORE DIVERSE COMMITTEE IS A BETTER WAY TO
13	DEVELOP CONSENSUS AMONGST ALL THE STAKEHOLDERS, SO I
14	SUPPORT THAT. BUT GIVEN THAT THE CHAIRS OF THE
15	GOVERNANCE COMMITTEE HAVE REALLY BEEN DEALING WITH
16	THIS ISSUE AND HAVE EXAMINED WITH COUNSEL SOME OF
17	THE ISSUES OF CONFLICT OF INTEREST AND PROCESS, I
18	FEEL CONFIDENT THAT IF THEY'RE CHAIRS OF THIS, THAT
19	PROCESS WILL BE ADEQUATELY FIREWALLED AGAINST THOSE
20	I SSUES.
21	IF THIS MOTION FAILS, I WILL NOT SUPPORT
22	THE MOTION FOR A COMMITTEE WITHOUT THE CHAIRS NAMED.
23	I JUST THINK I JUST DON'T THINK IT'S APPROPRIATE
24	FOR PEOPLE BEING EVALUATED TO PICK THE CHAIRS OF THE
25	COMMITTEE THAT IS EVALUATING THEM. SO I THINK THAT
	230

1	THAT SHOULD BE DONE.
2	MS. LANSING: ORIGINALLY THIS STARTED WITH
3	JUST THE GOVERNANCE COMMITTEE DOING THE EVALUATION.
4	MR. SHEEHY: JUST AS A SUGGESTION, WE CAN
5	DISCUSS THIS OFF, BUT LET'S JUST GO THROUGH SOME
6	VOTES. IF EVERYTHING GOES DOWN, IT WILL BE BACK TO
7	GOVERNANCE, BUT WE DO NEED TO GET TO THE GRANTS.
8	MS. LANSING: I THINK SO TOO.
9	MR. SHEEHY: I DON'T THINK WE'RE ADDING
10	ANYTHING TO THE CONVERSATION AT THIS POINT.
11	MS. LANSING: SO CAN I HAVE
12	DR. PRIETO: JUST ANOTHER SUGGESTION. I'M
13	SORRY TO COMPLICATE THIS MORE, BUT FOR THOSE WHO
14	THINK THAT THIS IS TOO LARGE AND CUMBERSOME, IF WE
15	CHANGE THE WORDING OF 1(A) TO THE CHAIR OR VICE
16	CHAIR OF THOSE COMMITTEES, IT WOULD REDUCE THE
17	EVALUATIONS OF COMMITTEES BY THREE.
18	MS. LANSING: SO I WOULD LIKE ANY
19	PUBLIC COMMENT? YES, JOHN SIMPSON.
20	DR. SIMPSON: JOHN SIMPSON FROM CONSUMER
21	WATCHDOG. I SHARE WITH CHAIRMAN KLEIN A GREAT NEED
22	OR SENSE OF NEED FOR SOME KIND OF FORMAL EVALUATION
23	PROCESS. THIS SEEMS TO BE STEPS IN THE RIGHT
24	DIRECTION. I'VE WATCHED IT UNFOLD IN GOVERNANCE AND
25	SO ON. BUT I HAVE TO SAY THAT I SHARE, IF IT WERE

1	10 BE VOIED RIGHT NOW, MEMBER SHEEHY'S POSTITON,
2	THAT IT WOULD BE COMPLETELY INAPPROPRIATE TO HAVE
3	THE COMMITTEE THAT IS BEING SOME OF WHOSE MEMBERS
4	ARE BEING REVIEWED PICKING THE CHAIRMAN OF THAT
5	COMMITTEE.
6	I SUGGEST THAT MAYBE YOU NEED TO TAKE THIS
7	BACK. THE WHOLE STRUCTURE IS A BIT LIKE A RUBE
8	GOLDBERG MACHINE IN TERMS OF COMPLEXITY, AND IT DOES
9	NOT LEND ITSELF TO TRANSPARENCY. SO I WOULD BE
10	INCLINED TO VOTE NO ON EVERYTHING TODAY IF I HAD
11	THAT OPPORTUNITY. THANK YOU.
12	CHAIRMAN KLEIN: WOULD THE MAKER OF THE
13	MOTION AGREE TO A FRIENDLY AMENDMENT THAT THE BOARD
14	SELECTS THE CHAIR AND VICE CHAIR OF THIS COMMITTEE?
15	MR. SHEEHY: NO. I THINK NO. I MEAN I
16	HAVE A MOTION. YOU KNOW, THIS ENTIRE DISCUSSION HAS
17	DISTURBED ME GOING BACK TO GOVERNANCE. THIS WAS A
18	COMPROMISE THAT I KIND I'M SWALLOWING. I SHARE A
19	LOT OF DR. AZZIZ' CONCERNS. BUT I GUESS I JUST
20	DON'T KNOW WHY THERE IS THIS SENSE THAT I JUST
21	I REALLY DON'T UNDERSTAND WHAT THE ISSUE IS HERE ON
22	THE DESIGNATING THE CHAIRS OF THE GOVERNANCE
23	SUBCOMMITTEE SINCE THEY DO SO MUCH OF THIS TO BEGIN
24	WITH.
25	NO. NO. SORRY.
	222

1	MS. LANSING: ALL RIGHT. LET'S SEE WHERE
2	WE ARE. AND IF IT PASSES, GREAT. IF IT DOESN'T
3	PASS, GREAT TOO. WE'LL COME BACK WITH SOMETHING
4	ELSE. LET'S DO
5	DR. AZZIZ: RESTATE THE MOTION, PLEASE.
6	MR. HARRISON: THE MOTION IS TO ADOPT THE
7	EVALUATION PROCEDURES SET FORTH IN TAB 13 WITH THE
8	MODIFICATION THAT THE CHAIR AND VICE CHAIR OF THE
9	EVALUATION SUBCOMMITTEE WOULD BE THE CHAIR AND VICE
10	CHAIR OF THE GOVERNANCE SUBCOMMITTEE.
11	DR. AZZIZ: I'M SORRY. TO CLARIFY, ARE WE
12	JUST VOTING ON THE AMENDMENT OR ON THE WHOLE THING
13	WITH THE AMENDMENT?
14	MR. HARRISON: YOU'RE VOTING ON THE WHOLE
15	EVALUATION PROCEDURE WITH THE DESIGNATION OF THE
16	CHAIR AND THE VICE CHAIR OF THE GOVERNANCE
17	SUBCOMMITTEE AS CHAIR AND VICE CHAIR OF THE
18	EVALUATION SUBCOMMITTEE.
19	MS. LANSING: DEPENDING ON WHAT HAPPENS,
20	WE CAN VOTE JUST ON THE AMENDMENTS LATER, RIGHT?
21	NOT ON THE AMENDMENT, JUST ON THE WE CAN VOTE
22	WITHOUT THE AMENDMENT. THAT'S WHAT OS IS GOING TO
23	SUGGEST.
24	MS. KING: RICARDO AZZIZ.
25	DR. AZZI Z: NO.
	233

1	MS. KING: ROBERT PRICE.
2	DR. PRICE: NO.
3	MS. KING: DAVID BRENNER.
4	DR. BRENNER: NO.
5	MS. KING: JACOB LEVIN.
6	DR. LEVIN: NO.
7	MS. KING: MARCY FEIT.
8	MS. FEIT: NO.
9	MS. KING: MICHAEL FRIEDMAN.
10	DR. FRIEDMAN: YES.
11	MS. KING: LEEZA GIBBONS.
12	MS. GIBBONS: NO.
13	MS. KING: MICHAEL GOLDBERG.
14	MR. GOLDBERG: YES.
15	MS. KING: BOB KLEIN.
16	CHAIRMAN KLEIN: NO.
17	MS. KING: SHERRY LANSING.
18	MS. LANSING: I THINK I HAVE TO RECUSE
19	MYSELF. I CAN'T VOTE FOR MYSELF.
20	MS. KING: GERALD LEVEY.
21	DR. LEVEY: YES.
22	MS. KING: TED LOVE.
23	DR. LOVE: NO.
24	MS. KING: ED PENHOET.
25	DR. PENHOET: NO.
	234

		Di	MIGIERS REPORTING SERVICE
1		MS.	KING: PHIL PIZZO.
2		DR.	PI ZZO: YES.
3		MS.	KING: CLAIRE POMEROY.
4		DR.	POMEROY: I THINK I ALSO SHOULD RECUSE
5	MYSELF.		
6		MS.	KING: FRANCISCO PRIETO.
7		DR.	PRI ETO: NO.
8		MS.	KING: CARMEN PULIAFITO.
9		DR.	PULI AFI TO: NO.
10		MS.	KING: ROBERT QUINT.
11		DR.	QUINT: NO.
12		MS.	KING: JEANNIE FONTANA.
13		DR.	FONTANA: NO.
14		MS.	KING: DUANE ROTH.
15		MR.	ROTH: ABSTAIN.
16		MS.	KING: JOAN SAMUELSON.
17		MS.	SAMUELSON: NO.
18		MS.	KING: DAVID SERRANO-SEWELL.
19		MR.	SERRANO-SEWALL: NO.
20		MS.	KING: JEFF SHEEHY.
21		MR.	SHEEHY: YES.
22		MS.	KING: JON SHESTACK.
23		MR.	SHESTACK: ABSTAIN.
24		MS.	KING: OSWALD STEWARD.
25		DR.	STEWARD: ABSTAIN.
			225
			235

	DARRISTERS REFORTING SERVICE
1	MS. KING: ART TORRES.
2	MR. TORRES: I RECUSE.
3	MS. LANSING: IT DIDN'T CARRY. THAT'S
4	PRETTY OBVIOUS. SO NOW WHAT I'D LIKE TO DO IS ASK
5	FOR A MOTION JUST FOR THE PROPOSAL WITHOUT THE
6	AMENDMENT JUST SO WE CAN GET A SENSE OF WHERE WE
7	ARE.
8	DR. PRIETO: SO MOVED.
9	DR. STEWARD: I EITHER MOVE OR SECOND.
10	MS. LANSING: CAN I HAVE A MOTION THE
11	MOTION IS TO ADOPT THE ORIGINAL PROPOSAL FOR THE
12	EVALUATION WITHOUT DETERMINING WHO IS THE CHAIR OF
13	THE COMMITTEE.
14	MS. KING: AND WHO MADE THE MOTION? DR.
15	STEWARD. AND WHO WAS THE SECOND? DR. PRIETO.
16	RI CARDO AZZI Z.
17	DR. AZZIZ: NO.
18	MS. KING: ROBERT PRICE.
19	DR. PRI CE: YES.
20	MS. KING: DAVID BRENNER.
21	DR. BRENNER: YES.
22	MS. KING: JACOB LEVIN.
23	DR. LEVIN: NO.
24	MS. KING: MARCY FEIT.
25	MS. FEIT: YES.
	236

1	MS. KING: MICHAEL FRIEDMAN.
2	DR. FRIEDMAN: YES.
3	MS. KING: LEEZA GIBBONS.
4	MS. GIBBONS: YES.
5	MS. KING: MICHAEL GOLDBERG.
6	MR. GOLDBERG: YES.
7	MS. KING: BOB KLEIN.
8	CHAIRMAN KLEIN: YES.
9	MS. KING: SHERRY LANSING.
10	MS. LANSING: YES.
11	MS. KING: GERALD LEVEY.
12	DR. LEVEY: YES.
13	MS. KING: TED LOVE.
14	DR. LOVE: YES.
15	MS. KING: ED PENHOET.
16	DR. PENHOET: YES.
17	MS. KING: PHIL PIZZO.
18	DR. PI ZZO: YES.
19	MS. KING: CLAIRE POMEROY.
20	DR. POMEROY: YES.
21	MS. KING: FRANCISCO PRIETO.
22	DR. PRI ETO: YES.
23	MS. KING: CARMEN PULIAFITO.
24	DR. PULIAFITO: NO.
25	MS. KING: ROBERT QUINT.
	237

	DARRISTERS REPORTING SERVICE
1	DR. QUINT: NO.
2	MS. KING: JEANNIE FONTANA.
3	DR. FONTANA: YES.
4	MS. KING: DUANE ROTH.
5	MR. ROTH: ABSTAIN.
6	MS. KING: JOAN SAMUELSON.
7	MS. SAMUELSON: YES.
8	MS. KING: DAVID SERRANO-SEWELL.
9	MR. SERRANO-SEWALL: YES.
10	MS. KING: JEFF SHEEHY.
11	MR. SHEEHY: NO.
12	MS. KING: JON SHESTACK.
13	MR. SHESTACK: ABSTAIN.
14	MS. KING: OS STEWARD.
15	DR. STEWARD: YES.
16	MS. KING: ART TORRES.
17	MR. TORRES: RECUSE.
18	MS. KING: THAT MOTION DOES CARRY.
19	MS. LANSING: SO WHAT WE HAVE TO DO, THEN,
20	IS DETERMINE WHO THE CHAIR AND THE VICE CHAIR ARE,
21	RI GHT?
22	MR. SHEEHY: WHY DON'T WE HAVE THE CHAIR
23	AND THE VICE CHAIRS NOMINATE THE CHAIRS AND THE VICE
24	CHAIRS OF THE COMMITTEE.
25	MS. LANSING: SOMEONE ASKED THE QUESTION
	220
	238

1	WHAT DO WE HAVE LEFT TO DO?
2	MR. SHEEHY: I'M NOT BEING FACETIOUS.
3	LET'S HAVE THE CHAIR AND THE VICE CHAIRS NOMINATE
4	THE CHAIRS OF THE COMMITTEE THAT WILL EVALUATE THEM.
5	CHAIRMAN KLEIN: I'D LIKE TO MAKE A MOTION
6	THAT THIS BOARD ELECT THE CHAIR AND VICE CHAIR FROM
7	AMONG THE MEMBERS OF THE COMMITTEE.
8	MR. SERRANO-SEWELL: DON'T YOU THINK WE
9	SHOULD FIRST ELECT THE TWO AT LARGE MEMBERS?
10	MS. LANSING: I'M CONFUSED NOW MYSELF. SO
11	WHAT DO WE HAVE LEFT TO DO, JAMES?
12	MR. HARRISON: IF THE BOARD WISHES, IT CAN
13	AT THIS POINT IN TIME APPOINT THE TWO AT LARGE
14	MEMBERS. AND IF IT SO WISHES, IT CAN APPOINT THE
15	CHAIR AND THE VICE CHAIR OF THE EVALUATION
16	SUBCOMMITTEE, OR IT CAN LEAVE THAT ACTION TO THE
17	EVALUATION SUBCOMMITTEE ITSELF.
18	CHAIRMAN KLEIN: COULD I ASK THIS
19	QUESTION? SINCE WE HAVE A GRANT A VERY CRITICAL
20	GRANT ROUND, CAN WE JUST WE HAVE THE BASIC
21	STRUCTURE, AND WE'LL GIVE PEOPLE TIME TO THINK ABOUT
22	OPTIONS, AND WE CAN DEAL WITH TWO MEMBERS AND THE
23	CHAIRS LATER. THANK YOU. THANK YOU FOR ALL THE
24	WORK THAT WENT INTO THIS.
25	AND AS WE DO HAVE ROBUST DISCUSSION, I DID
	239
	4J7

1	NOTE THAT, SHERRY, YOU GOT THIS DONE WITHIN YOUR
2	DESIGNATED TIME, BUT IT DID TAKE A LOT OF ROBUST
3	DISCUSSION. CERTAINLY I RESPECT THE OPINIONS
4	EXPRESSED HERE. AND I PERSONALLY AND I'M SURE THE
5	REST OF THE MEMBERS ON THIS COMMITTEE WILL TRY AND
6	FOLLOW THE SPIRIT AND INTENT OF ALL THE COMMENTS
7	MADE TO MAKE SURE WE HAVE THE BEST PROCESS POSSIBLE.
8	AND CERTAINLY LEGAL COUNSEL IS AWARE OF THIS. WE
9	HAVE A GOOD RECORD TO GUIDE US. AND WE'LL DO OUR
10	BEST, AS WE DO IN GRANTS WORKING GROUP, AS WE DO IN
11	THIS BOARD TO MAKE SURE THE RECUSALS ARE APPROPRIATE
12	AND CONFIDENTIALITY IS STRICT.
13	WE NEED TO MOVE ON TO THE GRANTS
14	CONSIDERATION IMMEDIATELY. AND, JEFF, I THINK IT
15	WOULD BE HELPFUL IF YOU COULD JUST REVIEW THE GRANT
16	CATEGORIES AND LEAD US THROUGH THIS PROCESS STARTING
17	WITH THE TIER 1.
18	MR. SHEEHY: JUST LOOKING, WE HAVE 15
19	APPLICATIONS IN TIER 1 RANGING FROM 94 TO 77. AND
20	JUST TO GIVE YOU A SENSE OF THE PROCESS WE GO
21	THROUGH, THE FIRST THING I'LL DO IS TAKE MOTIONS TO
22	MOVE APPLICATIONS OUT OF TIER 1, AND THE SECOND
23	PROCESS WE'LL GO THROUGH IS TO MOVE ANY APPLICATIONS
24	INTO TIER 1, AND THEN WE'LL DISPOSE OF THE REMAINING
25	APPLICATIONS BY VOTING THROUGH TIER 1 AND THEN

1	VOTING THE REST OF THE APPLICATIONS NOT FUNDABLE AT
2	THIS TIME.
3	SO I THINK THE FIRST MOTION I WOULD
4	ENTERTAIN IS A MOTION TO MOVE ANY APPLICATION
5	CURRENTLY IN TIER 1 OUT OF TIER 1. AND I WOULD ASK
6	THAT THE MAKER OF THE MOTION AND THE SECOND REFRAIN
7	FROM DISCUSSION TILL WE HAVE CONFLICTS OF INTEREST
8	IDENTIFIED BY COUNSEL.
9	DR. PENHOET: MAYBE FOR THE SAKE OF PEOPLE
10	LOOKING AT THIS, WE'RE NOW TALKING ABOUT TIER 1 PART
11	A AND PART B BECAUSE IT SAYS FUNDING LINE THERE
12	UNDER TIER 1, PART A.
13	MR. SHEEHY: I DESCRIBED IT IN THE RANGE
14	FROM 94 TO 77.
15	MR. SHESTACK: SO WHAT, JEFF, IS THIS
16	DESIGNATION OF THE DIFFERENCE BETWEEN WHITE AND
17	LIGHT BLUE? JUST TO HELP US UNDERSTAND THE
18	DIFFERENCE BETWEEN 81 AND 77?
19	CHAIRMAN KLEIN: JEFF, YOU MIGHT GIVE THEM
20	THE HISTORY OF THE GRANTS WORKING GROUP. AT THE
21	TIME THAT THE GRANTS WORKING GROUP WAS GOING THROUGH
22	THIS, THERE WAS CONCERN OF HOW MUCH FUNDS WE WOULD
23	HAVE AVAILABLE. JEFF, MAYBE YOU COULD GIVE THEM
24	THAT HISTORY SO IN THE CONTEXT THEY NOW UNDERSTAND
25	THE FACTUAL CHANGES THAT LED TO THAT.

1	MR. SHEEHY: SO ANTICIPATING A SHORTFALL
2	IN FUNDING, THE GRANTS WORKING GROUP BASICALLY
3	DIVIDED THE TIER 1 INTO TWO, ANTICIPATING WE
4	WOULDN'T HAVE FUNDS AVAILABLE TO FUND ALL OF TIER 1.
5	THEY, AS YOU CAN SEE, FOLLOWED THE NUMERICAL SCORES
6	AND DREW A LINE ROUGHLY HALFWAY BETWEEN THE TWO
7	GROUPS. SO THAT IS THE MEANING OF THAT.
8	MR. SHESTACK: SINCE THAT EVENTUALITY DID
9	NOT HAPPEN, THIS IS NOT AN IMPORTANT DESIGNATION FOR
10	US NOW?
11	MR. SHEEHY: ONLY IN THAT IT SEPARATES THE
12	SCORES. SO THERE IS A DIFFERENCE BETWEEN AN 84 AND
13	AN 81, SO THAT'S THE DISTINCTION THAT IS RELEVANT.
14	DR. PRIETO: I THINK I MADE THIS POINT
15	BEFORE, BUT I THINK THE DISTINCTION THE POINT
16	SCORES THAT ARE THREE POINTS APART ARE REALLY NOT
17	SIGNIFICANTLY DIFFERENT. AND GIVEN OUR CURRENT
18	FUNDING SITUATION, I WOULD LIKE TO JUST DISREGARD
19	THAT DIVISION BETWEEN 1(A) AND 1(B).
20	SO MOVED.
21	DR. LEVEY: SECOND.
22	MR. SHEEHY: I DON'T THINK THAT MOTION IS
23	APPROPRIATE OR NECESSARY. WE HAD THE CATEGORY AS
24	EXPRESSED AS TIER 1, WHICH IS RECOMMENDED FOR
25	FUNDING. THESE WERE NOT DIVIDED INTO RECOMMENDED
	242
	_ ·-

1	FOR FUNDING IF FUNDING WERE AVAILABLE. THEY WERE
2	ALL RECOMMENDED FOR FUNDING.
3	WHAT WE ASKED THE WORKING GROUP TO DO IS
4	IF WE WERE IN THE MOST DIRE SITUATION, WHICH WAS
5	EXTREMELY LIMITED FUNDS, DRAW A LINE. AND WE
6	ANTICIPATED PERHAPS THE LINE WOULD BE HALFWAY. BUT
7	WE ACTUALLY ASKED THEM TO RANK THEM, AND THEY KEPT
8	THEM ALL IN NUMERICAL ORDER. THE ONLY RERANKS THAT
9	OCCURRED WERE BETWEEN APPLICATIONS THAT HAD
10	IDENTICAL SCORES, AND I DON'T BELIEVE THAT HAPPENED
11	MORE THAN ONCE, IF AT ALL.
12	MR. SHESTACK: NOT AT ALL IN TIER 1.
13	MR. SHEEHY: NO. REMEMBER, THE WORKING
14	GROUP WAS LOOKING AT REMEMBER WHERE WE WERE A
15	WEEK AGO. AND WE WERE NOT ANTICIPATING HAVING
16	SUFFICIENT FUNDS TO FUND THIS PROGRAM. SO WE DID
17	SPEND A LOT OF TIME IN PROGRAMMATIC REVIEW ASKING
18	THE SCIENTISTS TO RANK THESE. THEY LEFT THEM
19	FUNDAMENTALLY IN NUMERICAL ORDER. THE ONLY
20	SIGNIFICANT CHANGES THE ONLY CHANGES AT ALL, AND,
21	AGAIN, I THINK MIGHT HAVE BEEN BETWEEN ONES THAT HAD
22	IDENTICAL NUMBERS; BUT AS YOU CAN SEE, THEY DID NOT
23	CHANGE THE ORDER BY NUMBER, BY THE NUMERICAL SCORE
24	IN ANY OF THESE. THAT WAS SIMPLY TO PROVIDE
25	GUI DANCE.
	242

1	WE DID NOT KNOW, FOR INSTANCE, AT THE
2	WORKING GROUP, WE WERE ANTICIPATING A SITUATION
3	WHERE WE WOULD START WITH THE TOP GRANT, THE 94, AND
4	DECIDE WE WERE ANTICIPATING NOT KNOWING WHERE OUR
5	FUNDING LINE WAS GIVEN THAT WE DIDN'T KNOW WHAT
6	FUNDS WOULD REALLY BE AVAILABLE. BUT THEY DID
7	RECOMMEND ALL OF TIER 1 FOR FUNDING.
8	MR. SHESTACK: NOW WE KNOW WHAT FUNDS ARE
9	AVAI LABLE.
10	MR. SHEEHY: I DON'T THINK WE NEED ANOTHER
11	MOTION BECAUSE THIS CATEGORY IS STILL RECOMMENDED
12	FOR FUNDING.
13	DR. PRIETO: I'LL WITHDRAW THE MOTION.
14	DR. FONTANA: IS IT APPROPRIATE NOW TO
15	DISCUSS WHAT FUNDS WE ARE GOING TO ALLOCATE TO THIS
16	ROUND OF GRANTS? IN OTHER WORDS, CAN WE DECIDE AS A
17	GROUP THAT WE'RE GOING TO ALLOCATE MORE THAN WHAT
18	WAS BUDGETED TO FUND MORE OF THE TIER 2 GRANTS AS
19	OPPOSED TO PICKING ONE OR TWO?
20	MR. SHEEHY: NO. I MEAN I TRUST THAT
21	BOARD MEMBERS ARE AWARE OF OUR FINANCIAL SITUATION.
22	WE TYPICALLY DON'T CHANGE THE FUNDS AVAILABLE FOR A
23	GRANT ROUND IN THE MIDDLE OF A GRANT ROUND. I THINK
24	IT'S INCUMBENT ON US AS STEWARDS OF OUR FUNDS TO
25	LOOK AT TIER 1, RECOGNIZE THAT IT IS OVER BUDGET.
	244

1	IF WE WANT TO PROCEED WITH APPROVING EVERYTHING IN
2	TIER 1, THEN THAT'S WHAT WE DO. AND THEN IF WE DO
3	MOVE GRANTS UP FROM TIER 2, TO RECOGNIZE THAT WE ARE
4	SPENDING MONEY. BUT, YOU KNOW, THIS HAS TO BE
5	CONSISTENT WITH OUR MISSION.
6	SO I HAVE OS AND THEN BOB.
7	DR. STEWARD: JUST FOR THE RECORD, COULD
8	WE STATE THE BUDGET FOR THIS GRANT ROUND AND EXACTLY
9	WHAT THE TOTAL OF THE GRANTS IN TIER 1 IS RIGHT NOW?
10	MR. SHEEHY: THE 60 MILLION IS UP THERE.
11	AGAIN, WE'RE RECAPITULATING SOME OF THE DISCUSSION
12	THAT WENT ON LAST NIGHT. I WOULD AGAIN NOTE THAT
13	REVIEWERS DID OBSERVE THAT SEVERAL GRANTS SEEMED
14	EXCESSIVE. WE CAN'T PUT A DOLLAR VALUE. MAYBE I
15	DON'T THINK IT'S APPROPRIATE FOR US TO ASSIGN THAT
16	OR TO LOOK AT ANY INDIVIDUAL GRANT, BUT THEY DID
17	COMMENT ON SEVERAL GRANTS THAT THEY THOUGHT THAT THE
18	BUDGETS WERE EXCESSIVE. STAFF HAS THE ABILITY TO
19	COLLECT ADDITIONAL INFORMATION AND JUSTIFICATION FOR
20	THOSE BUDGETS.
21	AND I SUSPECT MY ASSURANCE FROM STAFF,
22	AND STAFF HAS ASSURED US HERE LAST NIGHT, THAT
23	THEY'RE GOING TO DO THIS WITH ALL DUE DILIGENCE. SO
24	I THINK THAT YOU MAY AGAIN, THIS IS A JUDGMENT WE
25	EACH INDIVIDUALLY HAVE TO MAKE, WHETHER YOU THINK,

1	HAVING READ THROUGH ALL YOUR INFORMATION, THAT THE
2	POSSIBILITY IS THAT THESE MIGHT NOT ACTUALLY COME IN
3	AT THE FULL 67.7 MILLION.
4	CHAIRMAN KLEIN: SO IN LOOKING AT THE
5	BUDGET AND WHAT WE HAVE AVAILABLE, IF THE BOARD
6	DECIDES THAT THERE ARE INDIVIDUAL GRANTS THAT ARE IN
7	THE FUND IF AVAILABLE CATEGORY, FOR EXAMPLE, THAT
8	WOULD MEET A CRITICAL OBJECTIVE, AND IN DISCUSSION
9	HERE WE FIND THAT HAS MERIT AND THEY'RE INDIVIDUALLY
10	LISTED, WE HAVE THE OPTION OF INCREASING WHAT WE'RE
11	DOING IN THIS ROUND, AND/OR SEPARATELY I WOULD ALSO
12	SUGGEST THAT IF THERE ARE THREE OR FOUR GRANTS THAT
13	END UP IN THAT CATEGORY, TO THE EXTENT YOU DON'T
14	WANT TO COMMIT TO INCREASING WHAT WE'RE DOING IN
15	THIS ROUND AT THIS MOMENT, WE COULD DEFER THREE OR
16	FOUR GRANTS TO THE JUNE MEETING. AND I COULD IN
17	THAT TIME PERIOD HAVE ADDITIONAL TIME TO IDENTIFY
18	ADDITIONAL RESOURCES.
19	SO THAT IS ANOTHER OPTION FOR THE BOARD.
20	MR. SHEEHY: I THINK
21	MR. SHESTACK: I'M SORRY. THE BUDGET WE
22	HAVE AVAILABLE FOR THIS RFA IS 67?
23	CHAIRMAN KLEIN: YES.
24	MR. SHESTACK: THAT'S 60. AND THE
25	COMBINED ALL TIER 1, ALL 15 TIER 1 GRANTS ARE 67.
	246
	<u> </u>

CHAIRMAN KLEIN: ARE 67 MILLION.
MR. SHESTACK: OKAY.
CHAIRMAN KLEIN: ALMOST 68 MILLION.
DR. BRENNER: JEFF, IS IT APPROPRIATE NOW
TO MAKE A PROPOSAL TO FUND THE TIER 1 GRANTS?
MR. SHEEHY: COUNSEL, IS THAT AN
ACCEPTABLE MOTION? IT HAS TO COME FROM SOMEONE
WHO'S NOT CONFLICTED.
MR. HARRISON: CORRECT.
MR. ROTH: I WILL MAKE A MOTION THAT WE
FUND ALL OF TIER 1 GRANTS, 67.728767.
MS. GIBBONS: SECOND.
CHAIRMAN KLEIN: AND QUESTION, IS YOUR
MOTION INTENDED TO EXCLUDE OTHER GRANTS FROM BEING
APPROVED?
MR. ROTH: NO.
CHAIRMAN KLEIN: IT'S JUST TO FUND TIER 1.
SO THAT LEAVES OPEN THE ISSUE OF WHETHER ADDITIONAL
GRANTS ARE THEN ADDED TO IT.
MR. SHESTACK: OPEN ISSUE OF WHERE THIS \$7
MILLION IS GOING TO COME FROM. OKAY.
DR. LOVE: IS THERE ANY THINKING IN THE
RECOMMENDATION OR THE MOTION THAT THERE WILL BE SOME
PROCESS THAT MAYBE THAT 67 ISN'T 67 WHEN THE FUNDING
IS FINALLY I CAN'T DO THAT?
247

24 /

MR. HARRISON: YOU CAN, AND I ACTUALLY
WANTED TO ADD THAT. ALL OF YOUR GRANT APPROVALS
ARE, BY DEFINITION, UNDER THE REGULATIONS SUBJECT TO
PREFUNDING ADMINISTRATIVE REVIEW. AND WE SHOULD BE
CLEAR THAT THIS MOTION WOULD BE AS WELL; THAT IS,
IT'S APPROVAL OF THE GRANTS SUBJECT TO THE STAFF'S
PREFUNDING ADMINISTRATIVE REVIEW AND INCLUDING THE
REVIEW OF THE BUDGETS.
MR. ROTH: WHAT JAMES JUST SAID HAS ALWAYS
BEEN TRUE, AND WE SHOULDN'T PROBABLY CONSIDER THAT
NOW. WE SHOULD DO LIKE WE ALWAYS HAVE. BUT THAT'S
THE ABSOLUTE MAXIMUM THAT WOULD BE SPENT IF
EVERYTHING PASSES THROUGH THE GRANTS THE REVIEW
OF THE GRANT FOR FEASIBILITY. IT WON'T BE HIGHER
THAN THAT.
DR. LOVE: I SECOND.
MR. ROTH: I DO, IN MAKING THE MOTION,
UNDERSTAND THAT WE'LL BE SPENDING AT THIS POINT \$8
MILLION MORE THAN WE BUDGETED, BUT THEY WERE ALL IN
THE TIER TO BE FUNDED. IF I REMEMBER THE NUMBERS
FROM YESTERDAY, WE'RE STILL THROUGH THE TIME PERIOD
THAT JOHN ROBSON DESCRIBED, WE HAD 14 MILLION, I
THINK, OVER THE LINE.
DR. ROBSON: IT'S LESS THAN THAT. IF WE
FUND THE TRAINING GRANTS COMES DOWN TO
248

1	MR. ROTH: HOW MUCH ARE THE TRAINING
2	GRANTS?
3	DR. ROBSON: IF YOU WERE NEXT IN JUNE TO
4	START THE TRAINING GRANT II EARLIER, IMMEDIATELY,
5	FOR EXAMPLE, THAT WOULD ADD 13 MILLION TO OUR
6	COMMITMENT TO THE END OF 2010, WHICH WOULD DROP OUR
7	SORT OF CUSHION THERE TO ABOUT FOUR MILLION.
8	MS. SAMUELSON: DIDN'T WE VOTE TO DEFER
9	THAT THOUGH?
10	DR. ROBSON: NO. I'M JUST DID NOT.
11	CHAIRMAN KLEIN: THE POINT THAT IS BEING
12	MADE, JOAN, IS THAT I THINK THERE IS A POINT, GIVEN
13	THE AMENDED BUDGET AND GIVEN AN IDENTIFICATION OF
14	RESOURCES IN THE JUNE MEETING, TO RECONSIDER THIS
15	ISSUE OF WHETHER WE CAN, IN FACT, GO AHEAD AT THIS
16	TIME WITH FUNDING THE TRAINING GRANTS BECAUSE THERE
17	ARE INSTITUTIONS THAT HAVE PROVED HIGHLY PRODUCTIVE.
18	AT THE TIME WE DEFERRED IT, WE DIDN'T HAVE THE
19	RESOURCES WE HAVE. SO IT'S A SEPARATE DECISION
20	COMPLETELY SEPARATE FROM THIS DECISION.
21	AND IN THE JUNE MEETING, THERE WILL BE A
22	RECONSIDERATION OF WHETHER WE SHOULD FUND THE
23	TRAINING GRANTS ON A CASH FLOW BASIS BECAUSE WE WERE
24	OBLIGATED TO FUND THEM IN ANY CASE, BUT ON A CASH
25	FLOW BASIS, WHETHER WE WOULD FUND THEM NOW INSTEAD
	240

1	OF HAVING OUR FUNDS START BEING DISTRIBUTED IN A
2	YEAR FROM NOW. IN EITHER CASE, THE LIABILITY WOULD
3	HAVE ACCRUED DURING THAT PERIOD.
4	MS. SAMUELSON: BUT THAT WOULDN'T
5	CONSTRAIN US NOW FROM TAKING THIS STEP.
6	CHAIRMAN KLEIN: THAT'S A CORRECT
7	STATEMENT.
8	DR. TROUNSON: CHAIR, I THINK AS PRESIDENT
9	OF THE AGENCY, I WOULD PREDICT THAT WE WOULDN'T BE
10	ABLE TO REMOVE \$8 MILLION FROM THE BUDGET. I'LL BE
11	REALLY SURPRISED IF THAT'S POSSIBLE. SO I THINK WE
12	NEED TO BE REFLECTIVE.
13	YOU AND I HAVE DISCUSSED THE POSSIBILITY
14	OF IDENTIFYING A DIFFERENT SOURCE OF FUNDS TO ADD TO
15	THIS, IF THE BOARD FEELS THAT THAT'S APPROPRIATE,
16	AND I'D SUPPORT THAT. BUT THERE'S NO GUARANTEE, OF
17	COURSE, IF YOU DID IDENTIFY THEM.
18	BUT BEING FISCALLY RESPONSIBLE, I THINK,
19	IS STILL REQUIRED OF US. WE HAVE HAD A WONDERFUL
20	RETURN OF MONEY FROM THE GOVERNMENT, BUT WE'RE STILL
21	CLOSE HAULED. AND IF WE MOVE THE TRAINING GRANTS
22	UP, AS I HOPE YOU MAY DO IN JUNE, WE'RE GOING TO BE
23	VERY TIGHT HAULED ON THIS. I THINK SOME DEGREE OF
24	FISCAL RESPONSIBILITY IS NECESSARY TO POINT OUT TO
25	YOU, AND I HOPE YOU WILL BE RESPONSIVE BECAUSE IT'S
	250

1	REALLY QUITE STRESSFUL AND DIFFICULT TO TRY AND STAY
2	WITHIN THE BUDGET FRAMEWORK UNDER THE PRESENT
3	CI RCUMSTANCES.
4	MS. LANSING: WELL, I RESPECT VERY MUCH
5	WHAT YOU'RE SAYING, BUT THIS IS TRANSLATIONAL
6	RESEARCH, WHICH IS WHAT WE'VE REALLY ALL BEEN
7	GEARING TO. AND I THINK THAT THESE GRANTS, AND I'M
8	ACTUALLY GOING TO SUGGEST MOVING SOME UP THAT ARE IN
9	TIER 2, ARE EXTREMELY IMPORTANT. AND THE WORLD
10	CHANGED ON FRIDAY, AND WE FIND THAT WE ARE WELL
11	FUNDED FOR THE NEXT YEAR. AND I THINK THAT'S A REAL
12	COMMITMENT, THAT THE STATE, THE GOVERNOR, AND THE
13	TREASURER'S OFFICE HAS MADE TO US. AND I THINK THAT
14	THAT COMMITMENT, I'M HOPEFUL, WILL CONTINUE.
15	AND I THINK THAT THE PEOPLE OF CALIFORNIA
16	WHO VOTED FOR THIS ARE LOOKING FOR THESE
17	TRANSLATIONAL AND DISEASE TEAMS THAT ARE GOING TO
18	COME. I THINK THIS IS ACTUALLY A TIME, IF THE
19	SCIENCE JUSTIFIES IT, TO SPEND THE MONEY BECAUSE
20	THESE OPPORTUNITIES ARE WHAT WE HAVE BEEN WAITING
21	FOR.
22	DR. LOVE: I WAS JUST GOING TO SAY I THINK
23	WHAT SHERRY IS SAYING IS QUITE IMPORTANT. THE ONE
24	QUESTION I WANT TO RAISE, I'M NOT SURE HOW WE CAN
25	GET AT THIS, IS THAT I HAVE HEARD A COUPLE OF TIMES
	251

1	NOW PEOPLE TALK ABOUT POTENTIALLY THAT THE
2	SCIENTIFIC INTEGRITY OF THIS COMPETITION ISN'T AS
3	HIGH AS SOME OF THE OTHERS.
4	I GUESS THE THING I'M TRYING TO WORK
5	THROUGH IN MY HEAD IS BALANCING SHERRY'S POINT ABOUT
6	FUNDING THESE AND GETTING THIS GOING VERSUS
7	COMITTING TO THESE WHEN, IN FACT, IN SIX MONTHS OR
8	EIGHT MONTHS THE QUALITY OF WHAT WE COULD FUND MIGHT
9	ACTUALLY BE HIGHER. SO I DON'T KNOW WHO CAN TRY TO
10	GET AT THAT POINT, BUT I THINK THAT'S A REAL ISSUE
11	THAT WOULD HELP ME IN TERMS TRYING TO FIGURE OUT DO
12	WE REALLY TRY TO MOVE THINGS UP.
13	MR. SHESTACK: THE FIRST PART OF YOUR
14	COMMENT, YOU SAID THAT THERE WERE QUESTIONS ABOUT
15	DR. LOVE: THE QUALITY OF THE GRANTS.
16	CHAIRMAN KLEIN: CAN I ASK AS A POINT OF
17	ORDER
18	MR. SHESTACK: I APOLOGIZE FOR MISSING
19	THAT PART OF THE DISCUSSION.
20	CHAIRMAN KLEIN: WE HAVE A MOTION ON THE
21	TABLE. WHAT IS IN ORDER IN TERMS OF WHO CAN DISCUSS
22	THE CURRENT MOTION? I JUST WANT TO BE CAREFUL.
23	MR. HARRISON: IN TERMS OF THE MOTION
24	THAT'S ON THE TABLE, WHICH IS TO APPROVE THOSE
25	APPLICATIONS IN TIER 1, ONLY THOSE MEMBERS WHO DO
	252

1	NOT HAVE A CONFLICT OF INTEREST IN AN APPLICATION
2	WITHIN TIER 1 CAN ADDRESS THE MOTION.
3	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
4	MR. SHEEHY: COULD WE GO TO DR. FRIEDMAN,
5	WHO'S BEEN WAITING.
6	CHAIRMAN KLEIN: I'M ASKING THE QUESTION
7	TO MAKE CERTAIN WE'RE CAREFUL.
8	DR. FRIEDMAN: THANK YOU.
9	CHAIRMAN KLEIN: AND DO WE KNOW THAT
10	DR. FRIEDMAN, ARE WE AWARE? DO YOU HAVE A CONFLICT?
11	DR. FRIEDMAN: NOTHING THAT I HAVE TOLD ME
12	I'M IN CONFLICT UNLESS THERE'S ANYTHING THAT YOU
13	HAVE.
14	MR. HARRISON: YOU DO NOT.
15	DR. FRIEDMAN: THANK YOU. THESE MEETINGS
16	MAKE ME FEEL CONFLICTED, BUT THAT'S A DIFFERENT
17	I SSUE.
18	I'D LIKE TO MAKE A GENERAL STATEMENT
19	BEFORE WE GET INTO SOME OF THE VERY INTERESTING AND
20	MERITORIOUS GRANTS THAT WILL BE TALKED ABOUT LATER.
21	AND I WANT TO JUST SHARE WITH YOU MY SENSE THAT, AS
22	WE HAVE SEEN GRANTS EVOLVE OVER THE LAST SEVERAL
23	YEARS HERE, WE'VE SEEN INCREASING SOPHISTICATION AND
24	INCREASING PROMISE. AND THAT AT EACH MOMENT WHEN
25	WE'VE BEEN FORTUNATE ENOUGH TO REVIEW GRANTS, WE'VE
	253

1	COMMENTED ON HOW EXCITING AND INTERESTING THEY WERE.
2	I LOOK BACK AND WOULDN'T CHANGE ANY OF THOSE
3	DECISIONS AT ALL.
4	I THINK RIGHT NOW WE'RE FACING A LARGE
5	NUMBER OF TRULY ATTRACTIVE AND INTERESTING GRANTS
6	THAT WE'RE GOING TO HAVE TO CONSIDER, NOT JUST IN
7	THIS FIRST SET, WHICH EXCEEDS THE INITIAL AMOUNT
8	THAT WE HAD BUDGETED FOR THIS. BUT THERE WILL BE
9	MERITORIOUS GRANTS AND INTERESTING GRANTS THAT
10	PEOPLE WILL NOMINATE TO MOVE UP DURING THIS TIME.
11	MY OWN FEELING IS, AS ATTRACTIVE AS THESE
12	ARE, AS IMPORTANT CLINICALLY AS THESE PROBLEMS
13	REPRESENT, AS ATTRACTIVE THE PROPOSITION THAT WE MAY
14	BE ABLE TO MAKE AN IMPORTANT DISCOVERY, I REALLY
15	FEEL IT'S IMPORTANT FOR US TO STAY WITHIN OUR BUDGET
16	AT THIS TIME. AND I KNOW THAT SOUNDS ANTISCIENTIFIC
17	OR CONSTRAINING OUR HOPES FOR THE FUTURE, BUT I
18	REALLY THINK IT'S THE RIGHT POSITION FOR US RIGHT
19	NOW.
20	I HAVE A FEELING, I DON'T KNOW WHAT THE
21	NEXT ROUND OF PROPOSALS THAT WE'LL GET, BUT I HAVE A
22	FEELING THEY'RE GOING TO BE SPLENDID. AND I CAN
23	REASONABLY BET THAT THE ROUND AFTER THAT IS GOING TO
24	BE EQUALLY GOOD OR BETTER, AND I HAVE NO PROBLEM
25	WITH THOSE WHO SAY THERE'S SOME VERY ATTRACTIVE
	25.4

1	GRANTS HERE THAT WE SHOULD PARK, PUT ASIDE, COME
2	BACK AND LOOK AT AT A FUTURE TIME; AND SHOULD WE
3	FIND OURSELVES IN A MORE FLEXIBLE, MORE COMFORTABLE
4	FINANCIAL POSITION, REACH IN AND GRAB SOME OF THOSE.
5	I WANT TO MAKE THAT COMMENT NOW SO THAT LATER IT'S
6	NOT MISPERCEIVED THAT I'M AGAINST A CERTAIN GRANT OR
7	THAT I DON'T THINK A CERTAIN DISEASE IS IMPORTANT
8	ENOUGH OR I DON'T LIKE A TECHNOLOGY. THAT'S NOT
9	WHAT I'M TALKING ABOUT AT ALL.
10	I'M MAKING THE GENERAL POINT THAT I THINK
11	IT WOULD REALLY BE IMPORTANT FOR US TO PRESERVE THE
12	FISCAL INTEGRITY OF THE ENTIRE SYSTEM. AND THESE
13	ARE A GREAT BUNCH OF GRANTS. I WISH WE COULD HAVE
14	COME IN AT \$60 MILLION. I'M NOT GOING TO PROPOSE
15	THAT WE TRY AND DO THAT NOW BECAUSE THERE'S A
16	NATURAL CLEAVAGE POINT AT 67 PLUS MILLION DOLLARS.
17	BUT JUST PERSONALLY I WOULD URGE US ALL TO PLEASE
18	RECONSIDER AND EITHER PICK SOME OUT OF THE FIRST
19	RANK, IF YOU FEEL STRONGLY THAT THERE'S SOME THAT
20	YOU'D LIKE TO MOVE UP, OR STICK WITH THESE. SORRY
21	TO GO ON SO LONG. THANK YOU.
22	DR. CSETE: I'D LIKE TO ANSWER TED'S
23	QUESTION WHICH HE RAISED AND ALSO THE QUESTION THAT
24	DR. FRIEDMAN RAISED. SO WE WILL HAVE A SECOND ROUND
25	OF EARLY TRANSLATION PROBABLY AT THE VERY END OF

1	THIS YEAR. AND
2	MS. SAMUELSON: I DIDN'T HEAR WHEN.
3	DR. CSETE: THE VERY END OF THIS YEAR IT
4	WILL BE POSTED, SO A YEAR AFTER THE FIRST ROUND
5	BASICALLY. SO THAT IS, I THINK, SOMETHING VERY
6	IMPORTANT TO KEEP IN MIND.
7	AS REGARDS THE QUALITY, I THINK THAT THIS
8	ROUND WAS A LEARNING EXPERIENCE IN A LOT OF WAYS.
9	IN RETROSPECT, I SAW GRANTS THAT PROBABLY WERE MORE
10	WELL-SUITED TO A BASIC SCIENCE ROUND. IN
11	RETROSPECT, I SAW SOME GRANTS THAT WERE PROBABLY IN
12	RETROSPECT MORE SUITED TO A DISEASE TEAM ROUND. SO
13	I THINK THAT'S PART OF THE DISCOMFORT THAT PEOPLE
14	WERE FEELING, OUR REVIEWERS, US, EVERYTHING. BUT
15	THIS IS NEW. WE'LL LEARN FROM IT. AND I THINK
16	THERE CERTAINLY ARE PROPOSALS HERE THAT ARE NOT
17	QUITE READY FOR PRIME TIME THAT WILL BE IN THE
18	SECOND ROUND. SO I THINK THAT HELPS IN YOUR
19	DELI BERATI ONS.
20	DR. STEWARD: I REALIZE I AM IN CONFLICT,
21	AND I'M NOT SPEAKING TO THE MOTION EXACTLY. I'LL
22	JUST THIS IS A POINT OF ORDER. IN TERMS OF OUR
23	PAST, I THOUGHT THAT PRIOR TO VOTING TO APPROVE TIER
24	1, WE FIRST CONSIDERED THE COMPOSITION OF TIER 1.
25	IN OTHER WORDS, WENT THROUGH MOTIONS TO CONSIDER
	05/

1	MOVING OTHER GRANTS UP INTO TIER 1 BEFORE WE VOTED
2	THAT APPROVAL. AM I MISSING THAT?
3	MR. HARRISON: WE'VE DONE IT A VARIETY OF
4	WAYS. I BELIEVE THAT JEFF SHEEHY STARTED THIS
5	DISCUSSION BY ASKING WHETHER ANY MEMBER WANTED TO
6	MAKE A MOTION TO MOVE AN APPLICATION OUT OF TIER 1.
7	AND THE APPROVAL OF THE APPLICATIONS WITHIN TIER 1
8	DOES NOT EXCLUDE THE POSSIBILITY THAT OTHER
9	APPLICATIONS COULD BE MOVED UP FOR FUNDING.
10	DR. STEWARD: I JUST WANTED TO CLARIFY
11	THAT. THAT'S FINE. THANK YOU.
12	MR. SHEEHY: SO I THINK WE'VE HAD A VERY
13	HEALTHY DISCUSSION. I WAS GOING TO ASK FOR PUBLIC
14	COMMENT AND THEN A VOTE IF EVERYBODY IS COMFORTABLE
15	WITH THAT. IS THERE PUBLIC COMMENT?
16	MS. PETERSON: IN REGARD TO THE FUNDING.
17	MR. SHEEHY: COULD YOU PLEASE I'M
18	SORRY. COULD YOU PLEASE STATE YOUR NAME TO KEEP IT
19	IN THE RECORD?
20	MS. PETERSON: OH, SORRY. I'M SUZANNE
21	PETERSON. I'M FROM JEAN LORING'S LAB AT SCRIPPS. I
22	JUST WANTED TO SAY, LIKE, THAT I THOUGHT WE WERE
23	GOING TO HAVE SORT OF MILESTONES THAT WE HAD TO GET
24	TO AT A CERTAIN POINT IN THE GRANT. AND SO PERHAPS
25	A LOT OF THOSE PEOPLE WILL NOT GET TO THAT
	257

25/

1	MILESTONE, AND SO IT WON'T BE \$7 MILLION OVER.
2	MR. SHEEHY: WE DID DISCUSS THAT A LITTLE
3	BIT LAST NIGHT. THE TERM WE'RE USING IS SUCCESS
4	CRITERIA. BUT THESE GRANTS THERE IS THAT, AS I
5	UNDERSTAND FROM STAFF, AND I WANT TO RECAPITULATE
6	THIS ACCURATELY, AND IT VARIES BECAUSE IT DIFFERS ON
7	WHETHER YOU'RE ATTACKING A BOTTLENECK OR ATTACKING A
8	DISEASE TARGET. BUT THAT THESE GRANTS THE STAFF
9	DOES HAVE THE ABILITY TO SAY THAT SUCCESS IS NOT
10	GOING TO HAPPEN, AND SO IT'S NOT NECESSARILY TRUE
11	THAT ALL THESE GRANTS WILL GO FULL TERM.
12	MS. PETERSON: SO IT MAY NOT BE AS MUCH AS
13	67 MILLION.
14	MR. SHEEHY: YEAH. THAT POINT WAS MADE A
15	LOT LAST NIGHT. I APOLOGIZE FOR NOT MAKING IT
16	TODAY. I THINK THAT'S A VALUABLE POINT.
17	MR. ROTH: THAT'S WHAT I SAID EARLIER.
18	THAT'S TRUE OF ALL THE GRANTS WE'VE EVER GIVEN; AND,
19	THEREFORE, THAT IS NOT A VALID CONSIDERATION TO TAKE
20	A HAIRCUT ON THIS ONE. WE'VE NEVER DONE THAT
21	BEFORE. THAT'S THE MAXIMUM NUMBER. WE ALL KNOW
22	IT'S GOING TO BE SOMETHING LESS THAN THAT, BUT
23	THAT'S BEEN TRUE OF ALL OUR GRANTS WITH THE
24	EXCEPTION MAYBE OF THE FACILITIES.
25	MR. SHEEHY: I THINK WHAT SHE'S ALLUDING
	258

1	TO IS THAT WE'RE GOING INTO ROUNDS NOW WHERE
2	APPLICANTS ARE SUPPOSED TO PROVIDE SUCCESS CRITERIA
3	SO THAT OVER THE COURSE OF THE GRANT THE EARLIER
4	GRANTS, WE KIND OF PUT OUT THE MONEY, WE GET
5	PROGRESS REPORTS. AND WE'LL HEAR FROM THAT, I
6	THINK, AT SOME POINT IN THE FUTURE WHAT'S GOING ON
7	WITH THAT.
8	THESE ACTUALLY HAVE A LITTLE BIT WHEN
9	WE GET TO DISEASE TEAMS, THERE'S GOING TO BE MUCH
10	HARDER LINES, BUT WE'RE MOVING TOWARDS A LITTLE BIT
11	MORE AGGRESSIVE GRANT MANAGEMENT. THIS IS, CORRECT
12	ME IF I'M WRONG, MAYBE MIDDLE OF THE ROAD AS OPPOSED
13	TO WHERE WE'RE GOING TO BE ON DISEASE TEAMS. WE'RE
14	GOING TO HAVE HARD AND FAST MILESTONES. YOU DON'T
15	MAKE IT, FUNDING STOPS, IT'S RECYCLED BACK FOR MORE
16	PEOPLE TO USE. IS THAT CORRECT? IS THAT ROUGHLY
17	SOMEWHERE BETWEEN NO AND FULL HARD MILESTONES?
18	WE'RE KIND OF IN THE MIDDLE HERE ON THIS PARTICULAR
19	SET WHERE THAT MIGHT FALL?
20	DR. OLSON: I THINK THAT'S CORRECT. I
21	THINK IT'S VERY YOU KNOW, IN DISEASE TEAMS
22	THERE'S USUALLY YOU HAVE TO HAVE A CERTAIN
23	PROFILE. IF YOU DON'T HAVE A PROFILE, YOU DON'T
24	IT'S NOT WORTH GOING FORWARD. THIS IS EARLIER.
25	THERE ARE MILESTONES WHERE YOU THINK YOU'LL BE AT A

1	CERTAIN TIME. IF THE SCIENCE OFFICE JUDGES THAT THE
2	PEOPLE ARE NOT MAKING PROGRESS, THAT IT'S NOT
3	HAPPENING, AS WITH ALL OUR GRANTS, WE CAN CALL THEM
4	TO TASK ON THAT. BUT I AGREE. I THINK I AGREE WITH
5	DUANE'S STATEMENT. FIRST YOU ALWAYS YOU BUDGET
6	FOR SUCCESS, AND THAT'S WHERE YOU HAVE TO START.
7	CHAIRMAN KLEIN: SO, DR. OLSON, MY
8	UNDERSTANDING HERE AND, DR. TROUNSON, PLEASE
9	COMMENT, IS THAT IF, IN FACT, THESE SUCCESS POINTS
10	ARE NOT BEING MET, THE STAFF UNDER OUR GRANT
11	MANAGEMENT PROCESS HAS THE ABILITY TO TERMINATE A
12	GRANT. IT'S JUST NOT COMPLETING A CRITICAL STEP AND
13	DOESN'T APPEAR THAT THEY HAVE A PLAN TO COMPLETE
14	THAT CRITICAL STEP THAT THESE GRANTS CAN BE
15	TERMI NATED.
16	DR. TROUNSON: THAT'S CORRECT. THAT'S
17	ABSOLUTELY CORRECT, CHAIR. AND AS OTHERS HAVE SAID,
18	WE'VE HAD THAT ABILITY IN THE PAST. THESE ARE
19	THREE-YEAR GRANTS. I PRESUME YOU WON'T CLICK IN IN
20	THE FIRST, SO IT MAY CLICK IN IN THE SECOND OR THIRD
21	YEAR, BUT IT'S WE'RE GOING TO BE MORE
22	AGGRESSIVELY MANAGING THESE LARGER GRANTS TO ENSURE
23	THAT THEY MEET THE PRODUCTIVITY THAT WE'RE
24	ANTI CI PATI NG.
25	BUT IT WOULD BE DIFFICULT FOR US TO GIVE
	240

1	YOU ANY IDEA WHATSOEVER OF WHAT THAT SAVINGS MIGHT
2	BE, IF ANY.
3	MR. SHEEHY: LEEZA GIBBONS HAD A COMMENT.
4	MS. GIBBONS: CAN YOU CLARIFY FOR ME WHAT
5	HAPPENS, THE ONES THAT WE DON'T VOTE FOR TODAY OR
6	THAT DON'T GET MOVED UP, AND I KNOW WE'RE READY TO
7	VOTE ON THIS FIRST TIER THAT THE MOTION IS ON THE
8	TABLE. DO WE GET A SECOND BITE OF THAT APPLE, AND
9	DO THEY'RE GONE FOREVER. THEY CAN NEVER BE
10	AMENDED AND RE-PRESENTED IN THE SAME FORM.
11	MR. SHEEHY: TYPICALLY WHAT WE DO IS OUR
12	FINAL MOTION IS TO CONSIDER NOT FUNDING ALL THE
13	REMAINING GRANTS, AND WE USUALLY HAVE A MOTION THAT
14	WE PASS TO DO THAT.
15	DR. TROUNSON: JEFF, I THINK THE QUESTION
16	MIGHT BE IT'S PERFECTLY OKAY TO COME BACK IN THE
17	NEXT ROUND, FOR EXAMPLE, OF TRANSLATION.
18	MR. SHEEHY: GRANTS CAN RETURN. THAT'S
19	PART OF THE VALUE OF THE EXTENSIVE REVIEWER COMMENTS
20	THAT
21	DR. TROUNSON: THAT'S ALSO I THINK IT
22	ALSO NEEDS TO BE RECOGNIZED IT'S AN IMPORTANT PART
23	OF THE MATURING PROCESS IN SOME OF THE GRANTS, THAT
24	THEY'RE GIVEN EXTRA TIME TO REFLECT ON THE
25	REVIEWERS' COMMENTS. IT'S A NORMAL PART OF THE
	261

1	SCIENTIFIC PROCESS AND ONE WHICH IS EXPECTED,
2	ALTHOUGH NOT ALWAYS DELIGHTED ABOUT BY THE
3	RESEARCHERS, BUT IT'S A COMMON IT'S A COMMON
4	THING, VERY COMMON FOR THEM TO HAVE TO IMPROVE UPON
5	THEIR GRANT FOR THE NEXT ROUND.
6	MS. GIBBONS: SO A ROUND FOR WHICH THEY
7	MAY BE A BETTER FIT.
8	DR. TROUNSON: ABSOLUTELY.
9	MR. SHEEHY: CAN WE MAYBE JUST GO TO A
10	VOTE AT THIS POINT UNLESS SOMEONE HAS SOMETHING?
11	JEANNI E.
12	DR. FONTANA: AGAIN, I'M TALKING ABOUT THE
13	PROCESS HERE. HAVE WE AGREED THAT WE ARE GOING TO
14	VOTE OVER BUDGET? THAT'S ONE QUESTION.
15	MY SECOND QUESTION IS I WAS JUST LOOKING
16	AT FIRST OF ALL, I'D LIKE TO FUND EVERYTHING. SO
17	I WANT EVERYBODY TO KNOW THAT. BUT IF WE WERE TO
18	LOOK AT THESE TOP 15
19	CHAIRMAN KLEIN: LET ME ASK IS THERE A
20	CONFLICTS ISSUE HERE?
21	MR. HARRISON: YES. YOU CANNOT ADDRESS
22	THIS SPECIFIC MOTION.
23	DR. FONTANA: I'M ADDRESSING THE PROCESS.
24	I'M NOT ADDRESSING WHETHER THESE GRANTS
25	CHAIRMAN KLEIN: LET ME ASK JEANNIE, IT
	262
	<u> </u>

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MIGHT BE HELPFUL TO YOU TO KNOW THAT THIS VOTE DOES
2	NOT ADDRESS THE ISSUE OF WHETHER ADDITIONAL
3	GRANTS
4	DR. FONTANA: THAT WAS NOT MY QUESTION.
5	MY QUESTION IS REALLY IF WE'RE ALLOCATED \$60 MILLION
6	AND NORMALLY AND IF YOU LOOK AT ALL THESE GRANTS
7	HERE, WITH THE EXCEPTION OF THE BOTTOM TWO IN TIER
8	1, THEY LOOK LIKE THEY'RE FUNDED THE SAME.
9	CHAIRMAN KLEIN: JEANNIE, I DON'T THINK
10	YOU CAN ADDRESS THIS AT THIS POINT.
11	DR. FONTANA: EVEN THOUGH IT'S A PROCESS.
12	MR. SHESTACK: I FEEL LIKE WE'RE TRYING TO
13	UNDERSTAND THE PROCESS. WE'RE ALL TRYING TO
14	UNDERSTAND. THERE'S SEVERAL THINGS INVOLVED, WHICH
15	IS THERE'S A CERTAIN AMOUNT OF MONEY.
16	DR. LOVE: MAYBE I CAN HELP.
17	MR. SHESTACK: THERE'S TIER 1, AND THEN
18	THERE'S PEOPLE WHO WOULD LIKE TO MOVE THINGS UP FROM
19	TIER 2 INTO TIER 1 EITHER BY JUST MOVING THEM UP OR
20	BY DROPPING SOME THINGS OUT OF TIER 1. SO THERE'S
21	LIKE FOUR DIFFERENT WAYS TO SKIN THIS CAT, AND THE
22	MOTION ISN'T REALLY CLEAR IF IT MAKES THE OTHER
23	POSSIBILITIES POSSIBLE AFTERWARDS. SO SOMEBODY HAS
24	TO CLARIFY FOR JEANNIE OR ANY OF US.
25	MR. SHEEHY: LET ME CLARIFY THE PROCESS.
	263

1	I DID ENTERTAIN MOTIONS TO TAKE APPLICATIONS OUT OF
2	TIER 1. I DID NOT HEAR ANYONE MAKE A MOTION. SO
3	THE NEXT THING, WE HAD A CHOICE. WE COULD EITHER
4	ADOPT TIER 1 OR WE COULD START TO MOVE APPLICATIONS
5	UP. I HAD A MOTION TO ADOPT TIER 1. THAT DOES NOT
6	PRECLUDE US FOR CONSIDERING FUNDING OTHER
7	APPLICATIONS IN TIER 2 OR TIER 3, BUT NO ONE MADE A
8	MOTION TO MOVE ANYTHING OUT OF TIER 1. WE HAVE A
9	MOTION ON THE FLOOR TO CONSIDER TIER 1, AND I THINK
10	THAT WE SHOULD GO AHEAD AND DO THAT.
11	MR. TORRES: WHICH IMPLIES AN INCREASE OF
12	SEVEN MILLION.
13	MR. SHEEHY: THANK YOU, MEMBER TORRES. IT
14	DOES EXPLICITLY IMPLY THAT WE ARE INCREASING THE
15	BUDGET OVER THE STATED BUDGET, AND WE HAVE HEARD TWO
16	DIFFERENT EXPLANATIONS OF WHY WE MAY NOT REACH THAT
17	BUDGET, BY THE WAY. WE DO THINK THAT THERE'S GOING
18	TO BE SOME, AND WE DON'T WANT TO PUT A NUMBER, WE
19	DON'T WANT TO PUT A PERCENT, BUT THERE WILL BE SOME
20	EXAMINATION BETWEEN NOW AND THE GRANT AWARD OF THE
21	BUDGETS WHICH WERE NOTED AS BEING EXCESSIVE IN MANY
22	REVI EWS.
23	THESE ARE ALSO SUCCESS CRITERIA GRANTS,
24	AND WE DO IT IS ABSOLUTELY POSSIBLE THAT ALL OF
25	THESE GRANTS WILL NOT BE FUNDED TO THEIR FULL TERM.

1	AGAIN, THIS IS NOT SOMETHING THAT WE CAN SIT HERE
2	AND ASSIGN A PERCENTAGE OR A NUMBER TO AT THIS
3	POINT. BUT STAFF IS VERY VIGOROUSLY GOING TO DO
4	THEIR WORK, AS THEY ALWAYS DO. AND THAT'S WHERE WE
5	ARE.
6	SO IF YOU DON'T WANT TO VOTE FOR THIS
7	MOTION, THEN DON'T VOTE FOR IT.
8	MR. SHESTACK: I THINK IT WAS A QUESTION
9	OF UNDERSTANDING ALL THE POSSIBILITIES DOWN THE
10	DECISION CHAIN, SO I JUST WOULD HAVE ASKED, FOR
11	INSTANCE, IS THAT THE RIGHT ORDER TO DO IT, OR WOULD
12	IT HAVE MADE MORE SENSE TO SAY ANYONE WANTS TO MOVE
13	SOMETHING UP TO TIER 2, FROM TIER 2 TO TIER 1,
14	SUGGEST THAT NOW, AND THEN YOU HAVE ONE LOOK AT YOUR
15	WHOLE SORT OF PIE, THE CONSENSUS OF WHAT THE GROUP
16	WANTS TO
17	MR. ROTH: JON, IT WAS MY MOTION, AND IT
18	CAN BE DONE EITHER WAY, I THINK.
19	MS. SAMUELSON: MAY I CALL THE QUESTION?
20	MR. SHESTACK: WHAT'S THE EASIEST WAY FOR
21	THE GROUP TO WRAP THEIR MIND AROUND IT.
22	MS. SAMUELSON: I'D LIKE TO CALL THE
23	QUESTI ON.
24	MR. SHEEHY: CAN WE ALL TALK ONE AT A
25	TIME? IT'S VERY DIFFICULT FOR ME I MEAN I'M NOT
	265

,	TVDLCALLY THE CHAID COLL HAVE CO MICH CVADATING FOR
1	TYPICALLY THE CHAIR, SO I HAVE SO MUCH SYMPATHY FOR
2	BOB. BUT IT'S HELPFUL TO CONSIDER MOTIONS AS
3	THEY'RE MADE. THAT'S KIND OF THE PROCEDURE. AND I
4	CAN'T STATE WHETHER THIS IS A MOTION I WOULD HAVE
5	MADE OR NOT MADE SINCE I CAN'T. JOAN HAS ASKED TO
6	CALL THE QUESTION, WHICH I THINK IS REASONABLE.
7	WE'VE HAD PUBLIC COMMENT. I DON'T SEE ANYONE ELSE
8	WANTING PUBLIC COMMENT. AND SINCE I DO HAVE THE
9	CHAIR, I'M GOING TO USE THE PRIORITY OF THE CHAIR
10	AND ASK MELISSA TO CALL THE ROLL.
11	MR. HARRISON: THE MOTION IS TO APPROVE
12	THOSE APPLICATIONS IN TIER 1 SUBJECT TO CIRM'S
13	STANDARD PREADMINISTRATION PREFUNDING
14	ADMINISTRATIVE REVIEW.
15	MS. KING: RICARDO AZZIZ.
16	MR. HARRISON: I'M SORRY. IF I COULD JUST
17	REMIND MEMBERS WHO HAVE AN INTEREST IN AN
18	APPLICATION WITHIN TIER, 1 TO SPECIFY THAT THEY'RE
19	ONLY VOTING AS TO THOSE APPLICATIONS IN WHICH THEY
20	DO NOT HAVE A CONFLICT.
21	DR. AZZIZ: I'LL FINISH MY VOTE AGAIN.
22	YES, EXCEPT FOR THOSE APPLICATIONS WITH WHICH I HAVE
23	A CONFLICT.
24	MS. KING: ROBERT PRICE.
25	DR. PRICE: YES. I DO NOT BELIEVE I HAVE
	266

	DAMMISTERS REPORTING SERVICE
1	A CONFLICT; BUT IF I DO, THEN I'M NOT VOTING ON
2	THOSE IN WHICH I HAVE A CONFLICT.
3	MS. KING: DAVID BRENNER.
4	DR. BRENNER: YES, EXCEPT FOR THOSE
5	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
6	MS. KING: JACOB LEVIN.
7	DR. LEVIN: YES, EXCEPT FOR THOSE
8	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
9	MS. KING: MARCY FEIT.
10	MS. FEIT: YES, EXCEPT FOR THOSE
11	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
12	MS. KING: MICHAEL FRIEDMAN.
13	DR. FRIEDMAN: YES, EXCEPT FOR THOSE
14	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
15	MS. KING: LEEZA GIBBONS.
16	MS. GIBBONS: YES.
17	MS. KING: MICHAEL GOLDBERG.
18	MR. GOLDBERG: YES, EXCEPT FOR THOSE
19	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
20	MS. KING: BOB KLEIN.
21	CHAIRMAN KLEIN: YES.
22	MS. KING: GERALD LEVEY.
23	DR. LEVEY: YES, EXCEPT FOR THOSE
24	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
25	MS. KING: TED LOVE.
	0/7
	267

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	DARRISTERS REPORTING SERVICE
1	DR. LOVE: YES.
2	MS. KING: ED PENHOET.
3	DR. PENHOET: YES.
4	MS. KING: PHIL PIZZO.
5	DR. PIZZO: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: CLAIRE POMEROY. FRANCISCO
8	PRI ETO.
9	DR. PRI ETO: YES, EXCEPT FOR THOSE
10	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
11	MS. KING: CARMEN PULIAFITO.
12	DR. PULIAFITO: YES, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MS. KING: ROBERT QUINT.
15	DR. QUINT: YES.
16	MS. KING: JEANNIE FONTANA.
17	DR. FONTANA: YES, EXCEPT FOR THOSE
18	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
19	MS. KING: DUANE ROTH.
20	MR. ROTH: YES.
21	MS. KING: JOAN SAMUELSON.
22	MS. SAMUELSON: YES, AND I HAVE NO
23	CONFLI CTS.
24	MS. KING: JEFF SHEEHY.
25	MR. SHEEHY: YES, EXCEPT FOR THOSE
	268
	200

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
2	MS. KING: JON SHESTACK.
3	MR. SHESTACK: YES.
4	MS. KING: OSWALD STEWARD.
5	DR. STEWARD: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: ART TORRES.
8	MR. TORRES: NO CONFLICTS. AYE.
9	MS. KING: I'LL JUST CIRCLE BACK WITH
10	CLAIRE POMEROY. ARE YOU THERE? OKAY. THAT MOTION
11	CARRI ES.
12	(APPLAUSE.)
13	MR. SHEEHY: I THINK, AS ART TORRES SAID
14	VERY APPROPRIATELY, I THINK WE'VE JUST MADE HISTORY.
15	WE ARE THE GAME FOR TRANSLATIONAL RESEARCH NOW. SO
16	CONGRATULATI ONS.
17	SO I THINK THE NEXT MOTIONS I'LL ENTERTAIN
18	ARE ANY MOTION TO FUND ANY APPLICATION IN EITHER
19	TIER 2 OR TIER 3. AND I WOULD NOTE THAT WE ARE OVER
20	BUDGET JUST SO WE DON'T HAVE THAT DISCUSSION AGAIN,
21	THAT IMPLICIT IN THESE MOTIONS ARE MOTIONS THAT WE
22	ARE CLEARLY EXCEEDING THE BUDGET.
23	DR. LOVE: I'D LIKE TO MOVE THAT WE,
24	CONSISTENT WITH OUR GROUP DISCUSSION, I DON'T KNOW
25	HOW TO DESCRIBE THIS, BUT I'D LIKE FOR US TO TRY TO
	269

1	CREATE A PROCESS WHERE WE SEEK SOME FUNDING TO
2	SUPPORT 1212 AND 1236.
3	MR. TORRES: SECOND.
4	CHAIRMAN KLEIN: LET'S STATE THE
5	CONFLICTS, PLEASE.
6	MR. HARRISON: I WAS JUST GOING TO SUGGEST
7	WE TAKE THE APPLICATIONS ONE AT A TIME SO THAT WE
8	INCREASE PARTICIPATION. FOR APPLICATION 1212, THE
9	CONFLICTS ARE GOLDBERG AND PIZZO. AND 1236, THE
10	CONFLICT IS MEMBER PULIAFITO.
11	MR. SHEEHY: SO, COUNSEL, CAN WE TAKE
12	THOSE AS ONE MOTION, OR DO WE NEED TO TAKE THOSE AS
13	SEPARATE MOTIONS?
14	MR. HARRISON: IT'S OUR PRACTICE TO TAKE
15	APPLICATIONS WHEN WE MOVE THEM ONE AT A TIME.
16	MR. SHEEHY: IS THAT DR. LOVE, ARE YOU
17	COMFORTABLE WITH THAT?
18	DR. LOVE: THAT'S FINE.
19	MR. SHEEHY: AND WE HAVE A SECOND FOR
20	THAT?
21	MR. TORRES: YES.
22	MR. SHEEHY: AND THE MOTION IS, CAN YOU
23	RESTATE THAT? IT SEEMED TO BE
24	DR. LOVE: I'D LIKE TO MOVE THAT THE BOARD
25	SET UP A PROCESS TO SEEK TO FUND GRANT 1212.

270

1	MR. SHEEHY: SO I GUESS LET'S TRY TO GET
2	SOME CLARITY ON THE PROCESS. SO THIS WOULD BE TO
3	HOLD THIS GRANT, POTENTIALLY OTHER GRANTS, OVER TO
4	THE NEXT MEETING. DURING THAT INTERIM WE WOULD SEE
5	IF THERE ARE OTHER FUNDS AVAILABLE FOR THIS?
6	DR. LOVE: YES. AND THE REASON I'M
7	RAISING IT IS THAT I KNOW THERE HAS BEEN SOME
8	POTENTIAL DISCUSSION OF TRYING TO SEEK ADDITIONAL
9	FUNDS THAT ARE NOT CURRENTLY AVAILABLE. SO IT'S
10	REALLY A MOTION BEING MADE IN THE CONTEXT OF TRYING
11	TO EXERCISE SOME BALANCE AROUND FINANCIAL PRUDENCE,
12	BUT ALSO TO TRY TO HIGHLIGHT THESE AS SOMETHING THAT
13	IF WE COULD REALIZE FUNDING, THAT WE WOULD FUND.
14	MR. SHEEHY: BOB AND THEN DR. STEWARD.
15	CHAIRMAN KLEIN: SO LET ME CREATE A
16	FRAMEWORK FOR DISCUSSION HERE. IN THIS FISCAL YEAR
17	WE'RE SUBSTANTIALLY BELOW 300 MILLION, THE AVERAGE
18	ASSUMED BY THE VOTERS, IN TERMS OF OUR EXPENDITURES.
19	WE'RE SIGNIFICANTLY BELOW THAT FIGURE. GOING INTO
20	NEXT FISCAL YEAR, I DON'T THINK THAT WILL BE THE
21	CASE, BUT THAT'S WHERE WE STAND TODAY.
22	IN MY DISCUSSIONS WITH THE TREASURER IN
23	TERMS OF THE RECENT FUNDS THAT WERE RAISED, AND IN
24	TERMS OF OUR SUBMISSIONS TO THE DEPARTMENT OF
25	FINANCE, TO THE GOVERNOR'S OFFICE, TO THE TREASURER,
	271
	///

1	WE SHOWED A SIGNIFICANTLY HIGHER OPTIMIZED BUDGET
2	THAN THE ONES WE'RE WORKING WITH NOW. UNDERSTANDING
3	THE STATE'S CONSTRAINTS, WE HAVE, AS PART OF WORKING
4	WITH THE BUDGET SITUATION IN THE STATE, WORKED TO
5	OBTAIN THE CURRENT FUNDING, AND WE ALSO HAVE 125
6	MILLION IN ADDITIONAL PRIVATE PLACEMENT AUTHORITY,
7	POTENTIALLY 160 MILLION IN PRIVATE PLACEMENT
8	AUTHORITY THAT WE'RE CONCURRENTLY WORKING ON.
9	IT IS IMPORTANT TO NOTE THAT IN THE
10	PRIVATE PLACEMENT AUTHORITY CATEGORY THAT WE ARE
11	SPECIFICALLY NOT PULLING DEMAND THAT WOULD BE
12	AVAILABLE FOR OTHER STATE BOND ISSUES THAT ARE
13	CRITICAL. WE'RE MOVING OUTSIDE OF DIRECT
14	COMPETITION WITH THOSE SOURCES, TRYING TO HAVE THE
15	FUNDS TO MOVE OUR MISSION CRITICAL OBJECTIVES
16	FORWARD WITHOUT DETRACTING FROM OTHER PARTS OF THE
17	STATE'S PRIORITIES.
18	IT'S ALSO IMPORTANT TO NOTE THAT IN
19	OBTAINING THE EXISTING FUNDS THAT WE HAVE JUST
20	CONFIRMED, THAT WE HAVE WORKED WITH THE TREASURER'S
21	OFFICE AND THE DEPARTMENT OF FINANCE TO MOVE 195
22	MILLION OF OUR PRIOR FUNDING INTO BUILD AMERICA
23	BONDS UNDER WHICH THERE WAS A SUBSTANTIAL FEDERAL
24	SUBSIDY AND ACCESSED TAXABLE BOND PURCHASERS AT A
25	HIGHER RATE THAT WOULD NOT HAVE OTHERWISE BEEN
	272

1	POSSI BLE.
2	SO WE'RE TRYING IN EVERY WAY POSSIBLE TO
3	CONTRIBUTE TO AN ACUTELY FOCUSED FINANCIAL STRATEGY
4	THAT ALLOWS US TO SIZE TO THE BEST SCIENCE, ASSUMING
5	WE'RE ONLY GOING TO APPROVE THE BEST SCIENCE, BUT
6	GIVING SOME FLEXIBILITY TO THE BOARD.
7	SO IN THAT CONTEXT, THE OPTION THAT YOU
8	ARE SUGGESTING, I THINK, IS SOMETHING REASONABLE TO
9	LOOK AT, AND CERTAINLY WE COULD CALENDAR IT FOR THE
10	JUNE MEETING.
11	DR. STEWARD: I JUST ACTUALLY WANT TO GO
12	BACK TO THE POINT THAT MICHAEL FRIEDMAN RAISED
13	EARLIER ON. I THINK THAT FISCAL PRUDENCE AT THIS
14	POINT IN TIME IS REALLY CRITICAL BECAUSE THIS IS THE
15	FIRST ROUND OF TRANSLATION, BUT WE HAVE THE BIG ONE
16	COMING UP, THE DISEASE TEAM GRANTS. I SUSPECT WE'RE
17	GOING TO BE LOOKING AT THOSE AND SAYING, "OH, MY
18	GOSH, WE'VE NEVER SEEN ANYTHING AS BEAUTIFUL AS
19	THESE GRANTS. "
20	SO I START WITH THAT BECAUSE I TOO WANT TO
21	RAISE A GRANT FOR CONSIDERATION HERE, BUT I DON'T
22	WANT TO BUST OUR BUDGET. AND SO IF WE CAN COME UP
23	WITH SOME CONTINGENCY PLAN TO HAVE A SET OF GRANTS
24	THAT WOULD BE CONSIDERED FOR FUNDING IF, FOR
25	EXAMPLE, THE BUDGETS OF THESE GRANTS THAT WE'VE

1	APPROVED WERE REDUCED SIGNIFICANTLY, AND I DON'T
2	KNOW WHAT THE TIMEFRAME ON THAT, WHEN WE WOULD
3	ACTUALLY KNOW IF WE COULD CONSIDER THAT AT THE JUNE
4	MEETING. THAT MIGHT BE ONE POSSIBILITY. IF WE
5	COULD HAVE A CONTINGENCY WHEREBY THIS SECOND TIER OF
6	GRANTS WOULD BE FUNDED IF, AND ONLY IF, THERE WAS A
7	SUCCESSFUL PRIVATE PLACEMENT, THAT MIGHT BE ANOTHER
8	WAY TO PUT THESE IN A VERY DEFINITELY DIFFERENT
9	CATEGORY THAN WHAT WE JUST APPROVED.
10	MR. SHEEHY: DR. STEWARD, MY UNDERSTANDING
11	OF TED'S MOTION IS EXACTLY THAT, TO HOLD TO ALLOW
12	PEOPLE TO HOLD A GRANT OVER BASICALLY UNTIL THE NEXT
13	MEETING. AND AT THAT POINT, IF THERE'S BEEN A
14	CHANGE IN OUR FISCAL SITUATION AND MORE FUNDS ARE
15	AVAILABLE, THEN THOSE GRANTS COULD BE CONSIDERED
16	AGAI N.
17	DR. STEWARD: WHAT I'M SAYING IS I'D JUST
18	LIKE A LITTLE BIT MORE FLESH TO THOSE BONES, SO WE
19	REALLY HAVE A CLEAR UNDERSTANDING OF WHAT THE
20	CONTINGENCIES WOULD BE FOR THESE GRANTS THAT ARE IN
21	THAT STOCKPILE TO BE CONSIDERED. IF WE COULD JUST
22	STATE THAT, THAT WOULD BE GREAT.
23	MR. SHEEHY: AND JUST FROM MY PERSPECTIVE,
24	I THINK IT'S BETTER NOT TO TRY TO DEFINE THAT
25	BECAUSE WE DON'T KNOW. I MEAN LET'S SAY ART TORRES
	274

1	AND BOB ARE SUCCESSFUL WITH A HUGE PRIVATE PLACEMENT
2	WITH A PENSION FUND. I MEAN JUST TO PUT THESE OVER,
3	WE'RE NOT SAYING WE'RE GOING TO FUND THEM. AND I
4	WOULD BE RELUCTANT IN OTHER WORDS, I'M NOT SURE
5	WHETHER I WOULD, JUST PERSONALLY SINCE I'M NOT
6	CONFLICTED ON THIS GRANT, I'M NOT CERTAIN WHETHER
7	I'M NOT MY VOTE ON THIS MOTION IS NOT GOING TO BE
8	BASED ON WHETHER I WANT TO APPROVE THIS GRANT.
9	IT'S GOING TO BE TO HOLD IT OVER BECAUSE I
10	REALLY, LOOKING AT SOME OF THE TIER 2, PERSONALLY
11	DON'T KNOW THAT I FEEL THAT COMFORTABLE EXCEEDING
12	OUR BUDGET AT THIS TIME. AND I WOULD LIKE TO GIVE
13	MEMBERS WHO HAVE AN INTEREST IN SOME OF THESE
14	APPLICATIONS TO MAKE THEIR CASE IN A DIFFERENT
15	FISCAL ENVIRONMENT IF THAT EXISTS. THAT'S HOW I
16	PERCEIVE THIS MOTION IS TO ALLOW PEOPLE WHO HAVE
17	INTEREST IN APPLICATIONS THAT REALLY I THINK TO
18	BE FISCALLY PRUDENT, WE HAVE TO ACKNOWLEDGE WE ARE
19	ALREADY OVER BUDGET TO GIVE THEM ANOTHER BITE AT
20	THE APPLE IF OUR BUDGET SITUATION DOES CHANGE.
21	AND I DO THINK BOB MADE AN IMPORTANT
22	POINT. WE ARE BELOW BUDGET PER PROP 71 FOR WHAT WE
23	SHOULD BE SPENDING THIS YEAR OR COULD BE SPENDING.
24	THEN I HAVE DR. PRICE AND THEN DR. LEVEY.
25	MR. SHESTACK: BELOW BUDGET FOR WHAT?
	275
	210

1	MR. SHEEHY: WE'RE UNDER BUDGET, SO WE CAN
2	SPEND UP TO 300 MILLION A YEAR AND WE ARE NOT.
3	MR. SHESTACK: PER THE LEGISLATION.
4	DR. PRICE: SO I'D LIKE TO JUST PUT ON THE
5	TABLE ANOTHER OPTION WITH RESPECT TO HOW YOU CAN
6	PROCEED IF YOU WANT TO EXPAND THE NUMBER OF GRANTS
7	THAT WE ARE GOING TO FUND.
8	WHAT WE'VE HEARD SO FAR, BASED EITHER ON
9	OPTIMISTIC ASSUMPTIONS ABOUT OUR REVENUE STREAM OR
10	ON THE HOPE, DEFER FOR THE HOPE, THERE'S ANOTHER
11	OPTION IS THAT IF YOU WANT TO SPEND MORE MONEY HERE,
12	YOU HAVE TO TRADE SOMETHING OFF ON THE OTHER SIDE.
13	WE DO HAVE THE TRAINING GRANTS, WHICH HAVE BEEN
14	DEFERRED. LAST NIGHT THERE WAS A LOT OF OPTIMISM
15	ABOUT AT A JUNE MEETING WE WERE GOING TO TAKE THE
16	DEFERMENT OFF, BUT WE DO HAVE THE POSSIBILITY OF
17	DEFERRING THOSE EVEN FURTHER AND USING THAT REVENUE
18	THAT WE WERE GOING TO PUT TO THE TRAINING GRANTS TO
19	THE TRANSLATIONAL GRANTS IF IT IS THE BELIEF THAT
20	TRANSLATIONAL RESEARCH IS SO IMPORTANT THAT THAT'S
21	WHAT WE WANT TO DRIVE FORWARD RIGHT NOW.
22	DR. PIZZO: I'D LIKE TO SPEAK WHEN I CAN.
23	CHAIRMAN KLEIN: PHIL, ON THIS PARTICULAR
24	DISCUSSION ON THESE GRANTS, I THINK COUNSEL
25	BELIEVES IS HE IN CONFLICT ON THIS SPECIFIC
	276
	210

1	GRANT?
2	DR. PIZZO: I WASN'T GOING TO COMMENT ON A
3	SPECIFIC GRANT.
4	MR. HARRISON: DR. PIZZO HAS A CONFLICT
5	WITH RESPECT TO THE MOTION WHICH IS ON THE TABLE,
6	WHICH IS TO TRY TO IDENTIFY A PROCESS FOR
7	POTENTIALLY IDENTIFYING FUNDING FOR APPLICATION
8	1212.
9	DR. PIZZO: I'LL DEFER MY COMMENT AT THIS
10	TIME, BUT PERHAPS YOU COULD RECOGNIZE ME WHEN WE'RE
11	DONE WITH THE VOTE BECAUSE I HAVE A COMMENT THAT
12	RELATES TO A MORE GENERAL PRINCIPLE.
13	MR. SHEEHY: AGAIN, JUST TO GET SOME
14	CONTROL OVER THIS DIALOGUE, WHAT DR. PRICE HAS
15	RAISED IS AN ISSUE THAT I THINK WE SHOULD CONSIDER
16	AT THE NEXT MEETING IF WE GO AHEAD WITH THIS
17	PROCESS. I DON'T THINK THIS IS SOMETHING WE NEED TO
18	DECIDE NOW OR SHOULD DECIDE NOW. IT'S AGENDAD, BUT
19	WE SHOULD ALWAYS BE THINKING ABOUT ALL OF OUR
20	OBLIGATIONS WHENEVER WE VOTE TO FUND SOMETHING.
21	PER THIS PARTICULAR I WOULD NOTE THAT
22	WHAT WE'RE TALKING ABOUT IS VERY SIMILAR TO WHAT WE
23	DID WITH TOOLS AND TECHNOLOGIES EXCEPT WE BASICALLY
24	PUNTED ON A WHOLE TIER. WHAT WE'RE DOING HERE IS
25	THAT SOME MEMBERS ARE SAYING WE'D LIKE TO HAVE
	277

1	ANOTHER CHANCE TO CONSIDER THIS IN A DIFFERENT
2	FINANCIAL ENVIRONMENT AND NOT NECESSARILY LOOKING AT
3	THE WHOLE TIER.
4	BUT I WILL REMIND FOLKS THAT WHAT WE'RE
5	TALKING ABOUT IS EXACTLY WHAT WE DID WITH TOOLS AND
6	TECHNOLOGIES. WE BASICALLY SAID WE NOTE THAT THE
7	BUDGET SITUATION IS CHANGED, AND WE'RE PUTTING ALL
8	OF TIER 2 OFF UNTIL THE NEXT MEETING TO SEE IF THE
9	BUDGET SITUATION CHANGES. SO THAT'S REALLY ALL
10	WE'RE TALKING ABOUT. IT'S NOT MAKING A DEFINITIVE
11	DECISION ON SOME APPLICATIONS AT THIS TIME PENDING A
12	BUDGET RESOLUTION OF SOME SORT OR FISCAL RESOLUTION.
13	DR. LEVEY: A FEW POINTS I WANT TO MAKE
14	HERE. I DON'T THINK WE SHOULD BE PUT IN A POSITION
15	OF MICROMANIPULATING TIER 2. OUR GRANTS WORKING
16	GROUP SAID THESE SHOULD BE FUNDED IF MONEY IS
17	AVAILABLE. AND IF YOU LOOK AT THE SCORES, THE
18	SCORES ARE REALLY CLOSE WITH EACH OTHER. I DON'T
19	EVEN KNOW THAT THEY WOULD STAND UP TO STATISTICAL
20	EVALUATION IF YOU LOOKED AT THE DIFFERENCE BETWEEN
21	THE TWO OF THEM.
22	I THINK OUR GOAL SHOULD BE NOT TO IDENTIFY
23	IN A SUPERFICIAL WAY THAT DOES LACK SCIENTIFIC
24	INTEGRITY ONE OR TWO OF THESE GRANTS THAT SHOULD BE
25	MOVED UP AND ONE OR TWO OTHERS THAT SHOULD BE MOVED
	270

	DOWN WHATEVER LT LO L THANK WE CHOULD HAVE A COAL
1	DOWN, WHATEVER IT IS. I THINK WE SHOULD HAVE A GOAL
2	OF FINDING A WAY TO FUND TIER 2. AND WHATEVER THAT
3	GOAL IS, I THINK THAT'S WHAT WE SHOULD TRY TO DO.
4	NOW, WE'VE ELIMINATED APPARENTLY CUTTING
5	DOLLARS FROM TIER 1, AND THAT MAY BE FINE. BUT I
6	THINK THAT SHOULD BE OUR GOAL IS HOW TO FUND TIER 2
7	EN BLOCK AND NOT MANIPULATE THIS PROCESS.
8	MS. SAMUELSON: I AGREE.
9	DR. PULIAFITO: I AGREE WITH DR. LEVEY. I
10	THINK THAT'S I THINK THE ABILITY TO
11	DISCRIMINATE
12	CHAIRMAN KLEIN: DR. PULIAFITO, I THINK WE
13	NEED TO BE VERY CAREFUL BECAUSE WHEN WE'RE
14	ADDRESSING TIER 2, THERE'S A DIVERSITY OF
15	APPLICATIONS IN TIER 2. SO WE NEED TO BE VERY
16	CAREFUL IN THESE COMMENTS.
17	MR. SHEEHY: I WONDER, AND, COUNSEL, CAN
18	YOU ADVISE ME ON THIS, IS IT POSSIBLE FOR THE BOARD
19	TO NOT TAKE ACTION ON TIER 2, AND THAT DOESN'T
20	PRESENT CONFLICT PROBLEMS? WE COULD JUST DEFER
21	DISCUSSION OF TIER 2 EN BLOCK UNTIL THE NEXT
22	MEETING, AND WOULD THAT RAISE ANY CONFLICT ISSUES?
23	I THINK THAT'S HOW WE DID IT LAST TIME.
24	MR. HARRISON: YES. AS THE BOARD DID WITH
25	THE TOOLS AND TECHNOLOGIES APPLICATIONS, THE BOARD
	279

1	COULD DEFER CONSIDERATION OF APPLICATIONS IN TIER 2
2	UNTIL THE NEXT MEETING.
3	MR. SHESTACK: WHAT'S THE ADVANTAGE OF
4	THAT?
5	MR. SHEEHY: I'M ONLY CHAIRING. I THINK
6	MEMBERS HAVE THE ONLY THING THAT I WOULD NOTE IS,
7	AM I CORRECT, WE DON'T HAVE A GRANT ROUND AT THE
8	NEXT MEETING? ARE WE CONSIDERING GRANTS? I WOULD
9	NOTE THAT WE AREN'T CONSIDERING GRANTS, AND THAT WAS
10	A CONSIDERATION WITH TOOLS AND TECHNOLOGY.
11	SO I GUESS THE FIRST QUESTION IS FOR THE
12	MAKER OF THE MOTION IF HE WANTS TO CONSIDER WHAT HIS
13	COLLEAGUES HAVE SUGGESTED AND PERHAPS AMEND HIS
14	MOTION TO JUST DEFER CONSIDERATION OF THE ENTIRE
15	ROUND, WHICH WILL HAVE THE SAME EFFECT AS
16	MR. HARRISON: I'M SORRY. COULD I JUST
17	INTERRUPT. ANOTHER APPROACH, AND I BELIEVE THE
18	APPROACH THE BOARD TOOK WITH RESPECT TO TOOLS AND
19	TECHNOLOGIES SIMPLY WAS NOT TO TAKE ANY FINAL ACTION
20	WITH RESPECT TO TIER 2. IN OTHER WORDS, WHAT YOU
21	DID THE LAST TIME WAS TO CLOSE OUT FUNDING ON TIER 3
22	AFTER CONSIDERING WHETHER ANY SHOULD HAVE MOVED.
23	AND THEN THERE WAS NO MOTION ON TIER 2, WHICH BY
24	DEFINITION MEANT IT HAD TO COME BACK FOR THE NEXT
25	MEETI NG.
	280

1	DR. LOVE: I'M FINE WITH THAT. I THINK IT
2	ACHIEVES THE SAME OBJECTIVE. IN FACT, IT ACHIEVES
3	PROBABLY FOR SEVERAL PEOPLE WHO MIGHT NOMINATE
4	INDIVIDUAL GRANTS.
5	CHAIRMAN KLEIN: LOGISTICALLY, SINCE WE'VE
6	JUST GONE THROUGH EXECUTIVE SESSION AND WE'VE READ A
7	LOT OF THESE, IF WE USE THE INTELLECTUAL LEARNING
8	THAT WE'VE JUST GONE THROUGH TO AT LEAST CREATE A
9	HIERARCHY IN TIER 2, I THINK IT WOULD THEN PUT US IN
10	A PRODUCTIVE POSITION RATHER THAN HAVING TO GO BACK
11	THROUGH IN EXECUTIVE SESSION IN THE NEXT MEETING AND
12	BACK THROUGH ALL OF THE SCIENTIFIC PREPARATION THAT
13	GOES INTO THAT. FOR CONSIDERATION, AT LEAST IF WE
14	COULD RANK THEM.
15	MR. SHEEHY: AGAIN, I THINK PERSONALLY I
16	WOULD BE MORE COMFORTABLE TAKING NO ACTON ON TIER 2
17	AND JUST LETTING THAT AND JUST SENSE OF THE
18	COMMITTEE, IF THE MAKER OF THE MOTION IS WITHDRAWING
19	THE MOTION, AND
20	MR. TORRES: SECOND WITHDRAWS.
21	MR. SHEEHY: THE SECOND WITHDRAWS AS
22	WELL, ACTUALLY WHAT I MIGHT PREFER IS A MOTION TO
23	DISPENSE WITH TIER 3, WHICH I DON'T THINK ANYONE HAS
24	AN INTEREST IN BRINGING ANYTHING UP FROM TIER 3.
25	AND WE HAVE IT'S 1 O'CLOCK. I'VE BEEN HERE SINCE
	281
	ı 40 i

1	
1	YESTERDAY. AND MAYBE WE CAN JUST MOVE FORWARD, AND
2	WE CAN LOOK AT THIS NEW NEXT MONTH. I DON'T REALLY
3	WANT TO GET INTO PLAYING INTO TIER 2. SOME OF THE
4	MEMBERS WHO HAD INTEREST IN TIER 2 ARE NOT HERE NOW.
5	I PERSONALLY DID NOT LOOK AT TIER 2 BECAUSE I DIDN'T
6	THINK IT WOULD BE FUNDED. AND THERE IS AN HIV GRANT
7	THERE, WHICH I'M NOT CONFLICTED ON, SO I CAN
8	MENTION. AND, FRANKLY, IN THIS BUDGET ENVIRONMENT,
9	I WOULDN'T HAVE FELT COMFORTABLE MOVING THAT UP.
10	BUT I MIGHT TAKE A DIFFERENT VIEW ON THAT
11	APPLICATION IF THERE WAS FULL FUNDING.
12	SO I THINK THE FAIREST THING IS JUST TO
13	NOT ACT ON TIER 2. BUT ANY OTHER COMMENTS?
14	DR. LOVE: SO TO YOUR POINT, I'M HAPPY TO
15	WITHDRAW THE MOTION, ASSUMING THAT ART AGREES, AND
16	MOVE THAT WE SIMPLY VOTE TO NOT FUND TIER 3.
17	MR. SHEEHY: COULD I GET A SECOND?
18	MR. ROTH: I'LL SECOND.
19	MR. SHEEHY: DI SCUSSI ON?
20	MR. SHESTACK: AGAIN, JUST TRYING TO
21	UNDERSTAND THE MECHANICS. BY VOTING NOT TO FUND
22	TIER 2 AND TIER 3, IS THERE
23	MR. SHEEHY: WE'RE NOT TAKING ANY ACTION
24	ON TIER 2 TODAY.
25	MR. SHESTACK: NOT FUNDING TIER 3.
	202
	282

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

MR. SHEEHY: BASICALLY AT THE END OF THIS
MOTION, ASSUMING THAT WE'RE DONE WITH THIS GRANT
ROUND FOR THIS SESSION, WE WILL HAVE FUNDED TIER 1,
WE WILL HAVE NOT FUNDED TIER 3, AND TIER 2 IS STILL
OPEN FOR CONSIDERATION AT OUR NEXT MEETING.
MR. SHESTACK: DOES THAT MEAN THAT TIER 2
WILL BE AGENDIZED FOR DISCUSSION AT OUR NEXT
MEETI NG?
MR. SHEEHY: YES.
MS. GIBBONS: TO BOB'S POINT, DOES THAT
MEAN THAT WE STILL HAVE THE OPPORTUNITY TO EXAMINE
EACH OF THOSE INDIVIDUALLY ON THEIR MERITS?
MR. SHEEHY: YES.
MS. GIBBONS: WE'RE NOT COMMITTING TO
BLOCKING ANYTHING?
MR. SHEEHY: NO. NO. AND, IN FACT, WE DO
BLOCK VOTES OF APPLICATIONS ALMOST UNIVERSALLY IN
TIER 2 BECAUSE OF BOTH CONFLICTS AND ALSO BECAUSE
PEOPLE RECOGNIZE THAT THEY REQUIRE AN ADDITIONAL
LEVEL OF SCRUTINY.
CHAIRMAN KLEIN: WITHOUT COMMENTING AS
TO THIS PARTICULAR MOTION, I THINK WE CAN SAFELY
VOTE ON IT. WE SHOULD ALSO CONSIDER THERE MAY BE
SOME MEMBERS AT THIS MEETING THAT CAN'T BE AT THE
NEXT MEETING WHO MAY WANT TO ADDRESS A SPECIFIC
283

1	MOTION ON TIER 2. CERTAINLY WE CAN TAKE THE VOTE ON
2	THIS ITEM AND THEN CONSIDER THAT AS A SEPARATE
3	QUESTI ON.
4	MR. ROTH: JEFF, I WANT TO CALL THE
5	QUESTION ON THE MOTION THAT'S ON THE TABLE. BUT I
6	ALSO ASK A QUESTION JUST AS FOLLOW-UP TO SOMETHING
7	YOU SAID. YOU SAID I REALLY DIDN'T LOOK AT THESE
8	TIER 2 GRANTS. I WONDER IF THE PROGRAMMATIC REVIEW
9	WAS ADEQUATE ON THESE TIER 2 GRANTS.
10	MR. SHEEHY: I WOULD SAY THAT THERE WAS
11	NOT IT WAS NOT A GOOD USE OF ANYONE'S TIME
12	PROGRAMATICALLY TO LOOK AT TIER 2. THE ONLY AND
13	PERHAPS STAFF CAN CORRECT ME IF I'M WRONG. I THINK
14	THE ONLY PROGRAMMATIC THERE WAS ONLY ONE GRANT IN
15	TIER 2 BECAUSE WE HAVE CONFLICTS, I DON'T THINK
16	WE WANT TO DISCUSS THAT GRANT. THERE WAS ONE GRANT
17	THAT WAS DISCUSSED PROGRAMATICALLY. AM I CORRECT,
18	MARIE? I DON'T THINK WE TALKED ABOUT ANYTHING ELSE
19	OTHER THAN ONE IN WHICH THERE IS THE POTENTIAL OF A
20	MINORITY REPORT. OH, TWO. THERE WERE TWO. WELL,
21	ONE I KNOW I'M CONFLICTED ON ONE OF THEM.
22	MR. ROTH: JEFF, LET ME FINISH MY THOUGHT
23	PROCESS.
24	MR. SHEEHY: THERE WASN'T A DEEP
25	PROGRAMMATIC REVIEW OF TIER 2.

284

1	MR. ROTH: CAN THAT BE DONE FOR THE NEXT
2	MEETING AND BRING THAT FORWARD? IS THAT POSSIBLE
3	WITHIN THE CONFINES OF THE SYSTEM TO HAVE THE PEOPLE
4	THAT NORMALLY DO THE PROGRAMMATIC REVIEW RE-REVIEW
5	PROGRAMATI CALLY?
6	MR. SHEEHY: NO. NO. BECAUSE YOU'D HAVE
7	TO RECONVENE THE WORKING GROUP, AND I DON'T THINK
8	THAT WOULD BE APPROPRIATE.
9	MS. SAMUELSON: GIVEN THE WORKING GROUP'S
10	RECOMMENDATION, WOULD THAT BE NECESSARY?
11	MR. SHEEHY: THAT'S THE OTHER POINT.
12	THESE ARE RECOMMENDED FOR FUNDING IF FUNDS ARE
13	AVAILABLE. WE DID DRAW OUR LINES.
14	MR. ROTH: LET'S VOTE.
15	MR. SHEEHY: PUBLIC COMMENT?
16	MS. SAMUELSON: RIGHT NOW WE'RE FOCUSED ON
17	THE PENDING MOTION.
18	MR. SHEEHY: THIS IS A PUBLIC COMMENT ON
19	VOTING TO NOT FUND TIER 3.
20	MR. KRILL: MY NAME IS TED KRILL. MY
21	DAUGHTER HAS JUVENILE HUNTINGTON'S DISEASE. THAT'S
22	WHY I'M HERE. SHE WAS SHE'S 20 NOW. DIAGNOSED
23	AT 17, GOING DOWNHILL QUICKLY. SO THAT'S KIND OF
24	WHAT I'M ADDRESSING RIGHT NOW.
25	IN PARTICULAR, THERE'S ONE OF THE
	285
	70.1

CTREET COCTA MECA CA

1	APPLICATIONS, WHICH IS IN TIER 3, 1271. AND FROM
2	WHAT I UNDERSTAND, THE DESIGN TEAM WAS RESEARCH
3	TEAM WAS PRAISED AS BEING VERY IMPRESSIVE. THE
4	CRITICISM AGAINST THAT WAS THAT THEY WERE TRYING TO
5	DO TOO MUCH. I DON'T UNDERSTAND TRYING TO DO TOO
6	MUCH IF IT'S BEING IF YOU'RE WATCHING IT AND
7	CHECKING OVER IT. I THOUGHT THAT WAS A GOOD THING
8	TO GO AS FAR AS WE CAN AS FAST WE CAN AND GET AS
9	MUCH AS POSSIBLE DONE AS WE CAN.
10	FOR PERSONAL REASON, WE'RE RUNNING OUT OF
11	TIME. I'M TOLD SHE'S GOT, LIKE, FOUR TO FIVE YEARS.
12	SO THE SOONER THE BETTER. SO I'D JUST LIKE TO KNOW
13	IF THERE'S ANY POSSIBILITY THAT WE CAN POSSIBLY
14	RECONSIDER SOME OF THOSE TIER 3, MOVE THEM UP TO
15	TIER 2.
16	MR. SHEEHY: I THINK THE APPLICATION YOU
17	WERE TALKING ABOUT IS ACTUALLY IN TIER 2.
18	MR. KRILL: 1271.
19	MR. SHEEHY: I'M SORRY. I'M GETTING
20	DIZZY. I APOLOGIZE. ADDITIONAL PUBLIC COMMENT?
21	MR. HARRISON: I WOULD REMIND MEMBERS ONCE
22	AGAIN THAT IF THEY HAVE A CONFLICT WITH RESPECT TO
23	AN APPLICATION IN TIER 3 TO SPECIFY THAT THEY'RE
24	ONLY VOTING FOR THE MOTION AS TO THOSE APPLICATIONS
25	IN WHICH THEY DON'T HAVE A CONFLICT.

286

	BINNISTERS REPORTING SERVICE
1	MS. KING: DR. AZZIZ.
2	DR. AZZIZ: FOR, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: ROBERT PRICE.
5	DR. PRICE: FOR, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: DAVID BRENNER.
8	DR. BRENNER: FOR, EXCEPT FOR THOSE
9	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
10	MS. KING: JACOB LEVIN.
11	DR. LEVIN: YES, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: MARCY FEIT.
14	MS. FEIT: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: MICHAEL FRIEDMAN.
17	DR. FRIEDMAN: YES, EXCEPT FOR THOSE
18	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
19	MS. KING: LEEZA GIBBONS.
20	MS. GIBBONS: YES.
21	MS. KING: MICHAEL GOLDBERG.
22	MR. GOLDBERG: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: BOB KLEIN.
25	CHAIRMAN KLEIN: YES.
	287

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	Diministration in the service
1	MS. KING: GERALD LEVEY.
2	DR. LEVEY: YES, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: TED LOVE.
5	DR. LOVE: YES.
6	MS. KING: ED PENHOET.
7	DR. PENHOET: YES, EXCEPT FOR THOSE
8	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
9	MS. KING: FRANCISCO PRIETO.
10	DR. PRIETO: YES, EXCEPT FOR THOSE
11	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
12	MS. KING: CARMEN PULIAFITO.
13	DR. PULIAFITO: YES, EXCEPT FOR THOSE
14	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
15	MS. KING: ROBERT QUINT.
16	DR. QUINT: YES, I HAVE NO CONFLICTS.
17	MS. KING: JEANNIE FONTANA.
18	DR. FONTANA: YES, EXCEPT FOR THOSE
19	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
20	MS. KING: DUANE ROTH.
21	MR. ROTH: YES.
22	MS. KING: JOAN SAMUELSON.
23	MS. SAMUELSON: YES.
24	MS. KING: JEFF SHEEHY.
25	MR. SHEEHY: YES, EXCEPT FOR THOSE
	288
	200

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
2	MS. KING: JON SHESTACK.
3	MR. SHESTACK: YES.
4	MS. KING: OSWALD STEWARD.
5	DR. STEWARD: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: CLAIRE POMEROY. YOU'RE BACK.
8	I APOLOGIZE.
9	DR. POMEROY: YES, EXCEPT FOR THOSE
10	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
11	MS. KING: PHIL PIZZO.
12	DR. PI ZZO: YES, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MR. SHEEHY: I'LL TURN THE CHAIR ANY
15	OTHER MOTIONS RELATED TO THIS GRANT ROUND? I'M
16	GOING TO TURN THE CHAIR BACK OVER TO BOB. YOU
17	NOTICE I'M HURRYING TO RELINQUISH THOUGH I WILL NOTE
18	THAT DR. PIZZO DID HAVE A COMMENT. I DON'T KNOW IF
19	HE STILL HAS.
20	DR. PIZZO: YES. I'LL MAKE IT JUST VERY
21	QUICK. AND THAT IS THAT AS WE THINK ABOUT OUR
22	FUTURE FUNDING, I WOULD HOPE THAT WE WOULD NOT
23	SIMPLY SAY THAT BECAUSE WE HAVE \$300 MILLION A YEAR,
24	THAT WE NEED TO SPEND IT. RATHER, THAT WE WOULD
25	FOCUS ON ALWAYS LOOKING AT THE BEST SCIENCE AS WE
	289

1	CAN. IF A MISSED OPPORTUNITY, IF THERE'S CARRY-OVER
2	FUNDS, THEN WE'LL USE THOSE LATER ON AS BETTER
3	PROJECTS COME FORWARD.
4	CHAIRMAN KLEIN: OKAY. THANK YOU. THANK
5	YOU VERY MUCH. WE ARE IN A POSITION THAT ON OUR
6	AGENDA, I BELIEVE WE HAVE ONE ITEM REMAINING, THAT'S
7	CORRECT. AND IF WE COULD HAVE DR. ROBSON DO A
8	PRESENTATION. THIS IS AN ITEM DEALING WITH THE
9	ISSCR CONFERENCE. AND DO WE HAVE JEFF, ARE YOU
10	LEAVING? SO WE CAN MAINTAIN OUR QUORUM HERE.
11	I WOULD POINT OUT THAT THIS IS AN ITEM ON
12	WHICH IT HAS BEEN CRITICAL TO HAVE A SUBSTANTIAL
13	CONTRIBUTION FROM THE HOST INSTITUTION, AND THERE'S
14	A HISTORY WHERE IF THE HOST INSTITUTION COULDN'T
15	COME UP WITH THE MONEY TO ASSURE THE FINANCIAL
16	SOLVENCY OF THE CONFERENCE, THE CONFERENCE WAS
17	CANCELED AT THAT LOCATION AND MOVED TO ANOTHER
18	LOCATI ON.
19	I DO THINK, AS IT POINTS OUT IN THE
20	PRESENTATION, THAT THERE ARE SUBSTANTIAL SCIENTIFIC
21	BENEFITS TO OUR MISSION BY HAVING THIS CONFERENCE IN
22	CALIFORNIA. THE SYNERGY OF BRINGING PEOPLE FROM ALL
23	OVER THE WORLD WHO CAN, WHILE THEY'RE HERE, HAVE
24	SIDE TRIPS TO OUR RESEARCH INSTITUTIONS, PUBLIC AND
25	PRIVATE, IS TREMENDOUS IN TERMS OF OUR MISSION. AND
	200

1	NOT HAVING TO FUND THE TREMENDOUS AMOUNT OF TRAVEL
2	COST TO GET PEOPLE FROM CALIFORNIA TO ANOTHER
3	LOCATION IN THE WORLD IS A VERY SUBSTANTIAL SAVINGS
4	THAT OFFSETS, I THINK, THE COST OF THIS. AND I
5	ACTUALLY BELIEVE THAT THE ESTIMATE IN THE WRITE-UP
6	UNDERSTATES THAT SAVINGS SUBSTANTIALLY.
7	IN ADDITION TO THE COST IN TERMS OF CASH,
8	IF PEOPLE HAVE TO TRAVEL TO ANOTHER PART OF THE
9	WORLD FOR A CONFERENCE, THERE ARE DAYS LOST IN
10	TRAVEL THAT ARE OTHERWISE PRODUCTIVELY GOING INTO
11	RESEARCH ON OUR MISSION.
12	DR. ROBSON: LET ME JUST BACK UP A LITTLE.
13	BOB, I'M SURE YOU REMEMBER THIS ISSUE. I BROUGHT
14	THIS TO YOU IN JANUARY. AT THAT TIME WE DIDN'T HAVE
15	A LOT OF DETAILS FROM THE ISSCR ABOUT WHAT WAS
16	INVOLVED WITH COSPONSORSHIP, AND THEY HAD A REQUEST
17	TO US FOR \$400,000. YOU ASKED FOR MORE INFORMATION
18	ON THAT, MORE DETAILS ABOUT THE BUDGET, MORE DETAILS
19	ABOUT THE BENEFITS THAT WOULD BE PROVIDED. AND I
20	CERTAINLY WENT AWAY WITH A CLEAR SENSE THAT YOU
21	THOUGHT \$400,000 WAS EXCESSIVE.
22	SO OVER THE LAST COUPLE OF MONTHS, DON
23	GIBBONS AND I HAVE WORKED ON THIS. WE HAVE HAD A
24	NUMBER OF CONVERSATIONS WITH NANCY WITTE, WHO'S THE
25	EXECUTIVE DIRECTOR OF THE ISSCR, AND OTHER MEMBERS

1	OF HER STAFF. WE'VE NEGOTIATED BACK AND FORTH ON
2	THIS, DISCUSSED WHAT THE BENEFITS WOULD BE. AND
3	I'VE SORT OF SUMMARIZED THAT IN A DOCUMENT WHICH YOU
4	HAVE UNDER TAB 15, I THINK, IN YOUR BOOKS.
5	AND SO I'D JUST LIKE TO KIND OF RUN
6	THROUGH THE CASE A LITTLE BIT, REMIND YOU THAT THE
7	ISSCR IS THE LARGEST ORGANIZATION IN THE WORLD
8	THAT'S DEVOTED TO PLURIPOTENT HUMAN STEM CELLS.
9	THEIR ANNUAL MEETING IS THE BIGGEST GATHERING OF THE
10	SCIENTISTS AND RESEARCHERS IN THIS AREA. THEY HAVE
11	A FOCUS ON EDUCATION OF THE PUBLIC AND FOR CREATING
12	FORUMS FOR WHICH SCIENTISTS CAN GET TOGETHER AND
13	EXCHANGE I DEAS.
14	SO THE LAST MEETING THAT THEY HAD WAS IN
15	PHILADELPHIA IN 2008. AT THAT MEETING THEY HAD 1300
16	ABSTRACTS AND 2800 ATTENDEES; 320 OF THOSE WERE FROM
17	CALIFORNIA. NOW, THIS YEAR'S MEETING IS IN JULY.
18	IT'S IN BARCELONA. WE DON'T KNOW WHAT THE
19	ATTENDANCE WILL BE YET. WE DON'T KNOW HOW MANY
20	CALIFORNIANS WILL BE GOING, BUT WE DO KNOW THAT
21	THEY'VE HAD 1900 ABSTRACTS SUBMITTED. SO THERE'S
22	BEEN A BIG JUMP IN INTEREST IN THIS MEETING. AND
23	THE NEXT MEETING, THE ONE THAT WE'RE TALKING ABOUT
24	WILL BE IN THE SUMMER OF 2010.
25	AND, AGAIN, WE DON'T REALLY KNOW HOW MANY
	202

1	PEOPLE TO EXPECT TO ATTEND THAT MEETING. IT'S A
2	LITTLE BIT EARLY. BUT WITH CHANGES IN FEDERAL
3	POLICY AND THE INVESTMENTS THAT OTHER COUNTRIES ARE
4	MAKING IN STEM CELL RESEARCH, THERE'S EVERY REASON
5	TO BELIEVE THAT THIS WILL BE BY FAR THE LARGEST
6	MEETING THAT THEY'VE HAD. WE MADE AN ESTIMATE, AS
7	BOB SAID, THIS IS A VERY CONSERVATIVE ESTIMATE, THAT
8	500 WILL GO FROM CALIFORNIA. I SUSPECT IT'S GOING
9	TO BE CONSIDERABLY LARGER THAN THAT IN PART BECAUSE
10	IT WILL BE IN SAN FRANCISCO, AND WILL BE RELATIVELY
11	INEXPENSIVE FOR MANY OF OUR GRANTEES AND OUR OTHER
12	SCIENTISTS IN CALIFORNIA TO ATTEND.
13	BUT I WOULD POINT OUT THAT IF 500 PEOPLE
14	ATTENDED, IF IT WAS HELD SOMEWHERE ELSE EVEN IN THE
15	UNITED STATES, THAT COULD ADD FOUR TO \$500 PER
16	PERSON JUST IN TRAVEL EXPENSES. 500 PEOPLE, THAT'S
17	\$250,000. THAT MONEY COMES OUT OF OUR GRANT FUNDS
18	THAT OUR GRANTEES RECEIVE. SO WE'RE BASICALLY
19	THIS IS AN INVESTMENT THAT ALLOWS THEM TO HAVE MORE
20	MONEY FOR RESEARCH AND THEIR OTHER ACTIVITIES.
21	THE TOTAL BUDGET FOR THE MEETING IS \$1.5
22	MILLION, AND WE HAVE, LARGELY THROUGH DON GIBBONS'
23	EFFORTS, WE'VE NEGOTIATED WITH THE CONTACT AT THE
24	CITY OF SAN FRANCISCO. THEY HAVE DONATED IN-KIND
25	CONTRIBUTIONS THE USE OF THE MOSCONE FOR FREE.

1	THAT'S VALUED AT ABOUT \$100,000. AND THE ROTUNDA AT
2	CITY HALL, THEY SAID WE CAN USE FOR THE PRESIDENT'S
3	SYMPOSIUM. AGAIN, THAT'S AT ABOUT 25,000. I THINK
4	THIS AN INDICATION OF THE VALUE THAT SAN FRANCISCO
5	SEES IN BEING ABLE TO SERVE AS THE CITY HOST FOR THE
6	MEETI NG.
7	THE REQUEST FOR US NOW FOR COSPONSORSHIP
8	IS AN ADDITIONAL \$200,000 IN CASH, AND THAT MONEY
9	WOULD BE USED TO BRING IN SOME SPECIALIZED SPEAKERS
10	AND ALSO FOR SOME OF THE PUBLICITY AND OTHER
11	ACTIVITIES AT THE MEETING. SO WE'VE REDUCED THAT
12	AMOUNT HAS BEEN REDUCED FROM 440,000 TO 200,000.
13	AND OUR RECOMMENDATION TO THE BOARD WOULD BE THAT
14	THIS MONEY SHOULD COME FROM DONATED FUNDS THAT WE
15	HAVE AT CIRM, NOT FROM BOND-RAISED FUNDS. CURRENTLY
16	THERE ARE ABOUT \$3.4 MILLION IN DONATIONS THAT WE
17	HAVE AVAILABLE THAT WE COULD USE FOR THIS.
18	SO THIS IS A LIST. THERE ARE SOME
19	SPECIFIC BENEFITS. I THINK THERE'S TWO WAYS TO LOOK
20	AT THAT. WHAT ARE THE SORT OF SPECIFIC BENEFITS
21	THAT ARE DERIVED FROM COSPONSORSHIP? WHAT LIST OF
22	ITEMS DO WE GET? AND THEN THERE'S ANOTHER ISSUE.
23	WHAT'S THE VALUE TO US OF THAT? AND THIS LISTS SOME
24	OF THE SPECIFIC BENEFITS. AND THE ONE I JUST WENT
25	THROUGH IS MORE GRANTEES AND TRAINEES CAN GO TO THE
	294
	4 / ₹

1	MEETING. THEY CAN INTERACT WITH THE BEST STEM CELL
2	SCIENTISTS IN THE WORLD. THEY CAN HEAR WHAT'S NEW
3	IN TECHNOLOGY, WHAT'S NEW IN THE CONCEPT PHASE, SO
4	FORTH AND SO ON.
5	FOR OUR STAFF, THEY WILL BE ABLE TO ATTEND
6	FOR FREE AT NO REGISTRATION COST UP TO 25 OF OUR
7	STAFF MEMBERS. AND THIS IS A VERY IMPORTANT MEETING
8	FOR THEM. THIS IS WHERE THEY DO A LOT OF THEIR
9	RECRUITING FOR THE GRANTS WORKING GROUP. THEY GET
10	TO MEET POTENTIAL GRANT WORKING GROUP MEMBERS AND
11	EVALUATE THEM ON A ONE-ON-ONE BASIS. MANY OF THEM
12	GET TO INTERACT WITH SUBCOMMITTEES AT THE ISSCR FOR
13	EDUCATION AND SO FORTH. AND THEY ALSO GET TO
14	IMPROVE THEIR PRESENCE, TO JUST BE THERE AND BE
15	ACKNOWLEDGED AND RECOGNIZED AS LEADERS IN THIS
16	FIELD. IT'S PART OF THEIR DEVELOPMENT AS SCIENTIFIC
17	OFFICERS AT THE INSTITUTE. WE THINK THAT'S AN
18	IMPORTANT ASPECT.
19	WE GET TO ORGANIZE AS CO-SPONSORS A PUBLIC
20	SYMPOSIUM. THIS IS ONE OF THE MAIN EVENTS AT THE
21	MEETING, AND SO WE'RE THE ONES WHO WOULD BE PUT IN
22	CHARGE OF THAT. SO DON GIBBONS WOULD TAKE A LEAD
23	ROLE IN ORGANIZING THAT. WE GET ACKNOWLEDGED ON ALL
24	THEIR PUBLICITY AS THE COSPONSORS. WE WOULD BE THE
25	ONLY COSPONSORS OF THE MEETING. DR. TROUNSON WOULD

1	BE INVITED TO SPEAK AT THE OPENING CEREMONIES AND
2	GIVE AN UPDATE ON WHERE CIRM IS AND WHAT CIRM'S
3	ACCOMPLISHMENTS AND INFLUENCE IN THE FIELD IS. WE
4	WOULD HOST AT AN ALL ATTENDEES MIXER THAT THEY HAVE,
5	SO 3500 OR 5,000 OR HOWEVER MANY PEOPLE ARE THERE
6	ARE ALL INVITED TO THAT. WE WOULD BE THE OFFICIAL
7	HOST OF THAT. AND WE GET, THEN, TO SHOWCASE, ALL OF
8	THESE THINGS WILL ALLOW US TO SHOWCASE OUR
9	SCIENTISTS AND WHAT THEIR CONTRIBUTIONS ARE.
10	SO THE LAST POINT IS REALLY WHAT'S THE
11	VALUE OF THAT TO US? I THINK THE WORLD IS CHANGING
12	NOW IN STEM CELL RESEARCH. THERE'S A LOT OF NEW
13	PLAYERS COMING IN. THERE'S NEW FUNDING
14	OPPORTUNITIES. THERE'S NEW WAYS TO SORT OF
15	CHALLENGE OUR LEADERSHIP IN THIS FIELD. AND BY
16	BEING COSPONSORS OF THIS, IT WILL BE A CONSTANT
17	REMINDER TO ALL OF THE ATTENDEES OF THE IMPORTANCE
18	OF CIRM IN THIS FIELD. AND WE WANT TO KEEP POINTING
19	OUT TO THEM THAT CALIFORNIA IS THE PLACE TO BE IF
20	YOU WANT TO DO STEM CELL RESEARCH. SO IF YOU'RE A
21	YOUNG SCIENTIST AND WANT TO DEVELOP A CAREER IN STEM
22	CELLS, IF YOU'VE GOT A BIOTECH COMPANY AND YOU'RE IN
23	THIS FIELD OR YOU WANT TO GET IN THIS FIELD, WE WANT
24	TO BE ABLE TO KEEP REMINDING THEM THAT CALIFORNIA IS
25	THE PLACE TO BE TO DO THIS.

1	WE THINK THAT THAT VALUE IS REALLY WORTH
2	QUITE A BIT TO US. SO I PRESENT THAT TO YOU WITH A
3	REQUEST FOR \$200,000. OUR RECOMMENDATION WOULD BE
4	THAT THIS COME FROM DONATED FUNDS. I'M OPEN TO ANY
5	QUESTI ONS.
6	DR. PULIAFITO: I'D LIKE TO MAKE A MOTION,
7	MR. CHAIRMAN, THAT WE AUTHORIZE COSPONSORSHIP OF
8	THIS CONFERENCE FROM DONATED FUNDS.
9	CHAIRMAN KLEIN: WITH THE \$200,000.
10	MR. ROTH: SECOND.
11	CHAIRMAN KLEIN: SECOND BY DUANE ROTH.
12	MR. ROTH: WITH ONE REQUEST, BOARD MEMBERS
13	ALSO ATTEND FREE. THAT SHOULD HAPPEN. WE SHOULD BE
14	ABLE TO GO FREE.
15	DR. ROBSON: I CAN'T GUARANTEE.
16	MR. ROTH: NEGOTI ATE.
17	MR. SHEEHY: THAT'S CONDITIONAL. I ALSO
18	WOULD LIKE TO OFFER ANOTHER CONDITION BECAUSE WHEN
19	THIS MATTER FIRST CAME BEFORE US, I SPECIFICALLY
20	MENTIONED A POLICY AT THE CONFERENCE ON RETROVIRUS
21	AND OPPORTUNISTIC INFECTIONS, WHICH IS ONE OF THE
22	MAIN SCIENTIFIC CONFERENCES FOR PEOPLE WITH HIV.
23	AND WHAT THEY DO, WHICH I THINK IS EXTRAORDINARY AND
24	WISE, IS THAT THEY MAKE A SPECIFIC SCHOLARSHIP
25	STIPULATION FOR PATIENT ADVOCATES SO THEY CAN
	207

1	ATTEND. WE WOULDN'T BE HERE TODAY WITHOUT PATIENT
2	ADVOCATES, AND THE HEROIC WORK OF PATIENT ADVOCATES.
3	WE'RE SPONSORING THIS CONFERENCE. THE FACT THAT
4	THERE'S NO SCHOLARSHIPS FOR I THINK OF DON AND
5	ROMAN REED FOR THEM TO BE ABLE AND GLORIA TO BE ABLE
6	TO ATTEND.
7	BUT I WOULD, AT LEAST AS A CONDITION OF
8	OUR ACCEPTANCE, IS GET REGISTRATIONS THAT WE CAN
9	ALLOT TO PATIENT ADVOCATES. AND I WOULD LEAVE IT TO
10	MY OTHER MEMBERS, BUT I WOULD THINK WE WOULD WANT TO
11	HAVE AT LEAST TEN REGISTRATIONS THAT WE CAN GIVE OUT
12	TO PATIENT ADVOCATES.
13	THIS IS A REAL OPPORTUNITY FOR US TO
14	ACKNOWLEDGE THE PEOPLE THAT MADE THIS. WE WOULDN'T
15	BE SITTING HERE. AND IT'S SHORTSIGHTED FOR STEM
16	CELL SCIENCE TO NOT ENGAGE THE ADVOCATE COMMUNITY IN
17	THEIR CONFERENCE FRAMEWORK.
18	CHAIRMAN KLEIN: TWO THINGS. I WOULD SAY
19	THAT THIS IS A VERY GOOD IDEA. I THINK WE COULD
20	FUND THESE SCHOLARSHIPS. THEY HAVE BEEN CUT DOWN TO
21	A VERY MINIMUM BUDGET. THE SPONSORSHIP, I THINK, IN
22	BARCELONA WAS \$500,000. SO WE'VE CUT THIS DOWN TO
23	THE BONE WITH THEM. AND WHAT I WOULD LIKE TO
24	SUGGEST IS THAT WE DO HAVE THE FUNDS AND THE ABILITY
25	TO FOLLOW THROUGH ON JEFF'S SUGGESTION, WHICH IS A

1	VERY GOOD ONE.
2	MR. SHEEHY: ACTUALLY, BOB, THAT'S A
3	BRILLIANT IDEA. SINCE IT'S IN CALIFORNIA, CIRM
4	COULD ACTUALLY PERHAPS WE COULD \$200,000, WE
5	COULD AUGMENT THAT BUDGET. THERE'S A GREAT TEMPLATE
6	ON THE WEBPAGE, SO THERE'S STIPEND, THERE'S HOTEL
7	ROOMS. OBVIOUSLY THESE ARE PEOPLE CAN AFFORD TO
8	ATTEND. THEY SHOULD DO WHAT THEY CAN. BUT FOR
9	THOSE PATIENT ADVOCATES, WE SHOULD PERHAPS WE CAN
10	LEAVE STAFF TO DEVISE THE PROGRAM.
11	CHAIRMAN KLEIN: I THINK THAT'S EXCELLENT.
12	I'M GOING TO ASK STAFF TO BRING BACK TO THE JUNE
13	MEETING A SUGGESTION TO FOLLOW ON WHAT JEFF'S
14	SUGGESTION IS AND DON'T LIMIT YOURSELF TO TEN. THIS
15	IS AN IMPORTANT CONTRIBUTION.
16	MR. SHEEHY: I WOULD LEAVE IT TO STAFF AND
17	BOB.
18	MR. GIBBONS: I DID TALK TO NANCY WITTE,
19	THE HEAD OF THE ORGANIZATION, AFTER JEFF AND I FIRST
20	DISCUSSED THIS. AND SHE WAS A LITTLE CONCERNED
21	ABOUT THE PROCESS, BUT DID NOT CLOSE OUT THE OPTION.
22	SO I THINK IT IS DEFINITELY SOMETHING WE CAN DISCUSS
23	WITH HER AND MAKE IT HAPPEN.
24	CHAIRMAN KLEIN: AT THIS BUDGET, I DON'T
25	THINK IT'S GOING TO HAPPEN. I THINK MORE BROADLY WE
	299

1	SHOULD FOLLOW THROUGH ON JEFF'S SUGGESTION,
2	INCLUDING SOME STIPENDS FOR SOME PEOPLE TO ATTEND IN
3	OUR BUDGET.
4	MR. SHEEHY: I'M HAPPY OFFLINE TO TALK
5	WITH BOTH OF YOU SO YOU CAN SEE KIND OF A TEMPLATE
6	FOR DOING THIS. AND I THINK IT'S VERY VALUABLE FOR
7	US TO SPONSOR THIS INDEPENDENTLY, TO BE HONEST. I
8	THINK WHAT ISSCR COULD DO IS PERHAPS NOT ALLOW US
9	THE REGISTRATION COST, BUT THE REST OF THE COST FOR
10	HAVING PATIENT ADVOCATES ATTEND, WE COULD FIGURE OUT
11	SOME FORMULA FOR THAT.
12	CHAIRMAN KLEIN: I THINK THE REGISTRATION
13	COST TO US GETTING THIS PROGRAM WILL BE A SMALL
14	INCREMENT. SO LET'S KEEP IT CLEAN ON THAT. BUT WE
15	ALSO HAVE JOHN SIMPSON, I WANT TO GET HIS PUBLIC
16	COMMENT, PLEASE.
17	DR. ROBSON: I WOULD ASK THAT WE GET A
18	DECISION TODAY.
19	CHAIRMAN KLEIN: WE'RE GOING TO VOTE.
20	MR. SIMPSON: JOHN SIMPSON, CONSUMER
21	WATCHDOG. BACK IN DECEMBER WHEN THIS WAS INITIALLY
22	INTRODUCED, I WAS ONE OF THOSE WHO THOUGHT IT WAS
23	EXCESSIVE AND AN INAPPROPRIATE USE OF FUNDS. I
24	THOUGHT VERY LITTLE OF THE PROCESS THAT WAS RUSHING
25	IT THROUGH. YOU THEN HAD A TELEPHONE CONFERENCE
	300

1	WHERE YOU WERE GOING TO TRY TO PASS IT AND YOU
2	DIDN'T GET A QUORUM. THIS IS EXACTLY THE WAY IT
3	SHOULD HAVE BEEN DONE IN THE BEGINNING. IT'S A VERY
4	PERSUASIVE ARGUMENT. I HIGHLY SUPPORT THIS AND
5	ENDORSE THIS. IT MAKES PERFECT SENSE. I JUST WISH
6	THAT IT WOULD HAVE BEEN DONE RIGHT THE FIRST TIME,
7	BUT THIS IS A MODEL FOR HOW THINGS SHOULD BE
8	PRESENTED TO THE BOARD. THIS IS A WONDERFUL THING
9	TO DO, AND I ALSO THINK THAT THE IDEA OF STIPENDS IS
10	SOMETHING THAT CIRM SHOULD LOOK INTO ON ITS OWN
11	MERIT, NOT JUST THIS CONFERENCE, BUT FOR OTHER ONES.
12	THANK YOU.
13	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
14	ADDITIONAL BOARD COMMENTS?
15	DR. AZZIZ: THERE'S JUST TO BE CLEAR ON
16	THE MOTION, THE MOTION, OF COURSE, IS TO APPROVE THE
17	200,000. HAS THAT BEEN AMENDED TO STATE FREE
18	REGISTRATION FOR THE ICOC MEMBERS, OR IS THAT
19	SOMETHING THAT WILL ALSO BE INCLUDED IN THE PACKAGE
20	THAT WILL RETURN TO DISCUSS AT THE SUBSEQUENT
21	MEETING? WE HAD THE SECOND, WHICH WAS THE PATIENT
22	ADVOCATE SUPPORT.
23	CHAIRMAN KLEIN: I'D LIKE TO KEEP THIS
24	CLEAN. THEY REALLY HAVE COLLABORATED WITH US, AND I
25	THINK ICOC MEMBERS HAVE TO GO. WE NEED TO ALSO

301

1	ADDRESS COVERING ICOC MEMBERS' COST TO ATTEND. SO I
2	THINK WE SHOULD KEEP IT SEPARATE.
3	DR. AZZIZ: THAT'S RIGHT. I THINK WE NEED
4	TO CLARIFY THE MOTION.
5	CHAIRMAN KLEIN: DUANE ROTH SAID IT IS NOT
6	PART OF THE MOTION, SO WE'LL DO IT SEPARATELY.
7	SO WITH THAT, I'D LIKE TO CALL THE
8	QUESTION. WE COULD DO A VOICE VOTE, AND THEN DO
9	ROLL CALL ON THOSE ON THE PHONE. ALL IN FAVOR?
10	OPPOSED?
11	MS. KING: MARCY FEIT.
12	MS. FEIT: YES.
13	MS. KING: MICHAEL GOLDBERG.
14	MR. GOLDBERG: YES.
15	MS. KING: PHIL PIZZO.
16	DR. PI ZZO: YES.
17	MS. KING: CLAIRE POMEROY.
18	DR. POMEROY: YES.
19	MS. KING: SOUNDS LIKE THAT MOTION
20	CARRI ES.
21	CHAIRMAN KLEIN: THANK YOU VERY MUCH. WE
22	ARE CLEAR ON OUR AGENDA?
23	DR. TROUNSON: THANK YOU, CHAIR. THE
24	BOARD SHOULD KNOW THAT MY LACK OF INVOLVEMENT IN
25	DISCUSSION OF THAT MATTER IS JUST BECAUSE I HAVE A
	302

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CONFLICT. SO IT'S GOOD TO HAVE SOMETHING FINISHED
2	IN THAT AREA.
3	WHAT I'D LIKE TO DO, IF I MAY, CHAIR, IS
4	MAKE A SPECIAL THANKS TO THE SCIENTISTS WHO HAVE
5	BEEN WORKING WITH THE TRANSLATION PROGRAM. IT'S
6	BEEN A REALLY TOUGH PROGRAM. AS JEFF KNOWS, WE'VE
7	BEEN UP AND DOWN. WE'VE BEEN SORT OF FORCED TO THE
8	WALL NOT KNOWING WHETHER WE'RE GOING TO FUND ANY,
9	FUNDING SOME, WORKING WITH OUR SCIENTISTS WHO ARE
10	OUT THERE TAKING SOME HARD BLOWS. I THINK IT'S BEEN
11	QUITE A TRAUMATIC TIME THERE. I THINK THEY VE DONE
12	A WONDERFUL JOB, THE WHOLE SCIENCE GROUP, BUT I
13	WANTED TO PARTICULARLY THANK A COUPLE OF PEOPLE,
14	PARTICULARLY ROSA, WHO HAS PUT MOST OF HER WHOLE
15	SORT OF LIFE INTO THIS PROGRAM IN THE LAST SIX
16	MONTHS. SHE'S DONE A WONDERFUL JOB AND BEEN SO WELL
17	SUPPORTED BY MARIE AND PAT OLSON AND THE OTHER
18	SCIENCE MEMBERS.
19	I THINK YOU'VE GOT YOU'VE BEEN
20	PRESENTED A VERY GOOD PROGRAM, AND WE'VE WORKED IT
21	THROUGH. I'D JUST LIKE TO RECOGNIZE WHAT THEY'VE
22	DONE. IT'S BEEN FABULOUS.
23	(APPLAUSE.)
24	CHAIRMAN KLEIN: WITHOUT ADDITIONAL
25	COMMENT FROM THE BOARD, IS THERE ADDITIONAL ENDING
	303
	303

1	PUBLIC COMMENT? SEEING NONE, THANK THE BOARD
2	MEMBERS. THANK THE STAFF. MELISSA HAS AN
3	ANNOUNCEMENT FOR US.
4	MS. KING: THERE IS LUNCH AVAILABLE
5	DOWNSTAIRS. I INVITE YOU ALL TO JOIN US. I'D LIKE
6	TO HAVE AS MANY OF YOU AS POSSIBLE JOIN US. I KNOW
7	THERE'S PROBABLY A STRONG DESIRE TO LEAVE, BUT USC
8	AND DR. PULIAFITO'S TEAM HAS SEEN TO IT THAT A
9	WONDERFUL LUNCH HAS BEEN PREPARED. SO IF YOU'RE
10	HUNGRY AND HAVE TIME TO COME ON DOWN, PLEASE JOIN US
11	DOWNSTAIRS FOR LUNCH.
12	CHAIRMAN KLEIN: THANK YOU VERY MUCH. AND
13	THANK YOU, USC. LET'S GIVE A HAND TO USC.
14	(APPLAUSE.)
15	(THE MEETING WAS THEN CONCLUDED AT
16	01: 24 P. M.)
17	
18	
19	
20	
21	
22	
23	
24	
25	
	304

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

USC KECK SCHOOL OF MEDICINE
MAYER AUDITORIUM
1975 ZONAL AVENUE
LOS ANGELES, CALIFORNIA
ON
APRIL 29, 2009

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152

BARRISTER'S REPORTING SERVICE

1072 BRISTOL STREET

SUITE 100

COSTA MESA, CALIFORNIA

(714) 444-4100